

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

20 April 2023 (20.04.2023)



(10) International Publication Number

WO 2023/064886 A1

(51) International Patent Classification:

A61K 9/19 (2006.01) A61K 47/26 (2006.01)

A61K 47/02 (2006.01) A61P 7/04 (2006.01)

A61K 47/18 (2006.01) A61K 47/10 (2006.01)

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/078097

(22) International Filing Date:

14 October 2022 (14.10.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/256,432 15 October 2021 (15.10.2021) US

(71) Applicant: BIOVERATIV THERAPEUTICS INC.

[US/US]; 225 Second Avenue, Waltham, Massachusetts 02451 (US).

(72) Inventors: CARLAGE, Tyler; c/o Bioverativ Therapeutics Inc., 225 Second Avenue, Waltham, Massachusetts 02451 (US).

MAULDIN, Randall; c/o Bioverativ Therapeutics Inc., 225 Second Avenue, Waltham, Massachusetts 02451 (US).

MCCOY, Timothy R.; c/o Bioverativ Therapeutics Inc., 225 Second Avenue, Waltham, Massachusetts 02451 (US).

TAZI, Loubna Mzaalak; c/o Bioverativ Therapeutics Inc., 225 Second Avenue, Waltham, Massachusetts 02451 (US).

(74) Agent: VELEMA, James H. et al.; Lathrop GPM LLP, 28 State Street, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF

(57) Abstract: The present disclosure provides pharmaceutical compositions of a chimeric protein comprising a factor VIII (FVIII) polypeptide and a von Willebrand factor (VWF) polypeptide. Also disclosed are pharmaceutical kits and methods of using the disclosed pharmaceutical compositions to treat hemophilia A.

WO 2023/064886 A1

FORMULATIONS OF FACTOR VIII CHIMERIC PROTEINS AND USES THEREOF

RELATED APPLICATION

[0001] This application claims priority to U.S. provisional application no. 63/256,432, filed October 15, 2021, the contents of which are incorporated herein in their entirety.

REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

[0002] The content of the electronically submitted sequence listing in XML file format (Name: SA9-483PC_SL_ST26.xml; Size: 55,697 bytes; Created: October 4, 2022) is incorporated herein by reference in its entirety.

BACKGROUND OF THE DISCLOSURE

[0003] Hemophilia A is a bleeding disorder caused by defects in the gene encoding coagulation factor VIII (FVIII) and affects 1-2 in 10,000 male births. Graw *et al.*, *Nat. Rev. Genet.* 6(6): 488-501 (2005). Patients affected with hemophilia A can be treated with infusions of purified plasma FVIII or recombinantly produced FVIII. Many commercially available FVIII products are known to have a half-life of about 8-12 hours, requiring frequent intravenous administration to the patients. See Weiner M.A. and Cairo, M.S., *Pediatric Hematology Secrets*, Lee, M.T., 12. Disorders of Coagulation, Elsevier Health Sciences, 2001; Lillicrap, D. *Thromb. Res.* 122 Suppl 4:S2-8 (2008). In addition, a number of approaches have been tried in order to extend the FVIII half-life. For example, the approaches in development to extend the half-life of clotting factors include pegylation, glycopegylation, and conjugation with albumin. See Dumont *et al.*, *Blood.* 119(13): 3024-3030 (2012). Consistent results have been demonstrated in humans, for example, rFVIII-Fc was reported to improve half-life up to ~1.7-fold compared with ADVATE® in hemophilia A patients. See Powell *et al.*, *Blood.* 119(13): 3031-3037 (2012). Therefore, the half-life increases, despite minor improvements, indicate the presence of other half-life limiting factors, such as clearance by VWF. Pipe *et al.*, *Blood.* 128(16):2007-2016 (2016)).

[0004] Efanesoctocog alfa (also known as Efa and BIVV001) is a fusion protein that is designed to uncouple recombinant clotting factor VIII from VWF in circulation. The chimeric protein comprises a single recombinant factor VIII protein fused to dimeric Fc, a D'D3 domain of VWF, and two ELNN Polypeptides. Chhabra *et al.* *Blood* 135(17): 1484-1496 (2020). In

one early study involving patients with severe hemophilia A, a single intravenous injection of efanesoctocog alfa resulted in high sustained factor VIII activity levels, with a half-life that was up to four times the half-life associated with recombinant factor VIII. See Konkle et al., *NEJM*. 383:1018-27 (2020).

[0005] However, there remains a need for improved pharmaceutical compositions.

SUMMARY OF THE DISCLOSURE

[0006] The present disclosure is directed to, *inter alia*, pharmaceutical compositions comprising a Factor VIII ("FVIII") protein, kits comprising such pharmaceutical compositions, and therapeutic methods and uses of the pharmaceutical compositions.

[0007] In some embodiments, the pharmaceutical composition comprises a chimeric protein or protein which comprises a first polypeptide chain which comprises a FVIII protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof. In some embodiments, the chimeric protein comprises (i) a FVIII protein comprising a FVIII polypeptide, an ELNN Polypeptide inserted within the B domain (*e.g.*, replacing at least a portion of the B domain) of the FVIII polypeptide, and a first Fc region; and (ii) a VWF protein comprising a VWF fragment (*e.g.*, a fragment comprising the D'D3 domains of VWF, which fragment may comprise mutations), a second ELNN Polypeptide, a thrombin-cleavable linker (such as an $\alpha 2$ linker), and a second Fc region. In some embodiments, the chimeric protein disclosed herein is a FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer.

[0008] In some embodiments, the pharmaceutical composition comprises: (a) a FVIII protein; (b) about 1% (w/v) to about 7.5% (w/v) sucrose; (c) about 5 mM to about 15 mM histidine; (d) about 200 mM to about 300 mM arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.01% (w/v) to about 1.0% (w/v) of a poloxamer. In some embodiments, the pharmaceutical composition comprises: (a) a FVIII protein; (b) about 1% (w/v) to about 7.5% (w/v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine; (e) about 2.5 mM to about 10 mM calcium chloride; and (f) about 0.01% (w/v) to about 1.0% (w/v) of a poloxamer. In some embodiments, the pharmaceutical composition comprising: (a) a Factor VIII ("FVIII") protein; (b) about 1% (w/v) to about 7.5% (w/v) sucrose; (c) about 5 mM to about 15 mM L-histidine; (d) about 200 mM to about 300 mM L-arginine-HCl; (e) about 2.5 mM to about 10 mM calcium chloride dihydrate; and (f) about 0.008% (w/v) to about 0.1% (w/v) of a poloxamer.

[0009] In some embodiments, the composition comprises about 250 mM L-arginine. In some embodiments, the composition comprises about 250 mM L-arginine-HCl. In some embodiments, the poloxamer is poloxamer 188 (poloxamer 188, which is also known as P188). Poloxamer 188 is well known in the art.

[0010] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) a chimeric protein comprising a first polypeptide chain which comprises a Factor VIII ("FVIII") protein and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof;
- (b) about 1% (w/v) to about 7.5% (w/v) sucrose;
- (c) about 5 mM to about 15 mM histidine;
- (d) about 200 mM to about 300 mM arginine;
- (e) about 2.5 mM to about 10 mM calcium chloride; and
- (f) about 0.01% (w/v) to about 1.0% (w/v) of poloxamer 188.

[0011] In some embodiments, the pharmaceutical composition comprises about 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 250 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 300 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 500 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises at least about 500 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 85 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 100 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 200 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises at least about 200 IU/ml of the chimeric protein.

[0012] In some embodiments, the first polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 1 and the second polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between Fc domains in the first and second polypeptide chains. In some embodiments, the chimeric protein is efanesoctocog alfa.

[0013] In some embodiments, the pharmaceutical composition comprises about 1% (w/v) to about 5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises

about 5 mM to about 15 mM histidine. In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises poloxamer 188 (P188). In some embodiments, the pharmaceutical composition comprises about 0.01% (w/v) to about 1.0% (w/v) poloxamer 188.

[0014] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 1% (w/v) to about 5% (w/v) sucrose;
- (b) about 5 mM to about 15 mM histidine;
- (c) about 200 mM to about 300 mM arginine;
- (d) about 2.5 mM to about 10 mM calcium chloride; and
- (e) about 0.01% (w/v) to about 1.0% (w/v) poloxamer 188.

[0015] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 1%, 2%, or 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

[0016] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 5% (w/v) sucrose;
- (b) about 10 mM L-histidine;
- (c) about 250 mM L-arginine-HCl;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

[0017] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 2% (w/v) sucrose;
- (b) about 10 mM L-histidine;
- (c) about 250 mM L-arginine-HCl;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

[0018] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 1% (w/v) sucrose;
- (b) about 10 mM L-histidine;
- (c) about 250 mM L-arginine-HCl;
- (d) about 5 mM calcium chloride; and

(e) about 0.1% (w/v) poloxamer 188.

[0019] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.4 mg/mL to 0.9 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0020] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0021] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0022] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0023] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0024] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;

- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0025] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.5 mg/mL to 0.9 mg/mL calcium chloride dihydrate; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0026] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 50 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

[0027] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 20 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

[0028] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 20 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

[0029] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 20 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

[0030] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;

- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

[0031] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

[0032] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

[0033] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

[0034] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

[0035] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 50 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.7 mg/mL to 0.9 mg/mL calcium chloride dihydrate; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0036] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;

- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 50 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.4 mg/mL to 0.8 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0037] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 60 mg/mL L-arginine;
- (d) 0.7 mg/mL to 0.9 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0038] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 60 mg/mL L-arginine;
- (d) 0.4 mg/mL to 0.7 mg/mL calcium chloride dihydrate; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0039] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0040] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0041] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0042] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0043] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0044] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0045] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0046] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0047] In some embodiments, disclosed herein is a pharmaceutical composition comprising:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

- [0048] In some embodiments, disclosed herein is a pharmaceutical composition according to any of the disclosed embodiments, which further comprises a pH of about 6.5 to about 7.5. In some embodiments, the pharmaceutical composition disclosed herein has a pH of about 7.0. In some embodiments, the pharmaceutical composition disclosed herein has a pH of about 6.8. In some embodiments the pharmaceutical composition disclosed herein does not comprise NaCl. In some embodiments the pharmaceutical composition disclosed herein comprises less than 8.8 mg/mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition disclosed herein comprises L-histidine. In some embodiments, the pharmaceutical composition disclosed herein comprises L-arginine. In some embodiments, the pharmaceutical composition disclosed herein comprises arginine-HCl. In some embodiments, the pharmaceutical composition disclosed herein comprises L-arginine-HCl. In some embodiments, the pharmaceutical composition disclosed herein comprises calcium chloride dihydrate.
- [0049] In some embodiments, disclosed herein is a pharmaceutical composition according to any of the disclosed embodiments, wherein the pharmaceutical composition has a chimeric protein concentration of about 0.8 to about 1.2 mg/mL. In some embodiments, the pharmaceutical composition disclosed herein comprises 75 IU/mL to 2,000 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition disclosed herein has an osmolality about 525 to about 725 mOsm/kg. In some embodiments, the pharmaceutical composition disclosed herein has an osmolality about 500 to about 650 mOsm/kg. In some embodiments, the pharmaceutical composition disclosed herein has an osmolality about 600 to about 650 mOsm/kg. In some embodiments, the pharmaceutical composition disclosed herein has a turbidity of less than about 7 Nephelometric Turbidity Units (NTU).
- [0050] In some embodiments, disclosed herein is a method of storing a pharmaceutical composition, comprising maintaining a pharmaceutical composition disclosed herein at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

- [0051] In some embodiments, the pharmaceutical composition has been stored at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.
- [0052] In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 2-5 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 2 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 3 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 4 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 5 times.
- [0053] In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 10 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 2 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1.5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 2 mg/ml of the chimeric protein.
- [0054] Also disclosed herein is a method of treating hemophilia A in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition according to any of the embodiments disclosed herein. In some embodiments, the pharmaceutical composition is self-administered. In some embodiments, the pharmaceutical composition is administered intravenously. In some embodiments, the pharmaceutical composition is administered intravenously at a dose of about 20 IU/kg to about 70 IU/kg. In some embodiments, the pharmaceutical composition

is administered intravenously at a dose of about 50 IU/kg. In some embodiments, the pharmaceutical composition is administered intravenously once every 7-10 days. In some embodiments, the pharmaceutical composition is administered intravenously once weekly.

[0055] Also disclosed herein is a pharmaceutical kit comprising (i) a first container comprising a lyophilized pharmaceutical composition comprising

(a) a chimeric protein comprising a first polypeptide chain which comprises a Factor VIII ("FVIII") protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof;

(b) about 10 mg to about 200 mg sucrose;

(c) about 2.5 mg to about 7.5 mg histidine;

(d) about 140 mg to about 200 mg arginine;

(e) about 1.5 mg to about 5 mg calcium chloride; and

(f) about 1 mg to about 10 mg poloxamer 188, and

(ii) a second container comprising sterile water.

[0056] In some embodiments, the chimeric protein comprises a first polypeptide chain comprising the amino acid sequence set forth as SEQ ID NO: 1 and a second polypeptide chain comprising the amino acid sequence set forth as SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between Fc domains in the first and second polypeptide chains.

[0057] In some embodiments, the pharmaceutical kit disclosed herein comprises a lyophilized pharmaceutical composition comprising:

(a) about 10 mg to about 200 mg sucrose;

(b) about 2.5 mg to about 7.5 mg histidine;

(c) about 140 mg to about 200 mg arginine;

(d) about 1.5 mg to about 5 mg calcium chloride; and

(e) about 1 mg to about 10 mg poloxamer 188.

[0058] In some embodiments the pharmaceutical kit comprises a lyophilized pharmaceutical composition that does not comprise NaCl. In some embodiments the lyophilized pharmaceutical composition comprises less than 8.8 mg/mL sodium chloride (NaCl). In some embodiments, the lyophilized pharmaceutical composition comprises L-histidine. In some embodiments, the lyophilized pharmaceutical composition comprises L-arginine. In some embodiments, the lyophilized pharmaceutical composition comprises arginine-HCl. In some embodiments, the lyophilized pharmaceutical composition comprises L-arginine-

HCl. In some embodiments, the lyophilized pharmaceutical composition disclosed herein comprises calcium chloride dihydrate.

[0059] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition comprising:

- (a) about 33.7 mg sucrose;
- (b) about 5.2 mg L-histidine;
- (c) about 177.3 mg L-arginine-HCl;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0060] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition comprising:

- (a) about 67.3 mg sucrose;
- (b) about 5.2 mg L-histidine;
- (c) about 177.3 mg L-arginine-HCl;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0061] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition comprising:

- (a) about 67.3 mg sucrose;
- (b) about 5.2 mg L-histidine;
- (c) about 146.6 mg L-arginine-HCl;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0062] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition comprising:

- (a) about 168.3 mg sucrose;
- (b) about 5.2 mg L-histidine;
- (c) about 177.3 mg L-arginine-HCl;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0063] In some embodiments, the pharmaceutical kit comprises a lyophilized pharmaceutical composition having a moisture content of less than 2%. In some embodiments, the lyophilized pharmaceutical composition has a moisture content of less than 1.8%. In some embodiments, the lyophilized pharmaceutical composition has a moisture content of less than 1.6%. In some embodiments, the lyophilized pharmaceutical composition is in a

lyophilized cake. In some embodiments, the lyophilized cake is white. In some embodiments, the lyophilized cake is less than Y4 in the European Pharmacopoeia color scale. In some embodiments, the lyophilized pharmaceutical composition is a powder.

[0064] In some embodiments, the pharmaceutical kit comprises a first container comprising 100 IU to 10,000 IU of the chimeric protein. In some embodiments, the first container comprises 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of the chimeric protein. In some embodiments, the first container comprises more than about 250 IU of the chimeric protein. In some embodiments, the first container comprises more than about 300 IU of the chimeric protein. In some embodiments, the first container comprises more than about 500 IU of the chimeric protein. In some embodiments, the first container comprises at least about 500 IU of the chimeric protein.

[0065] In some embodiments, the pharmaceutical kit further comprises instructions for combining the lyophilized pharmaceutical composition and sterile water. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the lyophilized pharmaceutical composition is reconstituted within 7 to 12 seconds.

[0066] In some embodiments, the pharmaceutical composition comprises a second container comprising sterilized water at a volume sufficient to produce, when combined with the lyophilized powder of the first container, a solution comprising

[0067] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the osmolality of the resulting solution is about 525 to about 725 mOsm/kg. In some embodiments, the pharmaceutical composition disclosed herein has an osmolality about 500 to about 650 mOsm/kg. In some embodiments, the osmolality of the resulting solution is about 600 to about 650 mOsm/kg. In some embodiments, the pH of the resulting solution is about 6.5 to about 7.5. In some embodiments, the pH of the resulting solution is about 7.0. In some embodiments, the pH of the resulting solution is about 6.8. In some embodiments, the turbidity of the resulting solution is less than about 7 Nephelometric Turbidity Units (NTU). In some embodiments, the protein concentration of the resulting solution is about 0.8 to about 1.2 mg/mL. In some embodiments, less than 3% of the protein is aggregated.

[0068] In some embodiments, the pharmaceutical kit comprises a second container comprising sterilized water at a volume sufficient to produce, when combined with the lyophilized pharmaceutical composition of the first container, a solution comprising:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 70 mg/mL L-arginine-HCl;

- (d) 0.5 mg/mL to 0.9 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0069] In some embodiments of the pharmaceutical kit disclosed herein, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.5 mg/mL to 0.9 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

[0070] In some embodiments of the pharmaceutical kit disclosed herein, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0071] In some embodiments of the pharmaceutical kit disclosed herein, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0072] In some embodiments of the pharmaceutical kit disclosed herein, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 22.45 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0073] In some embodiments of the pharmaceutical kit disclosed herein, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

[0074] In some embodiments, the pharmaceutical kit comprises a second container comprising about 2 mL to about 5 mL of sterile water. In some embodiments, the pharmaceutical kit comprises a second container comprising about 3 mL of sterile water. In some embodiments, the pharmaceutical kit comprises a second container comprising about 3.3 mL of sterile water.

[0075] In some embodiments, the pharmaceutical kit is stored at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

[0076] In some embodiments, the pharmaceutical kit has been stored at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

[0077] In some embodiments, the pharmaceutical kit comprises a first container which is a glass vial comprising a rubber stopper. In some embodiments, the pharmaceutical kit comprises a second container which is a syringe body. In some embodiments, the sterile water is in the syringe body. In some embodiments, the syringe body is associated with a plunger. In some embodiments, the pharmaceutical kit further comprises an adaptor to connect the

glass vial to the syringe body. In some embodiments, the pharmaceutical kit further comprises infusion tubing associated with a needle to be connected to the syringe body, suitable for intravenous infusion.

[0078] Also disclosed herein is a method of treating hemophilia A in a subject in need thereof, comprising combining the lyophilized pharmaceutical composition and the sterile water of the pharmaceutical kit according to any of the embodiments disclosed herein, and administering to the subject an effective amount of the resulting combination (i.e. solution). In some embodiments, the subject combines the lyophilized pharmaceutical composition and the sterile water of the kit. In some embodiments, the combination is self-administered by the subject.

BRIEF DESCRIPTION OF THE DRAWINGS

[0079] FIG. 1 is a schematic representation of efanesoctocog alfa, an exemplary FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer. FVIII: factor VIII; VWF: von Willebrand Factor; A1, A2, A3, C1, C2: domains of FVIII; D'D3: domains of VWF; Fc: Fc region of immunoglobulin constant region.

[0080] FIG. 2 shows the aggregation levels (%HMWS) over time (hours) at room temperature (RT)/room light (RL) conditions for efanesoctocog alfa drug substance (DS) compositions (1 mg/mL) containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and either 1% or 5% (w/v) sucrose. Rates of change in aggregation levels (slope) are also provided (% per hour)

[0081] FIG. 3 shows the aggregation levels (%HMWS) over time (hours) at 2-8 °C for efanesoctocog alfa drug substance (DS) compositions (1 mg/mL) containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and either 1% or 5% (w/v) sucrose. Rates of change in aggregation levels (slope) are also provided (% per hour).

[0082] FIG. 4 shows the aggregation levels (%HMWS) of efanesoctocog alfa drug substance (DS) compositions flowed by dilution to 4000 IU bulk drug product at 7 hours and containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and 1% or 5% (w/v) sucrose. Samples were held at RT and tested after 0, 5, 7, 25, 43, and 55 hours. Samples were also tested after lyophilization (Post-Lyo).

[0083] FIG. 5 shows a frozen storage stability study which measured the aggregation levels (%HMWS) of efanesoctocog alfa DS compositions (1 mg/mL) containing 0.05% (w/v) PS80 as a surfactant. Compositions containing 0, 1, 2, or 5% (w/v) sucrose were held at freezing temperatures (-80°C or -30°C). Time points measured were pre-freeze, start of experiment (T0), one month (T1M), 3 months (T3M), and 6 months (T6M).

- [0084] FIG. 6 shows a frozen storage stability study which measured the aggregation levels (%HMWS) of efanesoctocog alfa DS compositions (1 mg/mL) containing 0.1% (w/v) poloxamer 188 as a surfactant. Compositions containing 0, 1, 2, or 5% (w/v) sucrose were held at freezing temperatures (-80°C or -30°C). Time points measured are pre-freeze, start of experiment (T0), one month (T1M), 3 months (T3M), and 6 months (T6M).
- [0085] FIG. 7 shows the results of an analysis of efanesoctocog alfa DS compositions (1 mg/mL) by particle testing using high accuracy liquid particle counter (HIAC). DS compositions containing 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose were held at -80°C and assessed at the following time points: pre-freeze, start of experiment (T0), one month (T1M), 3 months (T3M), and 6 months (T6M). Results for $\geq 10 \mu\text{m}$ particles are shown in FIG. 7A. Results for $\geq 25 \mu\text{m}$ particles are shown in FIG. 7B.
- [0086] FIG. 8 shows the aggregation levels (%HMWS) for compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 250 IU and comprising 0.1% (w/v) poloxamer 188 as surfactant. Lyo DP compositions containing 1% or 5% (w/v) sucrose were tested. Samples were held at 5°C, 30°C, or 40°C and tested at T0, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 8A (5°C), FIG. 8B (30°C), and FIG. 8C (40°C).
- [0087] FIG. 9 shows the aggregation levels (%HMWS) for compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 4000 IU and comprising 0.1% (w/v) poloxamer 188 as surfactant. Lyo DP compositions containing 1% or 5% (w/v) sucrose were tested. Samples were held at 5°C, 30°C, or 40°C and tested at T0, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 9A (5°C), FIG. 9B (30°C), and FIG. 9C (40°C).
- [0088] FIG. 10 shows the aggregation levels (%HMWS) of compositions of efanesoctocog alfa DS (1 mg/mL) before (pre freeze) and after stress by freeze/thaw (F/T) at either -80°C or -30°C for 5 cycles (5X)(not less than 24hrs, thaw at room temperature). FIG. 10 shows the results for DS compositions containing 0.05% (w/v) PS80 and 0, 1, 2, or 5% (w/v) sucrose.
- [0089] FIG. 11 shows the aggregation levels (%HMWS) of compositions of efanesoctocog alfa DS (1 mg/mL) before (pre freeze) and after stress by freeze/thaw (F/T) at either -80°C or -30°C for 5 cycles (5X)(not less than 24hrs, thaw at room temperature). FIG. 11 shows the results for DS compositions containing 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose.
- [0090] FIG. 12 shows protein concentration analysis by A280 (absorbance at 280nm) of different sucrose concentrations in efanesoctocog alfa DS (1 mg/mL) compositions following F/T stress. Samples were analyzed before (pre freeze) and after 1, 3, or 5 F/T cycles. Results for DS compositions containing 0.05% (w/v) PS80 and 0, 1, 2, or 5% (w/v) sucrose are

shown in FIG. 12A. Results for DS compositions containing 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose are shown in FIG. 12B.

- [0091] FIG. 13 shows an analysis of pH following F/T stress for efanesoctocog alfa DS compositions containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and 0, 1, 2, or 5% (w/v) sucrose. pH was measured after 0, 1, 3, or 5 F/T cycles.
- [0092] FIG. 14 shows the glass transition temperature (T_g) and residual moisture content (%) at the start of experiment (T₀) for compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 250 IU. Lyo DP compositions containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose were tested.
- [0093] FIG. 15 shows the glass transition temperature (T_g) and residual moisture content (%) at the start of experiment (T₀) for compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 4000 IU. Lyo DP compositions containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose were tested.
- [0094] FIG. 16 shows the glass transition temperature (T_g) of efanesoctocog alfa lyophilized drug product (Lyo DP) compositions at 4000 IU or 250 IU and containing 0.1% (w/v) poloxamer 188 as a surfactant and either 5% or 1% (w/v) sucrose. Samples were held at 5°C, 30°C, or 40°C and tested at T₀, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 16A (5°C), FIG. 16B (30°C), and FIG. 16C (40°C).
- [0095] FIG. 17 shows the glass transition temperature (T_g) of efanesoctocog alfa liquid bulk drug product (BDP) compositions at 250 IU or 4000 IU and containing either 0.05% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and 0, 1, 2, or 5% (w/v) sucrose.
- [0096] FIG. 18 shows the residual moisture content (%) of compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 4000 IU or 250 IU. Lyo DP compositions containing 0.1% (w/v) poloxamer 188 as surfactant and 1% or 5% (w/v) sucrose were tested. Samples were held at 5°C, 30°C, or 40°C and tested at T₀, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 18A (5°C), FIG. 18B (30°C), and FIG. 18C (40°C).
- [0097] FIG. 19 shows the aggregation levels (%HMWS) after stress by freeze/thaw (F/T) for compositions of efanesoctocog alfa DS (concentration: >2 mg/mL) comprising increasing concentrations of arginine (Arg). Compositions contained Arginine concentrations tested were 100, 125, 150, 175, 200, and 250 mM. Each column represents repeat injections from the same vial after thawing for 30 minutes at RT. Time points measured were immediately post-thaw and 40, 80, 120, and 160 minutes post-thaw.
- [0098] FIG. 20 shows the mean concentration (ng/mL) of efanesoctocog alfa over time as determined by ELISA following a single IV bolus injection of a composition comprising

either PS80 or P188. Vehicle 1: 10mM L-Histidine, 250mM Arginine-HCl, 5mM calcium chloride, 5% w/v Sucrose, 0.05% Polysorbate-80. Vehicle 2: 10mM L-Histidine, 250mM Arginine-HCl, 5mM Calcium Chloride, 5% w/v Sucrose, 0.1% Poloxamer-188.

[0099] FIG. 21 shows the mean FVIII activity (mIU/mL) of efanesoctocog alfa over time as determined by chromogenic assay following a single IV bolus injection of a composition comprising either PS80 or P188. Vehicle 1: 10mM L-Histidine, 250mM Arginine-HCl, 5mM Calcium Chloride, 5% w/v Sucrose, 0.05% Polysorbate 80. Vehicle 2: 10mM L-Histidine, 250mM Arginine-HCl, 5mM Calcium Chloride, 5% w/v Sucrose, 0.1% Poloxamer 188.

DETAILED DESCRIPTION OF THE DISCLOSURE

[0100] The present disclosure is directed to, *inter alia*, formulations (including aqueous and lyophilized formulations, as well as related kits) comprising FVIII proteins. In some embodiments, the FVIII protein is a chimeric FVIII protein such as efanesoctocog alfa comprising two polypeptides, i.e., a first polypeptide comprising a FVIII protein comprising a first ELNN Polypeptide sequence insert fused to a first Fc region, and a second polypeptide comprising a VWF protein fused to a second Ig constant region by a second ELNN Polypeptide sequence, wherein the first ELNN Polypeptide sequence contains about 288 amino acids and the second ELNN Polypeptide sequence contains about 144 amino acids, and the first Ig constant region and the second Ig constant region are covalently linked together by disulfide bonds.

[0101] The present disclosure provides to formulations (including aqueous and lyophilized formulations, as well as related kits) for a chimeric protein comprising (i) a factor VIII (FVIII) polypeptide and (ii) a von Willebrand factor (VWF) fragment comprising a D' domain of VWF and a D3 domain of VWF. Included herein are compositions that may be lyophilized, as well as compositions formed upon reconstitution of lyophilized formulations with a diluent. Therapeutic methods and uses are also provided.

I. Definitions

[0102] It is to be noted that the term "a" or "an" entity refers to one or more of that entity; for example, "a nucleotide sequence," is understood to represent one or more nucleotide sequences. As such, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0103] Furthermore, "and/or" where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term "and/or" as used in a phrase such as "A and/or B" herein is intended to include "A and B," "A or B,"

"A" (alone), and "B" (alone). Likewise, the term "and/or" as used in a phrase such as "A, B, and/or C" is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone).

[0104] It is understood that wherever aspects are described herein with the language "comprising," otherwise analogous aspects described in terms of "consisting of" and/or "consisting essentially of" are also provided.

[0105] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, may provide one of skill with a general dictionary of many of the terms used in this disclosure.

[0106] Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, amino acid sequences are written left to right in amino to carboxy orientation. The headings provided herein are not limitations of the various aspects of the disclosure. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0107] The term "about" is used herein to mean approximately, roughly, around, or in the regions of. When the term "about" is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term "about" can modify a numerical value above and below the stated value by a variance of, e.g., 10 percent, up or down (higher or lower). In some embodiments, the term indicates deviation from the indicated numerical value by $\pm 10\%$, $\pm 5\%$, $\pm 4\%$, $\pm 3\%$, $\pm 2\%$, $\pm 1\%$, $\pm 0.9\%$, $\pm 0.8\%$, $\pm 0.7\%$, $\pm 0.6\%$, $\pm 0.5\%$, $\pm 0.4\%$, $\pm 0.3\%$, $\pm 0.2\%$, $\pm 0.1\%$, $\pm 0.05\%$, or $\pm 0.01\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 10\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 5\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 4\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 3\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 2\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 1\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.9\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.8\%$. In

some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.7\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.6\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.5\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.4\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.3\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.1\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.05\%$. In some embodiments, "about" indicates deviation from the indicated numerical value by $\pm 0.01\%$.

[0108] Depending on context, the term "polynucleotide" or "nucleotide" may encompass a singular nucleic acid as well as plural nucleic acids. In some embodiments, a polynucleotide is an isolated nucleic acid molecule or construct, e.g., messenger RNA (mRNA) or plasmid DNA (pDNA). In some embodiments, a polynucleotide comprises a conventional phosphodiester bond. In some embodiments, a polynucleotide comprises a non-conventional bond (e.g., an amide bond, such as found in peptide nucleic acids (PNA)). The term "nucleic acid" may refer to any one or more nucleic acid segments, e.g., DNA or RNA fragments, present in a polynucleotide. By "isolated" nucleic acid or polynucleotide is intended a nucleic acid molecule, DNA or RNA, which has been removed from its native environment. For example, a recombinant polynucleotide encoding a Factor VIII polypeptide contained in a vector is considered isolated for the purposes of the present disclosure. Further examples of an isolated polynucleotide include recombinant polynucleotides maintained in heterologous host cells or purified (partially or substantially) from other polynucleotides in a solution. Isolated RNA molecules include *in vivo* or *in vitro* RNA transcripts of polynucleotides of the present disclosure. Isolated polynucleotides or nucleic acids according to the present disclosure further include such molecules produced synthetically. In addition, a polynucleotide or a nucleic acid can include regulatory elements such as promoters, enhancers, ribosome binding sites, or transcription termination signals.

[0109] Certain proteins secreted by mammalian cells are associated with a secretory signal peptide which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Those of ordinary skill in the art are aware that signal peptides are generally fused to the N-terminus of the polypeptide, and are cleaved from the complete or "full-length" polypeptide to produce a secreted or "mature" form of the polypeptide. In some embodiments, a native signal peptide or a functional derivative of that sequence that retains the ability to direct the secretion of the

polypeptide that is operably associated with it. Alternatively, a heterologous mammalian signal peptide, *e.g.*, a human tissue plasminogen activator (TPA) or mouse β -glucuronidase signal peptide, or a functional derivative thereof, can be used.

[0110] As used herein, the term "polypeptide" is intended to encompass a singular "polypeptide" as well as plural "polypeptides," and refers to a molecule composed of monomers (amino acids) linearly linked by amide bonds (also known as peptide bonds). The term "polypeptide" refers to any chain or chains of two or more amino acids, and does not refer to a specific length of the product. Thus, peptides, dipeptides, tripeptides, oligopeptides, "protein," "amino acid chain," or any other term used to refer to a chain or chains of two or more amino acids, are included within the definition of "polypeptide," and the term "polypeptide" can be used instead of, or interchangeably with any of these terms. The term "polypeptide" is also intended to refer to the products of post-expression modifications of the polypeptide, including without limitation glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, or modification by non-naturally occurring amino acids. A polypeptide can be derived from a natural biological source or produced recombinant technology, but is not necessarily translated from a designated nucleic acid sequence. It can be generated in any manner, including by chemical synthesis.

[0111] An "isolated" polypeptide or a fragment, variant, or derivative thereof refers to a polypeptide that is not in its natural milieu. No particular level of purification is required. For example, an isolated polypeptide can simply be removed from its native or natural environment. Recombinantly produced polypeptides and proteins expressed in host cells are considered isolated for the purpose of the disclosure, as are native or recombinant polypeptides which have been separated, fractionated, or partially or substantially purified by any suitable technique.

[0112] Also included in the present disclosure are fragments or variants of polypeptides, and any combination thereof. The term "fragment" or "variant" when referring to polypeptide binding domains or binding molecules of the present disclosure include any polypeptides which retain at least some of the properties (*e.g.*, FcRn binding affinity for an FcRn binding domain or Fc variant, coagulation activity for an FVIII variant, or FVIII binding activity for the VWF fragment) of the reference polypeptide. Fragments of polypeptides include proteolytic fragments, as well as deletion fragments, in addition to specific antibody fragments discussed elsewhere herein, but do not include the naturally occurring full-length polypeptide (or mature polypeptide). Variants of polypeptide binding domains or binding molecules of the present disclosure include fragments as described above, and

also polypeptides with altered amino acid sequences due to amino acid substitutions, deletions, or insertions. Variants can be naturally or non-naturally occurring. Non-naturally occurring variants can be produced using art-known mutagenesis techniques. Variant polypeptides can comprise conservative or non-conservative amino acid substitutions, deletions or additions.

[0113] The term "VWF protein" as used herein means any VWF fragment that interacts with FVIII and retains at least one or more properties that are normally provided to FVIII by full-length VWF, *e.g.*, preventing premature activation to FVIIIa, preventing premature proteolysis, preventing clearance, preventing association with phospholipid membranes that could lead to premature clearance, preventing binding to FVIII clearance receptors that can bind naked FVIII but not VWF-bound FVIII, and/or stabilizing the FVIII heavy chain and light chain interactions. A VWF fragment referred to herein is a VWF polypeptide that is less than the full-length VWF protein, wherein the VWF fragment retains the ability to interact with and/or bind to FVIII. In some embodiments, a VWF protein is a fragment (which may be mutated) of full-length VWF that binds to a FVIII protein such that the FVIII protein has reduced binding to, or does not bind, full length VWF (*e.g.*, endogenous VWF in a subject).

[0114] A "conservative amino acid substitution" is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (*e.g.*, lysine, arginine, histidine), acidic side chains (*e.g.*, aspartic acid, glutamic acid), uncharged polar side chains (*e.g.*, glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (*e.g.*, alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (*e.g.*, threonine, valine, isoleucine) and aromatic side chains (*e.g.*, tyrosine, phenylalanine, tryptophan, histidine). Thus, if an amino acid in a polypeptide is replaced with another amino acid from the same side chain family, the substitution is considered to be conservative. In some embodiments, a string of amino acids can be conservatively replaced with a structurally similar string that differs in order and/or composition of side chain family members.

[0115] As known in the art, "sequence identity" between two polypeptides is determined by comparing the amino acid sequence of one polypeptide to the sequence of a second polypeptide. Similarly, "sequence identity" between two polynucleotides is determined by comparing the nucleotide sequence of one polynucleotide to the sequence of a second polynucleotide. The terms "% identical", "% identity" or similar terms are intended to refer, in particular, to the percentage of nucleotides or amino acids (as applicable) which are identical in an optimal alignment between the sequences to be compared. Said percentage

is purely statistical, and the differences between the two sequences may be but are not necessarily randomly distributed over the entire length of the sequences to be compared. Comparisons of two sequences are usually carried out by comparing the sequences, after optimal alignment, with respect to a segment or "window of comparison", in order to identify local regions of corresponding sequences. For example, the optimal alignment for a comparison may be carried out manually or with the aid of the local homology algorithm by Smith and Waterman, 1981, *Adv. App. Math.* 2, 482, with the aid of the local homology algorithm by Needleman and Wunsch, 1970, *J. Mol. Biol.* 48, 443, with the aid of the similarity search algorithm by Pearson and Lipman, 1988, *Proc. Natl Acad. Sci. USA* 88, 2444, or with the aid of computer programs using said algorithms (GAP, BESTFIT, FASTA, BLAST P, BLAST N and TFASTA in Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, Wis.). In some embodiments, percent identity of two sequences is determined using the BLASTN or BLASTP algorithm, as available on the United States National Center for Biotechnology Information (NCBI) website (e.g., at blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE_TYPE=BlastSearch&BLAST_SPEC=blast2seq&LINK_LOC=align2seq). In some embodiments, the algorithm parameters used for BLASTN algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 28; (iii) Max matches in a query range set to 0; (iv) Match/Mismatch Scores set to 1, -2; (v) Gap Costs set to Linear; and (vi) the filter for low complexity regions being used. In some embodiments, the algorithm parameters used for BLASTP algorithm on the NCBI website include: (i) Expect Threshold set to 10; (ii) Word Size set to 3; (iii) Max matches in a query range set to 0; (iv) Matrix set to BLOSUM62; (v) Gap Costs set to Existence: 11 Extension: 1; and (vi) conditional compositional score matrix adjustment. When discussed herein, whether any particular polypeptide is at least about 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to another polypeptide can be determined using methods and computer programs/software known in the art such as, but not limited to, the BESTFIT program (Wisconsin Sequence Analysis Package, Version 8 for Unix, Genetics Computer Group, University Research Park, 575 Science Drive, Madison, WI 53711). BESTFIT uses the local homology algorithm of Smith and Waterman, *Advances in Applied Mathematics* 2:482-489 (1981), to find the best segment of homology between two sequences. When using BESTFIT or any other sequence alignment program to determine whether a particular sequence is, for example, 95% identical to a reference sequence according to the present disclosure, the parameters are set, of course, such that the percentage of identity is calculated over the full-length of the reference polypeptide

sequence and that gaps in homology of up to 5% of the total number of amino acids in the reference sequence are allowed.

- [0116]** As used herein, an "amino acid corresponding to" or an "equivalent amino acid" in a VWF sequence or a FVIII protein sequence is identified by alignment to maximize the identity or similarity between a first VWF or FVIII sequence and a second VWF or FVIII sequence. The number used to identify an equivalent amino acid in a second VWF or FVIII sequence is based on the number used to identify the corresponding amino acid in the first VWF or FVIII sequence.
- [0117]** As used herein, the term "insertion site" refers to a position in a FVIII polypeptide, or fragment, variant, or derivative thereof, which is immediately downstream of the position at which a half-life extending moiety or heterologous moiety can be inserted. An "insertion site" is specified as a number, the number being the number of the amino acid in mature native FVIII (SEQ ID NO: 9) to which the insertion site corresponds, which is immediately C-terminal to the position of the insertion. For example, the phrase "comprises an ELNN Polypeptide at an insertion site which corresponds to amino acid 1656 of SEQ ID NO: 9" indicates that the heterologous moiety is located between two amino acids corresponding to amino acid 1656 and amino acid 1657 of SEQ ID NO: 9.
- [0118]** The phrase "immediately downstream of an amino acid" as used herein refers to position right next to the terminal carboxyl group of the amino acid. For example, an insertion site immediately downstream of amino acid 745 corresponding to the mature wild type FVIII protein (SEQ ID NO: 9) means that the insertion site is between amino acid 745 and amino acid 746 corresponding to the mature wild type FVIII protein. Similarly, the phrase "immediately upstream of an amino acid" refers to the position right next to the terminal amine group of the amino acid.
- [0119]** The phrase "between two amino acids of an insertion site" as used herein refers to a position in which an ELNN Polypeptide or any other polypeptide is inserted between two adjacent amino acids. Thus, the phrases "inserted immediately downstream of an amino acid" and "inserted between two amino acids of an insertion site" are used synonymously with "inserted at an insertion site."
- [0120]** The terms "inserted," "is inserted," "inserted into" or grammatically related terms, as used herein with respect to insertions of ELNN Polypeptide into FVIII refers to the position of an ELNN Polypeptide in a chimeric protein relative to the analogous position in native mature human FVIII. As used herein the terms refer to the characteristics of the recombinant FVIII polypeptide relative to native mature human FVIII, and do not indicate, imply or infer any methods or process by which the chimeric protein was made. For example, in reference

to a chimeric protein provided herein, the phrase "an ELNN Polypeptide is inserted immediately downstream of residue 745 of the FVIII polypeptide" means that the chimeric protein comprises an ELNN Polypeptide immediately downstream of an amino acid which corresponds to amino acid 745 in native mature human FVIII, e.g., bounded by amino acids corresponding to amino acids 745 and 746 of native mature human FVIII (without requiring the presence of an amino acid corresponding to 746 of native mature human FVIII), and does not connote an order or method of production for which the chimeric protein was constructed.

[0121] As used herein, the terms "ELNN Polypeptide" and "ELNN" are synonymous, and refer to extended length polypeptides with non-naturally occurring, substantially non-repetitive sequences that are composed mainly of small hydrophilic amino acids, with the sequence having a low degree or no secondary or tertiary structure under physiologic conditions. ELNNs can confer certain desirable pharmacokinetic, physicochemical and pharmaceutical properties when linked to a VWF protein or a FVIII sequence of the disclosure to create a chimeric polypeptide. Such desirable properties include but are not limited to enhanced pharmacokinetic parameters and solubility characteristics. As used herein, the terms "ELNN Polypeptide" and "ELNN" specifically exclude antibodies or antibody fragments such as single-chain antibodies or Fc fragments of a light chain or a heavy chain. ELNN polypeptides are known in the art, and non-limiting descriptions relating to and examples of ELNN polypeptides known as XTEN® polypeptides are available in Schellenberger et al., (2009) *Nat Biotechnol* 27(12):1186-90; Brandl et al., (2020) *Journal of Controlled Release* 327:186-197; and Radon et al., (2021) *Advanced Functional Materials* 31, 2101633 (pages 1-33), the entire contents of each of which are incorporated herein by reference.

[0122] A "fusion" or "chimeric" protein comprises a first amino acid sequence linked to a second amino acid sequence with which it is not naturally linked in nature. The amino acid sequences which normally exist in separate proteins can be brought together in the fusion polypeptide, or the amino acid sequences which normally exist in the same protein can be placed in a new arrangement in the fusion polypeptide, e.g., fusion of a Factor VIII domain of the disclosure with an Ig Fc domain. A fusion protein is created, for example, by chemical synthesis, or by creating and translating a polynucleotide in which the peptide regions are encoded in the desired relationship. A chimeric protein can further comprise a second amino acid sequence associated with the first amino acid sequence by a covalent, non-peptide bond or a non-covalent bond.

[0123] With respect to sequences, the term "linked" as used herein refers to a first amino acid sequence or nucleotide sequence covalently or non-covalently joined to a second amino acid sequence or nucleotide sequence, respectively. The first amino acid or nucleotide sequence can be directly joined or juxtaposed to the second amino acid or nucleotide sequence or alternatively an intervening sequence can covalently join the first sequence to the second sequence. Depending on context, the term "linked" means not only a fusion of a first amino acid sequence to a second amino acid sequence at the C-terminus or the N-terminus, but also includes insertion of the whole first amino acid sequence (or the second amino acid sequence) into any two amino acids in the second amino acid sequence (or the first amino acid sequence, respectively). In some embodiments, the first amino acid sequence can be linked to a second amino acid sequence by a peptide bond or a linker. The first nucleotide sequence can be linked to a second nucleotide sequence by a phosphodiester bond or a linker. The linker can be a peptide or a polypeptide (for polypeptide chains) or a nucleotide or a nucleotide chain (for nucleotide chains) or any chemical moiety (for both polypeptide and polynucleotide chains). The term "linked" may also be indicated by a hyphen (-).

[0124] With respect to two polypeptides, the term "associated with" refers to one or more covalent or non-covalent bonds formed between a first polypeptide and a second polypeptide. In some embodiments, the term "associated with" means a covalent, non-peptide bond or a non-covalent bond. This association can be indicated by a colon, *i.e.*, (:). In some embodiments, it means a covalent bond except a peptide bond. For example, the amino acid cysteine comprises a thiol group that can form a disulfide bond or bridge with a thiol group on a second cysteine residue. In most naturally occurring IgG molecules, the CH1 and CL regions are associated by a disulfide bond and the two heavy chains are associated by two disulfide bonds at positions corresponding to 239 and 242 using the Kabat numbering system (position 226 or 229, EU numbering system). Examples of covalent bonds include, but are not limited to, a peptide bond, a metal bond, a hydrogen bond, a disulfide bond, a sigma bond, a pi bond, a delta bond, a glycosidic bond, an agnostic bond, a bent bond, a dipolar bond, a Pi backbond, a double bond, a triple bond, a quadruple bond, a quintuple bond, a sextuple bond, conjugation, hyperconjugation, aromaticity, hapticity, or antibonding. Non-limiting examples of non-covalent bond include an ionic bond (*e.g.*, cation-pi bond or salt bond), a metal bond, a hydrogen bond (*e.g.*, dihydrogen bond, dihydrogen complex, low-barrier hydrogen bond, or symmetric hydrogen bond), van der Waals force, London dispersion force, a mechanical bond, a halogen bond, aurophilicity, intercalation, stacking, entropic force, or chemical polarity. In some

embodiments, the one or more covalent bonds between the first amino acid chain and the second amino acid chain is two disulfide bonds. In some embodiments, the one or more covalent bonds between the first amino acid chain and the second amino acid chain is two disulfide bonds between a first Fc portion on the first amino acid chain and a second Fc portion on the second amino acid chain, wherein the two disulfide bonds occur in the hinge region of the two Fc portions.

[0125] In some embodiments, a polypeptide has an enzymatic cleavage site cleaved by an enzyme that is activated during the clotting cascade, such that cleavage of such sites occurs at the site of clot formation. Exemplary such sites include, e.g., those recognized by thrombin, Factor XIa or Factor Xa. SEQ ID NO: 9 SEQ ID NO: 15 Other enzymatic cleavage sites are known in the art and described in elsewhere herein. In constructs that include more than one processing or cleavage site, it will be understood that such sites can be the same or different. As used herein, the term "half-life" refers to a biological half-life of a particular polypeptide *in vivo*. Half-life can be represented by the time required for half the quantity administered to a subject to be cleared from the circulation and/or other tissues in the animal. In some embodiments, when a clearance curve of a given polypeptide is constructed as a function of time, the curve is usually biphasic with a rapid α -phase and longer β -phase. The α -phase typically represents an equilibration of the administered Fc polypeptide between the intra- and extra-vascular space and is, in part, determined by the size of the polypeptide. The β -phase typically represents the catabolism of the polypeptide in the intravascular space. In some embodiments, FVIII and chimeric proteins comprising FVIII are monophasic, and thus do not have an alpha phase, but just the single beta phase. Therefore, in some embodiments, the term half-life as used herein refers to the half-life of the polypeptide in the β -phase. The typical beta phase half-life of a human antibody in humans is 21 days. In some embodiments, the half-life is expressed as the half-life of the terminal phase.

[0126] In some embodiments, a subject has hemophilia A. In some embodiments, the hemophilia A is severe hemophilia A.

[0127] "Administer" or "administering," as used herein refers to delivering to a subject a composition described herein, e.g., a chimeric protein. The composition, e.g., the chimeric protein, can be administered to a subject using methods known in the art. In particular, the composition can be administered intravenously, subcutaneously, intramuscularly, intradermally, or via any mucosal surface, e.g., orally, sublingually, buccally, nasally, rectally, vaginally or via pulmonary route. In some embodiments, the administration is intravenous. In some embodiments, the administration is subcutaneous. In some

embodiments, the administration is self-administration. In some embodiments, a parent administers the chimeric protein to a child. In some embodiments, the chimeric protein is administered to a subject by a healthcare practitioner such as a medical doctor, a medic, or a nurse.

[0128] As used herein, the term "dose" refers to a single administration of a composition to a subject. A single dose can be administered all at once, e.g., as a bolus, or over a period of time, e.g., via an intravenous infusion. The term "multiple doses" means more than one dose, e.g., more than one administration.

[0129] When referring to co-administration of more than one composition, a dose of composition A can be administered concurrently with a dose of composition B. Alternatively, a dose of composition A can be administered before or after a dose of composition B. In some embodiments, composition A and composition B are combined into a single formulation.

[0130] As used herein, the term "interval" or "dosing interval" refers to the amount of time that elapses between a first dose of composition A and a subsequent dose of the same composition administered to a subject. A dosing interval can refer to the time that elapses between a first dose and a second dose, or a dosing interval can refer to the amount of time that elapses between multiple doses.

[0131] The term "dosing frequency" as used herein refers to the number of doses administered per a specific dosing interval. For example, a dosing frequency can be written as once a week, once every two weeks, etc. Therefore, a dosing interval of 7 days can be also written as a dosing interval of once in 7 days or once every week, or once a week.

[0132] As used herein the term "prophylactic treatment" refers to the administration of a therapy for the treatment of hemophilia A, where such treatment is intended to prevent or reduce the severity of one or more symptoms of hemophilia A, e.g., bleeding episodes, e.g., one or more spontaneous bleeding episodes, and/or joint damage. See Jimenez-Yuste et al., *Blood Transfus.* 12(3):314-19 (2014). To prevent or reduce the severity of such symptoms, e.g., bleeding episodes and the progression of joint disease, hemophilia A patients may receive regular infusions of clotting factor as part of a prophylactic treatment regimen. The basis of such prophylactic treatment is the observation that hemophilia patients with a clotting factor, e.g., FVIII, level of 1% or more rarely experience spontaneous bleeding episodes and have fewer hemophilia-related comorbidities as compared to patients with severe hemophilia. See, e.g., Coppola A. et al, *Semin. Thromb. Hemost.* 38(1): 79-94 (2012). Health care practitioners treating these hemophilia patients surmised that maintaining factor levels at around 1% with regular infusions could potentially reduce the risk of hemophilia symptoms, including bleeding episodes and joint damage. See id.

Subsequent research has confirmed these benefits in pediatric hemophilia patients receiving prophylactic treatment with clotting factor, rendering prophylactic treatment the goal for people with severe hemophilia. See id.

[0133] A "prophylactic" treatment can also refer to the preemptive administration of the composition described herein, e.g., a protein (such as a chimeric protein), to a subject in order to control, manage, prevent, or reduce the occurrence or severity of one or more symptoms of hemophilia A, e.g., bleeding episodes. In some embodiments, prophylactic treatment with a clotting factor, e.g., FVIII, is used to treat subjects with severe hemophilia A. In some embodiments, prophylactic treatment refers to administering a composition disclosed herein to a subject in need thereof to reduce the occurrence of one or more symptom of hemophilia A. A prophylactic treatment can include administration of multiple doses. The multiple doses used in prophylactic treatment are typically administered at particular dosing intervals. In some embodiments, the annualized bleeding rate can be reduced to less than 10, less than 9, less than 8, less than 7, less than 6, less than 5, less than 4, less than 3, less than 2, or less than 1.

[0134] The term "on-demand treatment" or "episodic treatment" refers to the "as needed" administration of a chimeric molecule in response to symptoms of hemophilia A, e.g., a bleeding episode, or before an activity that can cause bleeding. In some aspects, the on-demand treatment can be given to a subject when bleeding starts, such as after an injury, or when bleeding is expected, such as before surgery. In some aspects, the on-demand treatment can be given prior to activities that increase the risk of bleeding, such as contact sports. In some embodiments, the on-demand treatment is given as a single dose. In some embodiments, the on-demand treatment is given as a first dose, followed by one or more additional doses. When the chimeric protein is administered on-demand, the one or more additional doses can be administered at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, at least about 60 hours, at least about 72 hours, at least about 84 hours, at least about 96 hours, at least about 108 hours, or at least about 120 hours after the first dose. It should be noted, however, that the dosing interval associated with on-demand treatment is not the same as the dosing interval used for prophylactic treatment.

[0135] In some embodiments, the subject in need of a general hemostatic agent is undergoing, or is about to undergo, surgery. The chimeric protein of the disclosure can be administered prior to or after surgery. The chimeric protein of the disclosure can also be administered during or after surgery to control an acute bleeding episode. When the chimeric protein is administered prior to surgery, the administration can be at least about 1 hour, at least

about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, or at least about 72 hours prior to surgery. When the chimeric protein is administered to after surgery, the administration can be at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, at least about 24 hours, at least about 36 hours, at least about 48 hours, or at least about 72 hours after surgery. The surgery can include, but is not limited to, liver transplantation, liver resection, dental procedures, or stem cell transplantation.

[0136] “Treat”, “treatment”, “treating”, as used herein refers to, e.g., the reduction in severity of a disease or condition; the reduction in the duration of a disease course; the amelioration of one or more symptoms associated with a disease or condition; the provision of beneficial effects to a subject with a disease or condition, without necessarily curing the disease or condition, or the prophylaxis of one or more symptoms associated with a disease or condition. In some embodiments, treating or treatment comprises maintaining a FVIII trough level at least about 1 IU/dL, 2 IU/dL, 3 IU/dL, 4 IU/dL, 5 IU/dL, 6 IU/dL, 7 IU/dL, 8 IU/dL, 9 IU/dL, 10 IU/dL, 11 IU/dL, 12 IU/dL, 13 IU/dL, 14 IU/dL, 15 IU/dL, 16 IU/dL, 17 IU/dL, 18 IU/dL, 19 IU/dL, or 20 IU/dL in a subject by administering a chimeric protein of the disclosure. As used herein, a “trough level” in a hemophilia A patient is the measurement of the lowest concentration reached by a factor therapy, e.g., a FVIII therapy, before the next dose is administered. In some embodiments, treating or treatment means maintaining a FVIII trough level of at least about 1 IU/dL between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII trough level of at least about 3 IU/dL between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII trough level of at least about 5 IU/dL between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII trough level between about 1 and about 20 IU/dL, about 2 and about 20 IU/dL, about 3 and about 20 IU/dL, about 4 and about 20 IU/dL, about 5 and about 20 IU/dL, about 6 and about 20 IU/dL, about 7 and about 20 IU/dL, about 8 and about 20 IU/dL, about 9 and about 20 IU/dL, or about 10 and about 20 IU/dL during the dosing interval.

[0137] In some embodiments, treatment or treating of a disease or condition comprises maintaining FVIII activity in a subject at a level comparable to at least about 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20% of the FVIII activity in a non-hemophiliac subject between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 1% between the dosing interval. In some embodiments, treating or treatment means

maintaining a FVIII activity level of at least about 2% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 3% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 4% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 5% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 6% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 7% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 8% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 9% between the dosing interval. In some embodiments, treating or treatment means maintaining a FVIII activity level of at least about 10% between the dosing interval. In some embodiments, the minimum trough level required for treatment can be measured by one or more known methods (for example, the activated partial thromboplastin time (aPTT) assays or chromogenic assays, which are well known in the art) and can be adjusted (increased or decreased) for each person. Non-limiting examples of assays for measuring trough level are disclosed in U.S. Application Publication No. 20190375822, which is hereby incorporated by reference in its entirety.

II. Chimeric Proteins

[0138] In an aspect, the present disclosure is directed to pharmaceutical compositions comprising a chimeric protein or protein which comprises a first polypeptide chain which comprises a Factor VIII ("FVIII") protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof. In some embodiments, the chimeric protein comprises (i) a FVIII protein comprising a FVIII polypeptide, an ELNN Polypeptide inserted within the B domain of the FVIII polypeptide, and a first Fc region; and (ii) a VWF protein comprising a VWF fragment, a second ELNN Polypeptide sequence, an $\alpha 2$ linker, and a second Fc region. In some embodiments, the chimeric protein disclosed herein is a FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer.

[0139] In some embodiments, the chimeric protein is efanesoctocog alfa. Efanesoctocog alfa, also known as "BIVV001", "efanesoctocogum alfa", "rFVIII-Fc-VWF-ELNN", and "rFVIII-Fc-VWF-XTEN", is described in Chhabra et al. *Blood* 135(17): 1484-1496 (2020), the entire contents of which are hereby incorporated by reference in its entirety. A schematic

representation of efanesoctocog alfa, as an exemplary FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer, is presented in FIG. 1.

- [0140]** Efanesoctocog alfa is a large protein (over 300 kDa) comprising multiple parts on each of two polypeptide chains that are associated by covalent bonds and non-covalent interactions. The protein has a tendency to aggregate under certain conditions, which can reduce the stability of formulations unless an excipient such as L-arginine is selected and present in an amount that is sufficient to reduce the aggregation. For example, the aggregation may be reduced by adding high levels of L-arginine (e.g., about 250 mM).
- [0141]** Additional information regarding efanesoctocog alfa can be found in the International Nonproprietary Names for Pharmaceutical Substances (INN) WHO Drug Information, 2019, Vol. 33, No. 4, p.828-30. In some embodiments, the chimeric protein is a FVIII-ELNN-Fc/D'D3-ELNN-Fc heterodimer comprising (i) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and (ii) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises (i) a first polypeptide and (ii) a second polypeptide that are covalently linked via one or more disulfide bonds (e.g., two disulfide bonds). In some embodiments, the chimeric protein comprises a FVIII protein encoded by the nucleic acid sequence of SEQ ID NO: 4. In some embodiments, the chimeric protein comprises a VWF protein encoded by the nucleic acid sequence of SEQ ID NO: 6. In some embodiments, the efanesoctocog alfa has an activity of at least 1600 IU/mg. In some embodiments, the efanesoctocog alfa has an activity of at least 1700 IU/mg. In some embodiments, the efanesoctocog alfa has an activity of at least 1800 IU/mg. In some embodiments, the efanesoctocog alfa has an activity of at least 1900 IU/mg. In some embodiments, the efanesoctocog alfa has an activity of 1600 IU/mg to 2000 IU/mg.
- [0142]** In some embodiments, the chimeric protein comprises a FVIII protein comprising the amino acid sequence of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII protein comprising one or more disulfide bridges at one or more of the following locations: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, and/or 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII protein comprising one or more disulfide bridges at each of the following locations: residues 153-179, 248-329, 528-554, 630-711, 1220-1246, 1287-1291, 1409-1557, 1562-1714, 1761-1821, and 1867-1925 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII protein comprising one or more Cys-SH residues at residues 310, 692, and/or 1388 of SEQ ID

NO: 1. In some embodiments, the chimeric protein comprises a FVIII protein comprising a Cys-SH residues at each of residues 310, 692, and/or 1388 of SEQ ID NO: 1.

[0143] In some embodiments, the chimeric protein comprises a FVIII protein comprises one or more N-glycosylation sites at residues N41, N239, N1198, N1506, and/or N1797 of SEQ ID NO: 1. In some embodiments, the chimeric protein comprises a FVIII protein comprises one or more O-glycosylation sites at residues 746-1036 of SEQ ID NO: 1 and/or the Ser and Thr residues in the linker peptides. In some embodiments, the chimeric protein comprises a FVIII protein comprises one or more Tyr-sulfation sites at residues 346, 718, 719, 723, 729, 1052, and/or 1068 of SEQ ID NO: 1.

[0144] In some embodiments, the chimeric protein comprises a VWF protein comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein comprising one or more disulfide bridges at one or more of the following locations: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758, and/or 804-862 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein comprising one or more disulfide bridges at each of the following locations: residues 4-45, 13-41, 25-36, 29-64, 47-58, 66-88, 83-100, 86-95, 104-233, 126-268, 135-230, 151-158, 283-326, 297-321, 308-348, 328-334, 338-363, 367-410, 386-406, 390-402, 394-433, 414-427, 436-464, 459-474, 462-471, 698-758, and/or 804-862 of SEQ ID NO: 2.

[0145] In some embodiments, the chimeric protein comprises a VWF protein comprises one or more N-glycosylation sites at residues N94, N384, N734 of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a VWF protein comprises one or more O-glycosylation sites at residues 478-625 of SEQ ID NO: 2 and/or the Ser and Thr residues in the linker peptides. In some embodiments, the chimeric protein comprises a VWF protein comprises one or more Tyr-sulfation sites at residues 632, 633, 637, and/or 643 of SEQ ID NO: 2. In some embodiments, the VWF protein comprises a VWF fragment comprising a D1, D2, D', and/or D3 domain of VWF. In one embodiment, the VWF fragment comprises a D1D2 region of VWF comprising the amino acid sequence of SEQ ID NO: 20. In some embodiments, the VWF protein further comprises a VWF signal peptide sequence. In one embodiment, the VWF signal peptide comprises the amino acid sequence of SEQ ID NO: 19. In one specific embodiment, the VWF protein comprises a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 19, a D1D2 region of VWF comprising the amino acid sequence of SEQ ID NO: 20, a D' domain of VWF

comprising the amino acid sequence of SEQ ID NO: 21, a D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 22, an ELNN Polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 14 (AE144_5A), an a2 linker comprising the amino acid sequence of SEQ ID NO: 15, and/or a Fc region comprising the amino acid sequence of SEQ ID NO: 23.

[0146] In some embodiments, the chimeric protein of the present disclosure comprises: (i) a FVIII protein comprising a FVIII polypeptide, a first ELNN Polypeptide sequence, and a first Fc region; and (ii) a VWF fragment comprising a D' domain of VWF and a D3 domain of VWF, a second ELNN Polypeptide sequence, an a2 linker of FVIII, and a second Fc region; wherein: the FVIII protein has a deletion of amino acids 746 to 1648 corresponding to mature FVIII; the first ELNN Polypeptide sequence is inserted within the FVIII polypeptide immediately downstream of amino acid 745 corresponding to mature FVIII; the first ELNN Polypeptide sequence comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence of AE288 (SEQ ID NO: 9); the first Fc region is fused to the C-terminus of the FVIII polypeptide; the second ELNN Polypeptide sequence is fused to the C-terminus of the VWF fragment; the second ELNN Polypeptide sequence comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence of AE144_5A (SEQ ID NO: 14); the a2 linker is fused to the C-terminus of the ELNN Polypeptide; the a2 linker comprises an amino acid sequence having at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% sequence identity to the amino acid sequence of SEQ ID NO: 9; the second Fc region is fused to the C-terminus of the a2 linker; and the first Fc region is covalently linked to the second Fc region by a disulfide bond(e.g., two disulfide bonds).

[0147] In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 1; and a second polypeptide sequence comprising a VWF fragment comprising a D' domain of VWF and a D3 domain of VWF and an Fc region. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first

polypeptide sequence comprising FVIII polypeptide and an Fc region; and a second polypeptide sequence comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 7 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked to each other by a disulfide bond. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence and the second polypeptide sequence are linked to each other by two disulfide bonds. In some embodiments, the chimeric protein of the disclosure comprises two polypeptide sequences, a first polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 1 and a second polypeptide sequence comprising the amino acid sequence set forth in SEQ ID NO: 2, wherein the first polypeptide sequence comprises a first Fc portion, wherein the second polypeptide sequence comprises a second Fc portion, wherein the first Fc portion and the second Fc portion are linked to each other by two disulfide bonds in the hinge region.

[0148] In some embodiments, the chimeric protein of the disclosure comprises a FVIII protein comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to SEQ ID NO: 7, SEQ ID NO: 3, or SEQ ID NO: 1; and a VWF protein comprising an amino acid sequence at least about 80%, 90%, 95%, or 100% identical to SEQ ID NO: 2 or SEQ ID NO: 5.

[0149] In some embodiments, the chimeric protein of the disclosure comprises: (i) a FVIII protein comprising a first FVIII polypeptide fragment comprising the amino acid sequence of SEQ

ID NO: 17; a first ELNN Polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 9 (AE288); a second FVIII polypeptide fragment comprising the amino acid sequence of SEQ ID NO: 18; and a first Fc region comprising the amino acid sequence of SEQ ID NO: 23; and (ii) a VWF protein comprising: a D' domain of VWF comprising the amino acid sequence of SEQ ID NO: 21; a D3 domain of VWF comprising the amino acid sequence of SEQ ID NO: 22; a second ELNN Polypeptide sequence comprising the amino acid sequence of SEQ ID NO: 14 (AE144_5A); an a2 linker comprising the amino acid sequence of SEQ ID NO: 15; and a second Fc region comprising the amino acid sequence of SEQ ID NO: 23, and wherein the first Fc region is covalently linked to the second Fc region by a disulfide bond (e.g., two disulfide bonds).

[0150] In some embodiments, the chimeric protein of the disclosure comprises a FVIII protein comprising a FVIII polypeptide, a first ELNN Polypeptide sequence, a first Fc region, and a VWF protein comprising a D' domain of VWF, a D3 domain of VWF, a second ELNN Polypeptide sequence, an a2 linker of FVIII and a second Fc region, wherein the FVIII polypeptide comprises the amino acid sequence of SEQ ID NO: 17, the first ELNN Polypeptide sequence comprises the amino acid sequence of AE288 (SEQ ID NO: 9) and is fused to the C-terminus of SEQ ID NO: 17, the FVIII polypeptide further comprises the amino acid sequence of SEQ ID NO: 18, the first Fc region comprises the amino acid sequence of SEQ ID NO: 23 and is fused to the C-terminus of SEQ ID NO: 18; the D' domain of VWF comprises the amino acid sequence of SEQ ID NO: 21; the D3 domain of VWF comprises the amino acid sequence of SEQ ID NO: 214, the second ELNN Polypeptide sequence comprises the amino acid sequence of AE144_5A (SEQ ID NO: 14) and is fused to the C-terminus of the D3 domain of VWF; the a2 linker comprises the amino acid sequence of SEQ ID NO: 15 and is fused to the C-terminus of the second ELNN Polypeptide sequence; the second Fc region comprises the amino acid sequence of SEQ ID NO: 23 and is fused to the C-terminus of the a2 linker; and wherein the first Fc region is covalently linked to the second Fc region by a disulfide bond.

[0151] In some embodiments, the chimeric protein of the disclosure comprises a FVIII protein comprising a FVIII signal peptide comprising the amino acid sequence of SEQ ID NO: 16. In some embodiments, the chimeric protein comprises a VWF protein comprising a VWF signal peptide comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, the chimeric protein comprises a VWF protein comprising a D1D2 domain of VWF comprising the amino acid sequence of SEQ ID NO: 20.

[0152] In some embodiments, the chimeric protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 3 and a second polypeptide comprising the amino

acid sequence of SEQ ID NO: 5. In some embodiments, the chimeric protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 7 and a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2. In some embodiments, the chimeric protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2.

[0153] In some embodiments, the chimeric protein comprises one or more disulfide bridges between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises two disulfide bridges between the first polypeptide and the second polypeptide. In some embodiments, the chimeric protein comprises a first polypeptide comprising the amino acid sequence of SEQ ID NO: 1 and a second polypeptide comprising the amino acid sequence of SEQ ID NO: 2, wherein the chimeric protein comprises a disulfide bridge between residue 1726 of SEQ ID NO: 1 and residue 663 of SEQ ID NO: 2, and a disulfide bridge between residue 1729 of SEQ ID NO: 1 and residue 666 of SEQ ID NO: 2.

IV. Pharmaceutical Compositions

[0154] In an aspect, the present disclosure is directed to pharmaceutical compositions of a chimeric protein which are formulated to improve protein stability. In some embodiments, the disclosed pharmaceutical compositions demonstrate increased stability based on analysis by visual inspection, protein concentration, pH stability, formation of high molecular weight species (HMWS), and/or change in turbidity. Analysis of these properties of stability can be made using conventional techniques, including size exclusion chromatography (SEC), reversed-phase high-performance liquid chromatography (RP-HPLC), and many others.

[0155] The pharmaceutical compositions disclosed herein comprise a specified amount of the chimeric protein. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 0.8 to about 1.2 mg/mL. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 0.8 mg/mL. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 0.9 mg/mL. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 1.0 mg/mL. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 1.1 mg/mL. In some embodiments, the pharmaceutical composition has a chimeric protein concentration of about 1.2 mg/mL.

[0156] In some embodiments, the pharmaceutical composition comprises about 75 IU/mL to about 2,000 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 75 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 100 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 150 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 200 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 250 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 300 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 350 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 400 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 450 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 500 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 550 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 600 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 650 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 700 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 750 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 800 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 850 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 900 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 950 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1000 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 250 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 300 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 500 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises at least about 500 IU of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 85 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises more than about 100 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises

more than about 200 IU/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises at least about 200 IU/ml of the chimeric protein.

[0157] In some embodiments, the pharmaceutical composition comprises about 1100 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1150 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1200 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1250 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1300 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1350 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1400 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1450 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1500 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1550 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1600 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1650 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1700 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1750 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1800 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1850 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1900 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1950 IU/mL of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 2000 IU/mL of the chimeric protein.

[0158] Pharmaceutical compositions containing the chimeric protein of the present disclosure also contain a suitable pharmaceutically acceptable carrier. For example, they can contain excipients and/or auxiliaries that provide enhanced stability of the chimeric protein or facilitate processing of the active compounds into preparations designed for delivery to the site of action.

[0159] In an aspect, disclosed herein are pharmaceutical compositions comprising a specified amount of a chimeric protein along with excipients as disclosed. The pharmaceutical compositions disclosed herein comprise various concentrations of these excipients as disclosed, and the concentrations can be expressed in various ways. For example, the

concentration of a given excipient can be expressed as a molar concentration (e.g., M or mM), as a weight/volume percent, (e.g., grams per 100 ml diluent), or as milligrams per milliliter (mg/ml). Pharmaceutical compositions provided herein can contain specified amounts of the various excipients at a level of precision ranging from approximate, e.g., concentrations expressed only to one significant figure (e.g., about 0.1% (w/v)), or with more precision, e.g., out to 2, 3, 4, 5, or 6 significant figures (e.g., about 3.88 mg/ml, with precision out to three significant figures). The necessary level of precision can vary depending on, e.g., the requirements of a given regulatory agency, or the manufacturing process.

[0160] In some embodiments, the pharmaceutical composition comprises 1% (w/v) to 4% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises 2% (w/v) to 5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises 4% (w/v) to 8% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.5% (w/v) to about 2.5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 5% (w/v) to about 7.5% (w/v) sucrose.

[0161] In some embodiments, the pharmaceutical composition comprises about 1.0% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.1% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.2% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.3% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.4% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.6% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.7% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.8% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 1.9% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.0% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.1% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.2% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.3% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.4% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.6% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 2.7% (w/v) sucrose. In

[illegible]

comprises about 5.9% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.1% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.2% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.3% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.4% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.6% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.7% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.8% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 6.9% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.1% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.2% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.3% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.4% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.5% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.6% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.7% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.8% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 7.9% (w/v) sucrose. In some embodiments, the pharmaceutical composition comprises about 8% (w/v) sucrose.

[0162] In some embodiments, the pharmaceutical composition comprises about 33.67 mg sucrose. In some embodiments, the pharmaceutical composition comprises about 67.34 mg sucrose. In some embodiments, the pharmaceutical composition comprises about 168.35 mg sucrose. In some embodiments, the amount of sucrose can vary up to 10% of a specific amount. In some embodiments, the amount of sucrose can vary up to 5% of a specific amount. In some embodiments, the amount of sucrose can vary up to 1% of a specific amount. In some embodiments, the specific amount of sucrose is 33.67 mg, 67.34 mg, or 168.35 mg.

[0163] Pharmaceutical compositions disclosed herein may include a buffer. In some embodiments, the pharmaceutical compositions disclosed herein include specified amounts or concentrations of histidine. In some embodiments, the histidine included in the

pharmaceutical composition is L-histidine. In some embodiments, the pharmaceutical composition comprises about 5 mM to about 15 mM histidine.

[0164] In some embodiments, the pharmaceutical composition comprises about 5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 5.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 6 mM histidine. In some embodiments, the pharmaceutical composition comprises about 6.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 7 mM histidine. In some embodiments, the pharmaceutical composition comprises about 7.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 8 mM histidine. In some embodiments, the pharmaceutical composition comprises about 8.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 9 mM histidine. In some embodiments, the pharmaceutical composition comprises about 9.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 10 mM histidine. In some embodiments, the pharmaceutical composition comprises about 10.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 11 mM histidine. In some embodiments, the pharmaceutical composition comprises about 11.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 12 mM histidine. In some embodiments, the pharmaceutical composition comprises about 12.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 13 mM histidine. In some embodiments, the pharmaceutical composition comprises about 13.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 14 mM histidine. In some embodiments, the pharmaceutical composition comprises about 14.5 mM histidine. In some embodiments, the pharmaceutical composition comprises about 15 mM histidine. In some embodiments, the histidine is L-histidine.

[0165] In some embodiments, the pharmaceutical compositions disclosed herein include specified amounts or concentrations of arginine. In some embodiments, the pharmaceutical composition comprises arginine hydrochloride (HCl). In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl.

[0166] In some embodiments, the pharmaceutical composition comprises about 200 mM to about 300 mM arginine.

[0167] In some embodiments, the pharmaceutical composition comprises about 200 mM arginine. In some embodiments, the pharmaceutical composition comprises about 210 mM arginine. In some embodiments, the pharmaceutical composition comprises about 220 mM arginine.

In some embodiments, the pharmaceutical composition comprises about 230 mM arginine. In some embodiments, the pharmaceutical composition comprises about 240 mM arginine. In some embodiments, the pharmaceutical composition comprises about 250 mM arginine. In some embodiments, the pharmaceutical composition comprises about 260 mM arginine. In some embodiments, the pharmaceutical composition comprises about 270 mM arginine. In some embodiments, the pharmaceutical composition comprises about 280 mM arginine. In some embodiments, the pharmaceutical composition comprises about 290 mM arginine. In some embodiments, the pharmaceutical composition comprises about 300 mM arginine. In some embodiments, the arginine is L-arginine. In some embodiments, the composition comprises L-arginine-HCl.

[0168] Pharmaceutical compositions disclosed herein may include a bulking agent. In some embodiments, the pharmaceutical compositions disclosed herein include specified amounts or concentrations of calcium chloride (CaCl_2). In some embodiments, the composition comprises $\text{CaCl}_2 \bullet 2\text{H}_2\text{O}$, CaCl_2 (anhydrous), $\text{CaCl}_2 \bullet 4\text{H}_2\text{O}$, or $\text{CaCl}_2 \bullet 6\text{H}_2\text{O}$. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride. In some embodiments, the composition comprises calcium chloride dihydrate.

[0169] In some embodiments, the pharmaceutical composition comprises about 2.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 3 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 3.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 4 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 4.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 5.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 6 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 6.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 7 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 7.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 8 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 8.5 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 9 mM calcium chloride. In some embodiments, the pharmaceutical composition comprises about 9.5 mM calcium chloride.

In some embodiments, the pharmaceutical composition comprises about 10 mM calcium chloride. In some embodiments, the composition comprises calcium chloride dihydrate.

[0170] In some embodiments, the pharmaceutical compositions disclosed herein do not include bulking agents other than calcium chloride. In some embodiments, calcium chloride is the sole bulking agent. In some embodiments, the pharmaceutical composition comprises less than 8.8 mg/mL sodium chloride (NaCl). In some embodiments, the pharmaceutical composition is substantially free of sodium chloride. In some embodiments, the pharmaceutical composition is free of sodium chloride.

[0171] In some embodiments, the pharmaceutical compositions disclosed herein include specified amounts or concentrations of poloxamer 188 (P188). In some embodiments, the poloxamer is poloxamer 101, 105, 108, 122, 123, 124, 181, 182, 183, 184, 185, 188, 212, 215, 217, 231, 234, 235, 237, 238, 282, 284, 288, 331, 333, 334, 335, 338, 401, 402, 403, or 407. In some embodiments, the poloxamer is poloxamer 407. In some embodiments, the pharmaceutical composition comprises about .01 mg/ml to about 10 mg/ml of a poloxamer. In some embodiments, the pharmaceutical composition comprises at least about 1 mg/ml of a poloxamer.

[0172] In some embodiments, the pharmaceutical compositions disclosed herein include specified amounts or concentrations of poloxamer 188 (P188). Non-limiting disclosures relating to P188 may be found in Strickley and Lambert (2021) *Journal of Pharmaceutical Sciences* 110 2590–2608, the entire contents of each of which are incorporated herein by reference. In some embodiments, the pharmaceutical composition comprises about 0.01% (w/v) to about 1.0% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises at least about 0.1% poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.1% poloxamer 188.

[0173] In some embodiments, the pharmaceutical composition comprises about 0.01% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.02% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.03% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.04% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.05% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.06% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.07% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.08% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition

comprises about 0.09% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.1% (w/v) poloxamer 188.

[0174] In some embodiments, the pharmaceutical composition comprises about 0.11% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.12% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.13% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.14% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.15% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.16% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.17% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.18% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.19% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.2% (w/v) poloxamer 188.

[0175] In some embodiments, the pharmaceutical composition comprises about 0.3% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.4% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.5% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.6% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.7% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.8% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 0.9% (w/v) poloxamer 188. In some embodiments, the pharmaceutical composition comprises about 1.0% (w/v) poloxamer 188.

[0176] In some embodiments, the pharmaceutical composition is a pre-lyophilization solution. In some embodiments, pre-lyophilization solution does not comprise NaCl.

[0177] In some embodiments, the pharmaceutical composition comprises

- (a) about 1% (w/v) to about 8% (w/v) sucrose;
- (b) about 5 mM to about 15 mM histidine;
- (c) about 200 mM to about 300 mM arginine;
- (d) about 2.5 mM to about 10 mM calcium chloride; and
- (e) about 0.1% (w/v) to about 1.0% (w/v) poloxamer. In some embodiments, the poloxamer is poloxamer 188 (P188). In some embodiments, the composition comprises poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the

composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0178] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution does not comprise NaCl.

[0179] In some embodiments, the pharmaceutical composition comprises

- (a) about 1% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0180] In some embodiments, the pharmaceutical composition comprises

- (a) about 2% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0181] In some embodiments, the pharmaceutical composition comprises

- (a) about 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and

[0182] (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution. In some embodiments, the pharmaceutical composition comprises

- (a) about 1% (w/v) to about 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;

- (d) about 5 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0183] In some embodiments, the pharmaceutical composition comprises

- (a) about 1%, 2%, or 5% (w/v) sucrose;
- (b) about 5 mM to about 15 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0184] In some embodiments, the pharmaceutical composition comprises

- (a) about 1%, 2%, or 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 200 mM to about 300 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0185] In some embodiments, the pharmaceutical composition comprises

- (a) about 1%, 2%, or 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 2.5 mM to about 10 mM calcium chloride; and
- (e) about 0.1% poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0186] In some embodiments, the pharmaceutical composition comprises

- (a) about 1%, 2%, or 5% (w/v) sucrose;
- (b) about 10 mM histidine;

- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and

[0187] (e) about 0.008% (w/v) to about 0.1% (w/v) poloxamer 188. In some embodiments, the histidine is L-histidine. In some embodiments, the arginine is L-arginine. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0188] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 52.665 mg/ml L-arginine-HCl;
- (d) about 0.735 mg/ml calcium chloride; and
- (e) about 1 mg/ml poloxamer 188.

[0189] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 52.665 mg/ml L-arginine-HCl;
- (d) about 0.735 mg/ml calcium chloride dihydrate; and
- (e) about 1 mg/ml poloxamer 188.

[0190] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 52.665 mg/ml L-arginine-HCl;
- (d) about 0.555 mg/ml calcium chloride; and
- (e) about 1 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0191] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 43.550 mg/ml L-arginine;
- (d) about 0.735 mg/ml calcium chloride dihydrate; and
- (e) about 1 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0192] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 43.550 mg/ml L-arginine;
- (d) about 0.735 mg/ml calcium chloride; and
- (e) about 1 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0193] In some embodiments, the pharmaceutical composition comprises:

- (a) about 10, 20, or 50 mg/ml sucrose;
- (b) about 1.552 mg/ml L-histidine;
- (c) about 43.550 mg/ml L-arginine;
- (d) about 0.555 mg/ml calcium chloride; and
- (e) about 1 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate. In some embodiments, the pharmaceutical composition is a pre-lyophilization solution.

[0194] In some embodiments, the pharmaceutical composition comprises:

- (a) 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0195] In some embodiments, the pharmaceutical composition comprises:

- (a) 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0196] In some embodiments, the pharmaceutical composition comprises:

- (a) 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

[0197] In some embodiments, the pharmaceutical composition comprises:

- (a) 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0198] In some embodiments, the pharmaceutical composition has a pH of about 6.5 to about 7.5. In some embodiments, the pharmaceutical composition has a pH of about 7.0. In some embodiments, the pharmaceutical composition has a pH of about 6.8.

[0199] In some embodiments, the pharmaceutical composition has a pH of about 6.5. In some embodiments, the pharmaceutical composition has a pH of about 6.6. In some embodiments, the pharmaceutical composition has a pH of about 6.7. In some embodiments, the pharmaceutical composition has a pH of about 6.8. In some embodiments, the pharmaceutical composition has a pH of about 6.9. In some embodiments, the pharmaceutical composition has a pH of about 7.0. In some embodiments, the pharmaceutical composition has a pH of about 7.1. In some embodiments, the pharmaceutical composition has a pH of about 7.2. In some embodiments, the pharmaceutical composition has a pH of about 7.3. In some embodiments, the pharmaceutical composition has a pH of about 7.4. In some embodiments, the pharmaceutical composition has a pH of about 7.5.

[0200] In some embodiments, the pharmaceutical composition has a pH of 6.5. In some embodiments, the pharmaceutical composition has a pH of 6.6. In some embodiments, the pharmaceutical composition has a pH of 6.7. In some embodiments, the pharmaceutical composition has a pH of 6.8. In some embodiments, the pharmaceutical composition has a pH of 6.9. In some embodiments, the pharmaceutical composition has a pH of 7.0. In some embodiments, the pharmaceutical composition has a pH of 7.1. In some embodiments, the pharmaceutical composition has a pH of 7.2. In some embodiments, the pharmaceutical composition has a pH of 7.3. In some embodiments, the pharmaceutical composition has a pH of 7.4. In some embodiments, the pharmaceutical composition has a pH of 7.5.

[0201] In some embodiments, a volume of 3.367 mL of the pre-lyophilization solution is added to a container or vial. In some embodiments, the pre-lyophilized solution is subjected to lyophilization, resulting in a lyophilized pharmaceutical composition.

[0202] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) about 10 mg to about 200 mg sucrose;
- (b) about 2.5 mg to about 7.5 mg histidine;
- (c) about 140 mg to about 200 mg arginine;
- (d) about 1.5 mg to about 5 mg calcium chloride; and
- (e) about 1 mg to about 10 mg poloxamer 188.

[0203] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) about 10 mg to about 200 mg sucrose;
- (b) about 2.5 mg to about 7.5 mg L-histidine;
- (c) about 140 mg to about 200 mg L-arginine;
- (d) about 1.5 mg to about 5 mg calcium chloride; and
- (e) about 1 mg to about 10 mg poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0204] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 2.5 mg to 7.5 mg histidine;
- (c) 140 mg to 200 mg arginine;
- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 1 mg to 10 mg poloxamer 188.

[0205] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 140 mg to 200 mg L-arginine-HCl;
- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 1 mg to 10 mg poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0206] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 140 mg to 200 mg L-arginine;
- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 1 mg to 10 mg poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0207] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) about 33.7, 67.3, or 168.4 mg sucrose;

- (b) about 5.2 mg L-histidine;
- (c) about 177.3 mg L-arginine-HCl;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0208] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) about 33.7, 67.3, or 168.4 mg sucrose;
- (b) about 5.2 mg L-histidine;
- (c) about 146.6 mg L-arginine;
- (d) about 2.5 mg calcium chloride; and
- (e) about 3.4 mg poloxamer 188.

[0209] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 177.3 mg L-arginine-HCl;
- (d) 2.5 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0210] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 146.6 mg L-arginine;
- (d) 2.5 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0211] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35 mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 2.47 mg calcium chloride dihydrate; and

[0212] (e) 3.37 mg poloxamer 188. In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 1.87 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188.

[0213] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 2.47 mg calcium chloride dihydrate; and
- (e) 3.37 mg poloxamer 188.

[0214] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 1.87 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188.

[0215] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 177.3 mg L-arginine-HCl;
- (d) 2.5 mg calcium chloride dihydrate; and
- (e) 3.4 mg poloxamer 188.

[0216] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 177.3 mg L-arginine-HCl;
- (d) 1.9 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0217] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 146.6 mg L-arginine;
- (d) 2.5 mg calcium chloride dihydrate; and
- (e) 3.4 mg poloxamer 188.

[0218] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 10 mg to 200 mg sucrose;
- (b) 5.2 mg L-histidine;
- (c) 146.6 mg L-arginine;
- (d) 1.9 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0219] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 177.3 mg L-arginine-HCl;
- (d) 2.5 mg calcium chloride dihydrate; and
- (e) 3.4 mg poloxamer 188.

[0220] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 177.3 mg L-arginine-HCl;
- (d) 1.9 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0221] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 146.6 mg L-arginine;
- (d) 2.5 mg calcium chloride dihydrate; and
- (e) 3.4 mg poloxamer 188.

[0222] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.7, 67.3, or 168.4mg sucrose;
- (b) 2.5 mg to 7.5 mg L-histidine;
- (c) 146.6 mg L-arginine;
- (d) 1.9 mg calcium chloride; and
- (e) 3.4 mg poloxamer 188.

[0223] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 140 mg to 200 mg L-arginine;
- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188. In some embodiments, the composition comprises 140 mg to 200 mg L-arginine-HCl.

[0224] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;

- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188.

[0225] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 1.5 mg to 5 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188.

[0226] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 2.47 mg calcium chloride dihydrate; and
- (e) 1 mg to 10 mg poloxamer 188.

[0227] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 1.87 mg calcium chloride; and
- (e) 1 mg to 10 mg poloxamer 188.

[0228] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 2.47 mg calcium chloride dihydrate; and
- (e) 1 mg to 10 mg poloxamer 188.

[0229] In some embodiments, the lyophilized pharmaceutical composition comprises:

- (a) 33.67, 67.34, or 168.35mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 1.87 mg calcium chloride; and
- (e) 1 mg to 10 mg poloxamer 188.

[0230] In some embodiments, the lyophilized pharmaceutical composition has a moisture content of less than 2%. In some embodiments, the lyophilized pharmaceutical composition has a

moisture content of less than 1.8%. In some embodiments, the lyophilized pharmaceutical composition has a moisture content of less than 1.6%.

[0231] In some embodiments, the lyophilized pharmaceutical composition is in a lyophilized cake. In some embodiments, the lyophilized cake is white. In some embodiments, the lyophilized cake is less than Y4 in the European Pharmacopoeia color scale. See Degree of Coloration of Liquids (Method 2.2.2), European Pharmacopoeia, 10th Ed. (2021).

[0232] In some embodiments, the lyophilized pharmaceutical composition and sterile water are combined to produce an injectable solution. In some embodiments, the lyophilized pharmaceutical composition is combined with about 2 mL to about 5 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is combined with about 3 mL of sterile water. In some embodiments, the lyophilized pharmaceutical composition is combined with 3 mL of sterile water. In some embodiments, the sterile water is USP grade sterile water. In some embodiments, the sterile water is USP grade sterile water for injection. In some embodiments, the sterile water is pyrogen-free or nonpyrogenic. In some embodiments, the sterile water does not contain a bacteriostatic or antimicrobial agent. In some embodiments, the sterile water contains a bacteriostatic or antimicrobial agent. In some embodiments, the sterile water is sterilized using a filter. In some embodiments, the sterile water is sterilized using a 0.1µm filter. In some embodiments, the sterile water is distilled water. In some embodiments, the sterile water is sterile, nonpyrogenic, distilled water, hypotonic, with an osmolarity of zero mOsmol/L, and does not contain a bacteriostatic or antimicrobial agent.

[0233] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 50 mg/mL to 70 mg/mL L-arginine;
- (d) 0.7 mg/mL to 0.9 mg/mL calcium chloride dihydrate; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188. In some embodiments the composition comprises L-arginine-HCl.

[0234] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 50 mg/mL to 70 mg/mL L-arginine;
- (d) 0.5 mg/mL to 0.8 mg/mL calcium chloride; and

(e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate

[0235] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0236] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0237] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0238] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0239] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 10 mg/mL to about 60 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0240] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 10 mg/mL to about 60 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0241] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 10 mg/mL to about 60 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 44.88 mg/ml L-arginine;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188

[0242] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 10 mg/mL to about 60 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 44.88 mg/ml L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0243] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.5 mg/mL to about 2.0 mg/mL L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0244] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.5 mg/mL to about 2.0 mg/mL L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0245] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.5 mg/mL to about 2.0 mg/mL L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0246] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 22.45 mg/ml sucrose;
- (b) about 1.5 mg/mL to about 2.0 mg/mL L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0247] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 50 mg/mL to about 70 mg/mL L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0248] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 50 mg/mL to about 70 mg/mL L-arginine-HCl;

- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0249] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 40 mg/mL to about 60 mg/mL L-arginine;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0250] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 40 mg/mL to about 60 mg/mL L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0251] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.7 mg/mL to about 0.9 mg/mL calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0252] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.5 mg/mL to about 0.9 mg/mL calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments, the composition comprises calcium chloride dihydrate.

[0253] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.7 mg/mL to about 0.9 mg/mL calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl.

[0254] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.5 mg/mL to about 0.7 mg/mL calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0255] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 0.6 mg/mL to about 1.6 mg/mL poloxamer 188.

[0256] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 0.6 mg/mL to about 1.6 mg/mL poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0257] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;

- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 0.6 mg/mL to about 1.6 mg/mL poloxamer 188.

[0258] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 0.6 mg/mL to about 1.6 mg/mL poloxamer 188. In some embodiments the composition comprises L-arginine-HCl. In some embodiments, the composition comprises calcium chloride dihydrate.

[0259] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0260] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 59.11 mg/ml L-arginine-HCl;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188.

[0261] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;
- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.82 mg/ml calcium chloride dihydrate; and
- (e) about 1.12 mg/ml poloxamer 188.

[0262] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 11.23, 22.45, or 56.12 mg/ml sucrose;

- (b) about 1.74 mg/ml L-histidine;
- (c) about 48.88 mg/ml L-arginine;
- (d) about 0.62 mg/ml calcium chloride; and
- (e) about 1.12 mg/ml poloxamer 188.

[0263] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 33.67, 67.34, or 168.35 mg sucrose;
- (b) about 5.23 mg L-histidine;
- (c) about 177.32 mg L-arginine-HCl;
- (d) about 2.47 mg calcium chloride; and
- (e) about 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0264] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 33.67, 67.34, or 168.35 mg sucrose;
- (b) about 5.23 mg L-histidine;
- (c) about 146.63 mg L-arginine;
- (d) about 2.47 mg calcium chloride dihydrate; and
- (e) about 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0265] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) about 33.67, 67.34, or 168.35 mg sucrose;
- (b) about 5.23 mg L-histidine;
- (c) about 146.63 mg L-arginine;
- (d) about 1.87 mg calcium chloride; and
- (e) about 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0266] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 33.67, 67.34, or 168.35 mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 2.47 mg calcium chloride dihydrate; and
- (e) 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0267] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 33.67, 67.34, or 168.35 mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 177.32 mg L-arginine-HCl;
- (d) 1.87 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0268] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 33.67, 67.34, or 168.35 mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 2.47 mg calcium chloride dihydrate; and
- (e) 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0269] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the resulting solution comprises:

- (a) 33.67, 67.34, or 168.35 mg sucrose;
- (b) 5.23 mg L-histidine;
- (c) 146.63 mg L-arginine;
- (d) 1.87 mg calcium chloride; and
- (e) 3.37 mg poloxamer 188

in 3 mL of sterile water.

[0270] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the lyophilized pharmaceutical composition is reconstituted within 7 to 12 seconds.

[0271] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the osmolality of the resulting solution is about 525 to about 725 mOsm/kg. In some embodiments, the pharmaceutical composition disclosed herein has an osmolality about 500 to about 650 mOsm/kg. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the osmolality of the resulting solution is about 600 to about 650 mOsm/kg.

- [0272] In some embodiments, the pharmaceutical composition has an osmolality of about 525 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 550 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 575 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 600 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 625 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 650 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 675 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 700 mOsm/kg. In some embodiments, the pharmaceutical composition has an osmolality of about 725 mOsm/kg.
- [0273] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.5 to about 7.5. In some embodiments, the pharmaceutical composition has a pH of about 7.0. In some embodiments, the pharmaceutical composition has a pH of about 6.8. In some embodiments, the pharmaceutical composition has a pH of 6.8.
- [0274] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.5. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.6. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.7. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.8. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 6.9. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 7.0. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 7.1. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 7.2. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 7.3. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is

about 7.4. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the pH of the resulting solution is about 7.5.

[0275] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 0.8 to about 1.2 mg/mL.

[0276] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 0.8 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 0.9 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 1.0 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 1.1 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is about 1.2 mg/mL.

[0277] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is 0.8 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is 0.9 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is 1.0 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is 1.1 mg/mL. In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the protein concentration of the resulting solution is 1.2 mg/mL.

[0278] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, then the turbidity of the resulting solution is less than about 7 Nephelometric Turbidity Units.

[0279] In some embodiments, when the lyophilized pharmaceutical composition and the sterile water are combined, less than 3% of the chimeric protein is aggregated.

[0280] Disclosed herein is a method of storing a pharmaceutical composition, comprising maintaining a pharmaceutical composition disclosed herein at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -20°C, about -25°C, about

-30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical composition is stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

[0281] In some embodiments, the pharmaceutical composition has been stored at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical composition has been stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

[0282] In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 2-5 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 2 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 3 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 4 times. In some embodiments, the pharmaceutical composition is a liquid pharmaceutical composition that has been frozen and then thawed 5 times.

[0283] In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 10 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml to about 2 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 0.5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 1.5 mg/ml of the chimeric protein. In some embodiments, the pharmaceutical composition comprises about 2 mg/ml of the chimeric protein.

V. Pharmaceutical Kits

[0284] In some embodiments, the pharmaceutical composition is provided with a second container comprising sterile water. Disclosed herein are pharmaceutical kits which comprise a first container containing the pharmaceutical composition and a second container containing sterile water.

[0285] Disclosed herein is a pharmaceutical kit comprising:

- (i) a first container comprising a lyophilized pharmaceutical composition comprising
 - (a) a chimeric protein comprising a first polypeptide chain which comprises a Factor VIII ("FVIII") protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof;
 - (b) about 10 mg to about 200 mg sucrose;
 - (c) about 2.5 mg to about 7.5 mg histidine;
 - (d) about 140 mg to about 200 mg arginine;
 - (e) about 1.5 mg to about 5 mg calcium chloride; and
 - (f) about 0.5 mg to about 10 mg poloxamer 188, and
- (ii) a second container comprising sterile water.

[0286] In some embodiments, the first container comprises 100 IU to 10,000 IU of the chimeric protein.

[0287] In some embodiments, the first container comprises 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of the chimeric protein. In some embodiments, the first container comprises 250 IU of the chimeric protein. In some embodiments, the first container comprises 500 IU of the chimeric protein. In some embodiments, the first container comprises 1000 IU of the chimeric protein. In some embodiments, the first container comprises 2000 IU of the chimeric protein. In some embodiments, the first container comprises 3000 IU of the chimeric protein. In some embodiments, the first container comprises 4,000 IU of the chimeric protein. In some embodiments, the first container comprises more than about 250 IU of the chimeric protein. In some embodiments, the first container comprises more than about 300 IU of the chimeric protein. In some embodiments, the first container comprises more than about 500 IU of the chimeric protein. In some embodiments, the first container comprises at least about 500 IU of the chimeric protein.

[0288] In some embodiments, the second container comprises about 2 mL to about 5 mL of sterile water. In some embodiments, the second container comprises 2 mL to 5 mL of sterile

water. In some embodiments, the second container comprises about 3 mL of sterile water. In some embodiments, the second container comprises 3 mL of sterile water.

- [0289]** In some embodiments, the second container comprises about 2 mL of sterile water. In some embodiments, the second container comprises about 2.1 mL of sterile water. In some embodiments, the second container comprises about 2.2 mL of sterile water. In some embodiments, the second container comprises about 2.3 mL of sterile water. In some embodiments, the second container comprises about 2.4 mL of sterile water. In some embodiments, the second container comprises about 2.5 mL of sterile water. In some embodiments, the second container comprises about 2.6 mL of sterile water. In some embodiments, the second container comprises about 2.7 mL of sterile water. In some embodiments, the second container comprises about 2.8 mL of sterile water. In some embodiments, the second container comprises about 2.9 mL of sterile water. In some embodiments, the second container comprises about 3 mL of sterile water. In some embodiments, the second container comprises about 3.1 mL of sterile water. In some embodiments, the second container comprises about 3.2 mL of sterile water. In some embodiments, the second container comprises about 3.3 mL of sterile water. In some embodiments, the second container comprises about 3.4 mL of sterile water. In some embodiments, the second container comprises about 3.5 mL of sterile water. In some embodiments, the second container comprises about 3.6 mL of sterile water. In some embodiments, the second container comprises about 3.7 mL of sterile water. In some embodiments, the second container comprises about 3.8 mL of sterile water. In some embodiments, the second container comprises about 3.9 mL of sterile water. In some embodiments, the second container comprises about 4 mL of sterile water. In some embodiments, the second container comprises about 4.1 mL of sterile water. In some embodiments, the second container comprises about 4.2 mL of sterile water. In some embodiments, the second container comprises about 4.3 mL of sterile water. In some embodiments, the second container comprises about 4.4 mL of sterile water. In some embodiments, the second container comprises about 4.5 mL of sterile water. In some embodiments, the second container comprises about 4.6 mL of sterile water. In some embodiments, the second container comprises about 4.7 mL of sterile water. In some embodiments, the second container comprises about 4.8 mL of sterile water. In some embodiments, the second container comprises about 4.9 mL of sterile water. In some embodiments, the second container comprises about 5 mL of sterile water.
- [0290]** In some embodiments, the pharmaceutical kit further comprises instructions for combining the lyophilized pharmaceutical composition and the sterile water.

[0291] In some embodiments, the first container is a glass vial comprising a rubber stopper.

[0292] In some embodiments, the second container is a syringe body. In some embodiments, the syringe body is associated with a plunger. In some embodiments, the pharmaceutical kit further comprises an adaptor to connect the glass vial to the syringe body. In some embodiments, the pharmaceutical kit further comprises infusion tubing associated with a needle to be connected to the syringe body, suitable for intravenous infusion. In some embodiments, the second container is a pre-filled syringe.

[0293] Disclosed herein is a method of storing a pharmaceutical kit, comprising maintaining a pharmaceutical kit disclosed herein at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical kit is stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

[0294] In some embodiments, the pharmaceutical kit has been stored at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 3, 6, 9, 12, 18, 21, 24, 27, 30, 33, or 36 months. In some embodiments, the pharmaceutical kit has been stored at a temperature of about -30°C for at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12 months.

VI. Methods and Uses of the Pharmaceutical Composition

[0295] Also disclosed herein is a use of the pharmaceutical composition or a method for treating hemophilia A in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of the disclosure. In some embodiments, the treatment of hemophilia A comprises preventing a bleeding episode in a human subject in need thereof. In some embodiments, the treatment of hemophilia A comprises treating a bleeding episode in a human subject in need thereof. In some embodiments, the treatment of hemophilia A comprises controlling the incidence or frequency of a bleeding episode in a human subject in need thereof. In some

embodiments, the treatment of hemophilia A comprises decreasing the incidence or frequency of a bleeding episode in a human subject in need thereof.

- [0296]** In some embodiments, the composition is used to treat a bleeding disease or condition in a subject in need thereof. The bleeding disease or condition is selected from the group consisting of a bleeding coagulation disorder, hemarthrosis, muscle bleed, oral bleed, hemorrhage, hemorrhage into muscles, oral hemorrhage, trauma, trauma capitis, gastrointestinal bleeding, intracranial hemorrhage, intra-abdominal hemorrhage, intrathoracic hemorrhage, bone fracture, central nervous system bleeding, bleeding in the retropharyngeal space, bleeding in the retroperitoneal space, bleeding in the iliopsoas sheath and any combinations thereof. In still other embodiments, the subject is scheduled to undergo a surgery. In some embodiments, the treatment is prophylactic or on-demand.
- [0297]** In some embodiments, the use or method comprises combining the lyophilized pharmaceutical composition and the sterile water of a kit of the disclosure, and administering to the subject an effective amount of the resulting combination. In some embodiments, the subject combines the lyophilized pharmaceutical composition and the sterile water of the kit. In some embodiments, the combination is self-administered by the subject.
- [0298]** In some embodiments, the multiple doses comprise at least two doses, at least three doses, at least four doses, at least five doses, at least six doses, at least seven doses, at least eight doses, at least nine doses, at least ten doses, at least eleven doses, at least twelve doses, at least thirteen doses, at least fourteen doses, at least fifteen doses, at least sixteen doses, at least seventeen doses, at least eighteen doses, at least nineteen doses, at least twenty doses, or more. In some embodiments, the multiple doses are administered for at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 12 months, at least about 18 months, at least about 2 years, at least about 3 years, at least about 4 years, at least about 5 years, at least about 10 years, at least about 15 years, at least about 20 years, or for at least about 25 years.
- [0299]** A chimeric protein described herein can be administered by any means known in the art. In some embodiments, the chimeric protein is administered by a route selected from the group consisting of intravenous injection, intravenous infusion, subcutaneous administration, intramuscular administration, oral administration, nasal administration, and pulmonary administration. In some embodiments, the chimeric protein is administered intravenously. In some embodiments, the chimeric protein is administered subcutaneously.

[0300] Having now described the present disclosure in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting of the disclosure. All patents, publications, and articles referred to herein are expressly and specifically incorporated herein by reference.

EXAMPLES

Example 1: Evaluation of aggregation of efanesoctocog alfa compositions comprising different surfactants

[0301] The experiments described in this example assess the stability of efanesoctocog alfa in pharmaceutical compositions comprising a different surfactant (poloxamer 188) formulated with different concentrations of sucrose. In addition to sucrose, each composition also contained 10 mM L-histidine, 250 mM L-arginine-HCl, 5 mM CaCl₂, and 0.1% (w/v) poloxamer 188 (poloxamer 188), at a pH of 6.8. Stability attributes for poloxamer 188 compositions were also compared to stability attributes for otherwise identical PS80 compositions to evaluate the effect of selected surfactant.

[0302] To further analyze the impact on sucrose concentration on efanesoctocog alfa compositions containing poloxamer 188, pharmaceutical compositions of efanesoctocog alfa at 0, 1, 2, and 5% w/v sucrose were subjected to different stability conditions and stability was assessed using several methods. Compositions were tested at the following product stages: drug substance (DS, which was had not been lyophilized or adjusted for any particular IU strength) frozen storage stability, DS freeze/thaw (FT) stability, liquid DS post-thaw stability, diluted DS and drug product (DP) stability, DP lyophilization stability, and DP-post reconstitution.

[0303] Aggregation of efanesoctocog alfa compositions was measured by SEC assay (%HMWS). The SEC assay uses an HPLC instrument equipped with a pump, a temperature controlled autosampler, a column heater, and fluorescence detector. The sample solutions are analyzed using the following instrumentation and method parameters:

- Mobile Phase: Dulbecco's Phosphate- Buffered Saline (D-PBS) containing Calcium and Magnesium adding 0.36 M Sodium Chloride (0.9 mM Calcium Chloride, 0.5 mM Magnesium Chloride, 2.7 mM Potassium Chloride, 1.5 mM Potassium Phosphate Mono basic, 496 mM Sodium Chloride, 8.1 mM Sodium Phosphate Dibasic, pH 7.0 ± 0.1)
- Column Heater: 26°C
- Run Time: 40 minutes
- FL Detector: Ex/Em = 280/350 nm, PMT Gain = 5

- Injection Mass Load: 2 µg
- Autosampler Temperature: 5°C
- Flow Rate: 0.5 mL/min, Isocratic

[0304] Aggregation of efanesoctocog alfa drug substance (DS) compositions (1 mg/mL) containing either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and either 1% or 5% (w/v) sucrose were tested at room temperature (RT)/room light (RL) conditions or at 2-8 °C. Aggregation results for RT/RL conditions over time (hours) are shown in FIG. 2. At RT/RL conditions, reduction of sucrose from 5% to 1% increased aggregation by 2X for compositions containing either surfactant. At RT/RL conditions, aggregation rate increases were about the same for both poloxamer 188 compositions and PS80 compositions.

[0305] Aggregation results at 2-8°C over time (hours) are shown in FIG. 3. At 2-8°C conditions, reduction of sucrose from 5% to 1% increased aggregation by 2X in PS80 compositions, which was similar to the results at RT/RL conditions. However, at 2-8°C, reduction of sucrose from 5% to 1% increased aggregation by 10X for PS80 compositions. At 2-8°C, aggregation rate increases were lower in poloxamer 188 compositions than PS80 compositions.

[0306] Aggregation of efanesoctocog alfa drug substance (DS) liquid compositions at 4000 IU and containing either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant were assessed in a cumulative hold time assay. Efanesoctocog alfa liquid compositions were held at RT and tested after 0, 5, 7, 25, 43, and 55 hours. Samples were also tested after lyophilization.

[0307] Results of the cumulative hold time assay are shown in FIG. 4. Efanesoctocog alfa drug substance (DS) liquid compositions followed by subsequent dilutions to 4000 IU comprising 1% sucrose and 0.05% PS80 showed the highest increase in aggregation (see FIG. 4, square plot). The results of this cumulative hold time assay also show that compositions comprising poloxamer 188 may be moderately more stable than PS80 compositions in liquid state at RT.

[0308] Frozen storage stability of compositions of efanesoctocog alfa DS at 1 mg/mL was assessed for compositions comprising either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant. Compositions containing 0, 1, 2, or 5% (w/v) sucrose were held at freezing temperatures (-80°C or -30°C). Time points measured were pre-freeze, start of experiment (T0), one month (T1M), 3 months (T3M), and 6 months (T6M).

[0309] Results of the frozen storage stability assay for compositions comprising 0.5% (w/v) PS80 are shown in FIG. 5. Results of the frozen storage stability assay for compositions

comprising 0.1% (w/v) poloxamer 188 are shown in FIG. 6. No trend in aggregation was observed for any of the tested compositions at -80°C. However, at at -30°C, compositions comprising PS80 surfactant showed an increase in aggregation (see FIG. 5). This effect was most evident at lower sucrose concentrations (see, e.g., FIG. 5, 0% sucrose result). In contrast, compositions comprising poloxamer 188 did not show an increase in aggregation at -30°C (see FIG. 6). Compositions comprising poloxamer 188 showed comparable aggregation levels at both -80°C and -30°C. Thus, use of poloxamer 188 as a surfactant may provide improved frozen storage stability for efanesoctocog alfa compositions, particularly if compositions are stored at -30°C.

- [0310]** The frozen storage stability of efanesoctocog alfa DS compositions (1 mg/mL) comprising 0.1% (w/v) poloxamer 188 was further analyzed by particle testing using high accuracy liquid particle counter (HIAC). DS compositions containing 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose were held at -80°C and assessed at the following time points: pre-freeze, start of experiment (T0), one month (T1M), 3 months (T3M), and 6 months (T6M). Results for ≥ 10 μm particles are shown in FIG. 7A. Results for ≥ 25 μm particles are shown in FIG. 7B. The ≥ 10 μm particles are less than 6000 particles and ≥ 25 μm particles are less than 600 particles, and within the limit of <USP 787>. No significant trending in particles was observed over storage.
- [0311]** Aggregation of compositions of efanesoctocog alfa lyophilized drug product (Lyo DP) at 250 IU or 4000 IU and containing 0.1% (w/v) poloxamer 188 were tested at 5°C, 30°C, and 40°C. Lyo DP compositions containing 1% and 5% w/v sucrose were tested. Samples were tested at T0, 1 month, 2 months, 3 months, and 6 months.
- [0312]** Results of Lyo DP compositions with at 250 IU are shown in FIG. 8A (5°C), FIG. 8B (30°C), and FIG. 8C (40°C). For the 250 IU compositions, higher aggregation was generally demonstrated in poloxamer 188 compositions than PS80 compositions (data not shown). The 250 IU compositions comprising 0.1% (w/v) poloxamer 188 and 1% sucrose demonstrated significant increases in aggregation at all temperatures.
- [0313]** Results of Lyo DP compositions at 4000 IU are shown in FIG. 9A (5°C), FIG. 9B (30°C), and FIG. 9C (40°C). For all 4000 IU compositions comprising 0.1% (w/v) poloxamer 188, no aggregation trends were observed at any temperature for both sucrose concentrations. This result is consistent with results for Lyo DP compositions at 4000 IU comprising 0.5% (w/v) PS80, which also did not demonstrate notable aggregation trends based on sucrose concentration or temperature (data not shown).
- [0314]** Aggregation of efanesoctocog alfa compositions following freeze/thaw (F/T) stress was also analyzed for each surfactant. Compositions of efanesoctocog alfa DS at 1 mg/mL

and comprising either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as surfactant and 0, 1, 2, or 5% (w/v) sucrose were subjected to stress by F/T at either -80°C or -30°C for 5 cycles (5X)(not less than 24hrs, thaw at room temperature). Samples were tested before freezing (Pre Freeze) and after 5x F/T cycles.

[0315] Results for compositions comprising 0.5% (w/v) PS80 are shown in FIG. 10. Results for compositions comprising 0.1% (w/v) poloxamer 188 are shown in FIG. 11. DS compositions comprising 0.5% (w/v) PS80 showed a moderate increase in aggregation after 5x F/T cycles at -80°C (see FIG. 10). However, DS compositions comprising 0.1% (w/v) poloxamer 188 showed no change in aggregation after 5x F/T cycles at -80°C (see FIG. 11). Compositions comprising either surfactant showed increases in aggregation after 5x F/T cycles at -30°C. However, the increase in aggregation was significantly greater in DS compositions comprising 0.5% (w/v) PS80 than compositions comprising 0.1% (w/v) poloxamer 188 (compare FIG. 10 and FIG. 11). Thus, it appears that 0.1% (w/v) poloxamer 188 as a surfactant in efanesoctocog alfa compositions may provide slightly improved F/T stability at -80°C and significantly improved F/T stability at -30°C over 0.5% (w/v) PS80 as surfactant.

[0316] A summary of the results of the aggregation testing for efanesoctocog alfa compositions comprising 0.1% (w/v) poloxamer 188 is provided in Table 1.

Table 1: Summary of aggregation analysis (%HMWS) for 0.1% (w/v) poloxamer 188 formulations.

Sucrose conc, %	Frozen Storage, % (-80°C) (1 mg/mL)		Liquid DS Rate %/h (1 mg/mL)	Liquid BDP Rate%/h (4000 IU)		Cum. %/h (4000 IU)	Lyo DP (Δ6M) (4000 IU)			Lyo DP (Δ6M) (250 IU)		
	Δ6M	Δ5XFT	RT	5°C	RT	5°C/RT	5°C	30°C	40°C	5°C	30°C	40°C
5	0.5	0.2	0.00	0.00	0.05	0.02	0.2	0.0	0.0	1.2	0.8	-0.3
2	0.7	1.3	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND
1	0.3	1.3	0.08	0.03	0.04	0.03	0.2	0.3	-0.1	-0.2	-0.1	3.34
0	0.7	0.4	ND	ND	ND	ND	ND	ND	ND	ND	ND	ND

ND = Not Determined

[0317] Overall, these aggregation studies suggest that efanesoctocog alfa compositions may have improved stability when formulated with 0.1% (w/v) poloxamer 188 rather than 0.5% (w/v) PS80. poloxamer 188 compositions showed a significant improvement over PS80 compositions in F/T and Frozen Storage Stability assays at -30°C across all sucrose concentrations. Accordingly, poloxamer 188 may be preferable to PS80 for any

efanesoctocog alfa compositions to be stored at -30°C. Efanesoctocog alfa DS and BDP liquid compositions also showed improved stability with poloxamer 188 compositions over PS80 compositions. For compositions of efanesoctocog alfa lyophilized DP, poloxamer 188 compositions at 4000IU showed favorable stability over 6 months at 40°C. However, PS80 lyophilized drug product showed significantly increased stability at 250 IU as compared to poloxamer 188.

Example 2: Evaluation of additional stability attributes for efanesoctocog alfa compositions comprising different surfactants

[0318] In addition to aggregation, other measures of stability of efanesoctocog alfa compositions comprising different surfactants were evaluated.

[0319] Concentration of surfactant in efanesoctocog alfa compositions following F/T stress was analyzed by high performance liquid chromatography (HPLC). Compositions of efanesoctocog alfa DS at 1 mg/mL and comprising either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as surfactant and 0, 1, 2, or 5% (w/v) sucrose were subjected to stress by F/T for 5 F/T cycles at either -80°C or -30°C (not less than 24hrs, thaw at room temperature). Samples were tested before freezing (Pre Freeze) and after 1, 3, or 5 F/T cycles. Results for DS compositions containing 0.5% (w/v) PS80 and 0, 1, 2, or 5% (w/v) sucrose are shown in FIG. 12A. Results for DS compositions containing 0.1% (w/v) poloxamer 188 and 0, 1, 2, or 5% (w/v) sucrose are shown in FIG. 12B. No change in surfactant concentration was observed over all F/T cycles for either surfactant or sucrose concentration.

[0320] Change in pH of efanesoctocog alfa compositions following F/T stress was also analyzed. Compositions of efanesoctocog alfa DS at 1 mg/mL and comprising either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as surfactant and 0, 1, 2, or 5% (w/v) sucrose were subjected to stress by F/T for 5 F/T cycles at either -80°C or -30°C (not less than 24hrs, thaw at room temperature). Samples were tested before freezing (Pre Freeze) and after 1, 3, or 5 F/T cycles. Results of pH analysis are shown in FIG. 13. No significant pH trends or changes were observed for any composition tested.

[0321] Turbidity of compositions comprising efanesoctocog alfa DS at 1 mg/mL and poloxamer 188 were tested. Compositions comprising 1% or 5% sucrose were tested, and the results were compared to the turbidity results of efanesoctocog alfa DS at 1 mg/mL compositions comprising PS80. No trends or changes in turbidity were observed for any of the tested poloxamer 188 compositions (data not shown).

- [0322] The glass transition temperature (T_g) was measured for efanesoctocog alfa lyophilized drug product (Lyo DP) compositions at 250 IU or 4000 IU and containing 0.1% (w/v) poloxamer 188 as a surfactant and 0, 1, 2, or 5% (w/v) sucrose. T_g was measured by modulated differential scanning calorimetry (DSC), according to the following steps: (i) equilibration at 15°C, (ii) modulate at 1°C every 60 seconds, (iii) isothermal for 5 minutes; and (iv) ramp at 3°C/min to 130°C. Residual moisture content (%) was also measured for all samples. T_g and residual moisture content results for Lyo DP 250 IU at T₀ are shown in FIG. 14. T_g and residual moisture content results for Lyo DP 4000 IU at T₀ are shown in FIG. 15.
- [0323] T_g was determined for efanesoctocog alfa lyophilized drug product (Lyo DP) compositions at 4000 IU or 250 IU and containing 0.1% (w/v) poloxamer 188 as a surfactant and 5% or 1% (w/v) sucrose. Samples were held at 5°C, 30°C, or 40°C and tested at T₀, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 16A (5°C), FIG. 16B (30°C), and FIG. 16C (40°C).
- [0324] The glass transition temperature (T_g) was also determined for efanesoctocog alfa liquid bulk drug product (BDP) compositions at 250 IU or 4000 IU and containing either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 as a surfactant and 0, 1, 2, or 5% (w/v) sucrose. T_g results for both surfactants at all strengths and sucrose concentrations are shown in FIG. 17.
- [0325] For both 250 IU or 4000 IU compositions comprising either surfactant, T_g was generally observed to correlate with sucrose concentration, with the higher sucrose concentration showing lower T_g. No significant differences in T_g were observed based on surfactant type for either 250 IU or 4000 IU concentration.
- [0326] Residual moisture content was determined for efanesoctocog alfa lyophilized drug product (Lyo DP) compositions at 250 IU or 4000 IU and containing 0.1% (w/v) poloxamer 188 as a surfactant and 1% or 5% (w/v) sucrose. Samples were held at 5°C, 30°C, or 40°C and tested at T₀, 1 month, 2 months, 3 months, and 6 months. Results are shown in FIG. 18A (5°C), FIG. 18B (30°C), and FIG. 18C (40°C). No significant change in residual moisture content was observed for any of the poloxamer 188 compositions at any temperatures. All residual moisture values fell below the spec of 3% after 6 months.
- [0327] Upon visual inspection, concentration of sucrose had no effect on poloxamer 188 formulation cake appearance over 6 months at 2-8°C, 30°C, and 40°C (data not shown).
- [0328] The results of this study show that, except for aggregation, compositions of efanesoctocog alfa formulated with either 0.5% (w/v) PS80 or 0.1% (w/v) poloxamer 188 have similar stability attributes. Evaluation of other stability attributes such as glass transition

temperature, turbidity, and residual moisture did not show any significant differences based on choice of surfactant.

Example 3: Effect of arginine concentration on stability of efanesoctocog alfa compositions

- [0329] Efanesoctocog alfa has demonstrated a tendency to undergo reversible self-association following freeze/thaw (F/T) stress. Use of arginine in efanesoctocog alfa compositions may provide a protective effect against this F/T induced molecular self association. To determine the optimal concentration of arginine for efanesoctocog alfa compositions, several compositions comprising various concentrations of arginine were prepared and aggregation levels were tested by SEC. Each tested composition comprised concentrated efanesoctocog alfa (>2 mg/mL), 10 mM L-histidine, 5 mM CaCl₂, 5% (w/v) sucrose, 0.1% (w/v) poloxamer 188 (P188), and L-arginine-HCl at a concentration of 125, 150, 175, 200, or 250 mM.
- [0330] To prepare the compositions for testing, efanesoctocog alfa compositions were lyophilized using the LyoStar2 development-scale lyophilizer (Protein Pharmaceutical Development Laboratories, Cambridge, MA). To test each sample, compositions were thawed and injected immediately into the HPLC for SEC analysis. Samples were analyzed immediately after thawing, and after 40, 80, 120, and 160 minutes post-thaw.
- [0331] The results of the aggregation assessments (%HMWS) for all samples are shown in FIG. 19. Efanesoctocog alfa compositions comprising arginine HCl levels below 250 mM demonstrate increased aggregation levels immediately upon thawing, followed by a decrease in aggregate levels over time (FIG. 18). This aggregation trend suggests formation and disassociation of HMWS that were formed due to F/T induced molecular self association of efanesoctocog alfa. However, efanesoctocog alfa compositions comprising arginine HCl concentrations of 250 mM demonstrate relatively low aggregation levels immediately after thawing, and these levels remain consistent over time (see FIG. 18, far right columns).
- [0332] The results of this study indicate that efanesoctocog alfa compositions with arginine HCl concentrations of 250 mM may be better protected from F/T induced molecular self association. Thus 250 mM appears to be the preferred concentration of arginine HCl for use in formulating efanesoctocog alfa compositions.

Example 4: Evaluation of pharmacokinetics of efanesoctocog alfa compositions comprising different surfactants in non-human primates

- [0333] The objective of this study was to compare the pharmacokinetic (PK) profile of efanesoctocog alfa compositions comprising either polysorbate 80 (PS80) or poloxamer 188 (P188) in cynomolgus monkeys.
- [0334] The following two vehicles were tested:
- [0335] Vehicle 1: 10mM L-Histidine, 250mM Arginine-HCl, 5mM Calcium Chloride, 5% w/v Sucrose, 0.05% Polysorbate 80
- [0336] Vehicle 2: 10mM L-Histidine, 250mM Arginine-HCl, 5mM Calcium Chloride, 5% w/v Sucrose, 0.1% Poloxamer 188
- [0337] The first group of subjects were administered a single intravenous (IV) bolus injection of 75 IU/kg/dose of efanesoctocog alfa in Vehicle 1. The second group of subjects were administered a single intravenous (IV) bolus injection of 75 IU/kg/dose of efanesoctocog alfa in Vehicle 2. Both compositions included efanesoctocog alfa at a concentration of 37.5 IU/mL. A volume of 2 mL was administered to each subject. Blood samples were collected for PK analysis at Predose, 0.25, 1, 3, 8, 24, 48, 96, 168, 240, and 336 hours.
- [0338] For the dose formulations, the concentrations of formulation samples analyzed were 88.6% and 92.0% of their respective theoretical concentration, for groups 1 and 2, respectively. The chromogenic activity of the formulation samples analyzed (following repeat analysis) were on a lower range and were 70.5% and 64.9% of their respective theoretical concentration, for groups 1 and 2, respectively.
- [0339] Efanesoctocog alfa protein concentration was determined by ELISA. Efanesoctocog alfa protein concentration over time is shown in FIG. 20. Efanesoctocog alfa protein activity was determined using the chromogenic assay. Efanesoctocog alfa activity over time is shown in FIG. 21. Both protein concentration and activity profiles were comparable for compositions comprising either PS80 or P188.
- [0340] PK parameters for efanesoctocog alfa protein concentration and activity were determined and are presented in Table 2. Values are presented as mean ($\pm$ SD) and were generated from 4 animals for each group. As can be seen in Table 2, PK parameters were comparable for compositions comprising either PS80 or P188.
- [0341] Efanesoctocog alfa protein concentration and activity parameters were directly compared between subjects receiving P188 or PS80 compositions. For protein concentration, the $C_{\max}$ ratio and $AUC_{(0-t)}$ ratio were determined to be 91.8% and 89.8%, respectively. For chromogenic activity, the $C_{\max}$ ratio and $AUC_{(0-t)}$ ratio were determined to be 106% and 105%, respectively.

[0342] The T_{max} was observed at first time point after dosing (i.e., 0.25 hour post dose) for efanesoctocog alfa and efanesoctocog alfa activity. The mean C_{max} was 841 and 772 ng/mL for efanesoctocog alfa concentration and 2110 and 2230 mIU/mL for efanesoctocog alfa activity, with Vehicle 1 and 2, respectively. The mean $AUC_{(0-t)}$ was 25400 and 22800 hr*ng/mL for efanesoctocog alfa concentration and 59600 and 62800 hr*mIU/mL for efanesoctocog alfa activity, with Vehicle 1 and 2, respectively. The mean $t_{1/2}$ was 36.1 and 35.8 hours for efanesoctocog alfa concentration and 34.4 and 35.3 hours for efanesoctocog alfa activity, with vehicle 1 and 2, respectively. The mean CL_{plasma} was 1.33 and 1.44 mL/hr/kg for efanesoctocog alfa concentration and 1.29 and 1.20 mL/hr/kg for efanesoctocog alfa activity, with vehicle 1 and 2, respectively. The mean V_d was 69.0 and 74.4 mL/kg for efanesoctocog alfa concentration and 63.8 and 61.4 mL/kg for BIVV001 activity, with vehicle 1 and 2, respectively.

[0343] In conclusion, the PK parameters of efanesoctocog alfa compositions were relatively similar regardless of selection of vehicle between PS80 and P188. There were no test item-related clinical signs or any injection site irritation noted following administration to subjects. All toxicokinetic parameters for each group were generated from 4 animals. Values are rounded to 3 significant figures (except T_{max}).

Table 2. PK parameters for efanesoctocog alfa compositions in cynomolgus monkeys.

Analyte	Vehicle	C_{max} (ng/mL)	T_{max} Median (range) (hr)	$AUC_{(0-t)}$ (hr*ng/mL)	$t_{1/2}$ (hr)	CL_{plasma} (mL/hr/kg)	V_d (mL/kg)
Efa concentration	PS80	841 ± 119	0.25 (0.25 - 0.25)	25400 ± 4940	36.1 ± 3.53	1.33 ± 0.300	69.0 ± 14.2
	P188	772 ± 101	0.25 (0.25 - 0.25)	22800 ± 2200	35.8 ± 5.50	1.44 ± 0.133	74.4 ± 15.4
Analyte	Vehicle	C_{max} (mIU/mL)	T_{max} Median (range) (hr)	$AUC_{(0-t)}$ (hr*mIU /mL)	$t_{1/2}$ (hr)	CL_{plasma} (mL/hr/kg)	V_d (mL/kg)
Efa Activity	PS80	2110 ± 382	0.25 (0.25 - 0.25)	59600 ± 14300	34.4 ± 3.05	1.29 ± 0.276	63.8 ± 11.7
	P188	2230 ± 342	0.25 (0.25 - 0.25)	62800 ± 8640	35.3 ± 5.96	1.20 ± 0.153	61.4 ± 16.2

[0344] The foregoing description of the specific embodiments will so fully reveal the general nature of the disclosure that others can, by applying knowledge within the skill of the art, readily modify and/or adapt for various applications such specific embodiments, without

undue experimentation, without departing from the general concept of the present disclosure. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance.

[0345] Other embodiments of the disclosure will be apparent to those skilled in the art from consideration of the specification and practice of the disclosure disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the disclosure being indicated by the following claims.

[0346] All patents and publications cited herein are incorporated by reference herein in their entirety.

SEQUENCES

Table 3: Exemplary chimeric protein sequences

A-FVIII(ELNN)-Fc: SEQ ID NO: 1						
ATRRYYLGAV	ELSWDYMQSD	LGELPVDARF	PPRVPKSFPF	NTSVVYKCTL	FVEFTDHLFN	60
IAKPRPPWMG	LLGPTIQAEV	YDTVVITLKN	MASHPVSLHA	VGVSYWKASE	GAEYDDQTSQ	120
REKEDDKVFP	GGSHYYVWQV	LKENGPMASD	PLCLTYSYLS	HVDLVKDLNS	GLIGALLVCR	180
EGSLAKEKTQ	TLHKFILLFA	VFDEGKSWHS	ETKNSLMQDR	DAASARAWPK	MHTVNGYVNR	240
SLPGLIGCHR	KSVYWHVIGM	GTTPEVHSIF	LEGHTFLVRN	HRQASLEISP	ITFLTAQTLL	300
MDLGQFLLFC	HISSHQHDGM	EAYVKVDSCP	EEPQLRMKNN	EEAEDYDDDL	TDSEMDVVRV	360
DDDNSPSFIQ	IRSVAKKHPK	TWVHYIAAEE	EDWDYAPLVL	APDDRSYKSQ	YLNNGPQRIG	420
RKYKKVRFMA	YTDETFKTRE	AIQHESGILG	PLLYGEVGDT	LLIIFKNQAS	RPYNIYPHGI	480
TDVRPLYRR	LPGKGVKHLKD	FPILPGEIFK	YKWTVTVEDG	PTKSDPRCLT	RYYSSEFVME	540
RDLASGLIG	LLICYKESVD	QRGNQIMSDK	RNVILFSVFD	ENRSWYL TEN	IQRFLPNPAG	600
VQLEDPEFQA	SNIMHSINGY	VFDSLQLSVC	LHEVAYWYIL	SIGAQTDFLS	VFFSGYTFKH	660
KMVYEDTLTL	FPFSGETVFM	SMENPGLWIL	GCHNSDFRNR	GMTALLKVSS	CDKNTGDYVE	720
DSYEDISAYL	LSKNNAI EPR	SFSQNGTSES	ATPESGPGSE	PATSGSETPG	TSESATPESG	780
PGSEPATSGS	ETPGTSESAT	PESGPGTSTE	PSEGSAPGSP	AGSPTSTEEG	TSESATPESG	840
PGSEPATSGS	ETPGTSESAT	PESGPGSPAG	SPTSTEEGSP	AGSPTSTEEG	TSTEPSEGSA	900
PGTSESATPE	SGPGTSESAT	PESGPGTSES	ATPESGPGSE	PATSGSETPG	SEPATSGSET	960
PGSPAGSPTS	TEEGTSTEPS	EGSAPGTSTE	PSEGSAPGSE	PATSGSETPG	TSESATPESG	1020
PGTSTEPSEG	SAPASSEETR	TTLQSDQEEI	DYDDTISVEM	KKEDFDIYDE	DENQSPRSFQ	1080
KKTRHYFIAA	VERLWDYGMS	SSPHVLRNRA	QSGSVLPQFKK	VVFQEF TDGS	FTQPLYRGEL	1140
NEHLGLLGPY	IRAEVEDNIM	VTFRNQASRP	YSFYSSLISY	EEDQRQGAEP	RKNFVKPNET	1200
KTYFWKVQHH	MAPTKDEFDC	KAWAYFSDVD	LEKDVHSGLI	GPLL VCHTNT	LNPAHGRQVT	1260
VQEFALFFTI	FDETKSWYFT	ENMERNCRAP	CNIQMEDPTF	KENYRFHAIN	GYIMDTLPGL	1320
QMAQDQRIRW	YLLSMGNSNEN	IHSIHFSGHV	FTVRKKEEYK	MALYNLYPGV	FETVEMLPSK	1380
AGIWRVECLI	GEHLHAGMST	LFLVYSNKCQ	TPLGMASGHI	RDFQITASGQ	YGQWAPKLAR	1440
LHYSGSINAW	STKEPFSWIK	VDLLAPMIIH	GIKTQGARQK	FSSLYISQFI	IMYSLDGKKW	1500
QTYRGNSTGT	LMVFFGNVDS	SGIKHNIFNP	PIIARYIRLH	PTHYSIRSTL	RMELMGCDLN	1560
SCSMPLGMES	KAISDAQITA	SSYFTNMFAT	WSPSKARLHL	QGRSNAWRPQ	VNNPKEWLQV	1620
DFQKTMKVTG	VTTQGVKSLL	TSMYVKEFLI	SSSQDGHQWT	LEFQNGKVKV	FQGNQDSFTP	1680
VVNSLDPPLL	TRYLRIHQPS	WVHQIALRME	VLGCEAQDLY	DKTHTCPPCP	APELLGGPSV	1740
FLFPPKPKDT	LMI SRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	1800
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	LPPSRDELTK	1860
NQVSLTCLVK	GFYPDSIAVE	WESNGQPENN	YKTPPVLDSD	DGSFFLYSKL	TVDKSRWQQG	1920
NVFCSCVMHE	ALHNHYTQKS	LSLSPG				
VWF(D'D3)-ELNN-a2 Linker-Fc: SEQ ID NO: 2						
SLSCRPPMVK	LVC PADNLRA	EGLECTKTCQ	NYDLECMSMG	CVSGCLCPPG	MVRHENRCVA	60
LERPCFHHQ	KEYAPGETVK	IGCNTCVCRD	RKWNCTDHVC	DATCSTIGMA	HYLTFDGLKY	120
LFPGECCYVL	VQDYCGSNPG	TFRILVGNKG	CSHPSVKCKK	RVTILVEGGE	IELFDGEVNV	180
KRPMKDETHF	EVVESGRYII	LLLGKALSVV	WDRHLSISVV	LKQTYQEKVC	GLCGNFDGIQ	240
NNDLTSSNLQ	VEEDPVD FGN	SWKVSSQCAD	TRKVPLDSSP	ATCHNNIMKQ	TMVDSSCRIL	300
TSDVFQDCNK	LVDPEPYLDV	CIYDTCSCES	IGDCAAFCDT	IAAYAHVCAQ	HGKVVTWRTA	360
TLCPQSCEER	NLRENGYEAE	WRYN SCAPAC	QVTCQHPEPL	ACPVQCVEGC	HAHCPPGKIL	420
DELLQTCVDP	EDCPVCEVAG	RRFASGKKVT	LNPSDPEHCQ	ICHCDVVNLT	CEACQEPGTS	480
ESATPESGPG	SEPATSGSET	PGTSESATPE	SGPGSEPAT	GSETPGTSES	ATPESGPGTS	540
TEPSEGSAPG	SPAGSPTSTE	EGTSESATPE	SGPGSEPAT	GSETPGTSES	ATPESGPGSP	600
AGSPTSTEEG	SPAGSPTSTE	EGASSDKNTG	DYYEDSYEDI	SAYLLSKNNA	IEPRSFSDKT	660
HTCPCCPAPE	LLGGPSVFLF	PPKPKDTLMI	SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	720
VHNAKTKPRE	EQYNSTYRVV	SVLTVLHQDW	LNGKEYKCKV	SNKALPAPIE	KTISKAKGQP	780
REPQVYTLPP	SRDELTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	TPPVLDSDGS	840
FFLYSKLTVD	KSRWQQGNVF	SCSV MHEALH	NHYTQKSLSL	SPG		883
Amino acid sequence of FVIII protein (312A) – includes signal peptide: SEQ ID NO: 3						
1	MQIELSTCFF LCLLRFCFSA TRRYYLGA VE LSWDYMQSDL GELPVDARFP					
51	PRVPKSFPFN TSVVYKKTLE FVEFTDHLFNI AKPRPPWMGL LGPTIQAEVY					

101	DTVVITLKNM	ASHPVSLHAV	GVSYWKASEG	AEYDDQTSQR	EKEDDKVFPG
151	GSHTYVWQVL	KENGPMSADP	LCLTYSYLSH	VDLVKDLNSG	LIGALLVCRE
201	GSLAKEKTQT	LHKFILLFAV	FDEGKSWHSE	TKNSLMQDRD	AASARAWPKM
251	HTVNGYVNR	LPGLIGCHRK	SVYWHVIGMG	TTPEVHSIFL	EGHTFLVRNH
301	RQASLEISPI	TFLTAQTLLM	DLGQFLLFCH	ISSHQHDGME	AYVKVDSCPE
351	EPQLRMKNNE	EAEDYDDDLT	DSEMDVVRFD	DDNSPSFIQI	RSVAKKHPKT
401	WVHYIAAEEE	DWDYAPLVLA	PDDRSYKSQY	LNNGPQRIGR	KYKKVRFMAY
451	TDETFKTREA	IQHESGILGP	LLYGEVGDTL	LIIFKNQASR	PYNIYPHGIT
501	DVRPLYSRRL	PKGVKHLKDF	PILPGEIFKY	KWTVTVEDGP	TKSDPRCLTR
551	YYSSFVNMER	DLASGLIGPL	LICYKESVDQ	RGNQIMSDKR	NVILFSVFDE
601	NRSWYL TENI	QRFLPNPAGV	QLEDPEFQAS	NIMHSINGYV	FDSLQLSVCL
651	HEVAYWYILS	IGAQTDFLSV	FFSGYTFKHK	MVYEDTLTLF	PFSGETVFMS
701	MENPGLWILG	CHNSDFRNRG	MTALLKVSSC	DKNTGDYED	SYEDISAYLL
751	SKNNAIEPRS	FSQNGTSESA	TPESGPGSEP	ATSGSETPGT	SESATPESGP
801	GSEPATSGSE	TPGTSESATP	ESGPGTSTEP	SEGSAPGSPA	GSPTSTEEGT
851	SESATPESGP	GSEPATSGSE	TPGTSESATP	ESGPGSPAGS	PTSTEEGSPA
901	GSPTSTEEGT	STEPSEGSAP	GTSESATPES	GPGTSESATP	ESGPGTSESA
951	TPESGPGSEP	ATSGSETPGS	EPATSGSETP	GSAGSPSTST	EEGTSTEPSE
1001	GSAPGTSTEP	SEGSAPGSEP	ATSGSETPGT	SESATPESGP	GTSTEPSEGS
1051	APASSEITRT	TLQSDQEEID	YDDTISVEMK	KEDFDIYDED	ENQSPRSFQK
1101	KTRHYFIAAV	ERLWDYGMSS	SPHVLNRNAQ	SGSVPQFKKV	VFQEFDTGSGF
1151	TQPLYRGELN	EHLGLLGPYI	RAEVEDNIMV	TFRNQASRPY	SFYSSLISYE
1201	EDQRQGAEP	RNFVKPNETK	TYFWKVQHMM	APTKDEFDCK	AWAYFSDVDL
1251	EKDVHSGLIG	PLLVCHTNTL	NPAHGRQVTV	QEFALFFTIF	DETKSWYFTE
1301	NMERNCRAPC	NIQMEDPTFK	ENYRFHAING	YIMDTLPGLV	MAQDQIRWY
1351	LLSMGSENENI	HSIHFSGHVF	TVRKKEEYKM	ALYNLYPGVF	ETVEMLP SKA
1401	GIWRVECLIG	EHLHAGMSTL	FLVYSNKCQT	PLGMASGHIR	DFQITASGQY
1451	GQWAPKLARL	HYSGSINAWS	TKEPFSWIKV	DLLAPMI IHG	IKTQGARQKF
1501	SSLYISQFII	MYSLDGKKWQ	TYRGNSTGTL	MVFFGNVDSS	GIKHNI FNPP
1551	IIARYIRLHP	THYSIRSTLR	MELMGCDLNS	CSMPLGMESK	AISDAQITAS
1601	SYFTNM FATW	SPSKARLHLQ	GRSNAWRPQV	NNPKEWLQVD	FQKTMKVTGV
1651	TTQGVKSLLT	SMYVKEFLIS	SSQDGHQWTL	FFQNGKVKVF	QGNQDSFTPV
1701	VNSLDPPLLT	RYLRIHPQSW	VHQIALRMEV	LGCEAQDLYD	KTHTCPPCPA
1751	PELLGGPSVF	LFPPPKP KDTL	MISRTPEVTC	VVVDVSHEDP	EVKFNWYVDG
1801	VEVHNAKTKP	REEQYNSTYR	VVSVLTVLHQ	DWLNKGKEYKC	KVSNKALPAP
1851	IEKTISKAKG	QPREPQVYTL	PSPRDELTKN	QVSLTCLVKG	FYPSPDIAVEW
1901	ESNGQPENNY	KTTTPVLDS	GSFFLYSKLT	VDKSRWQQGN	VFSCSVMHEA
1951	LHNHYTQKSL	SLSPG*			

Nucleotide sequence encoding FVIII 312A: SEQ ID NO: 4

1	ATGCAAATAG	AGCTCTCCAC	CTGCTTCTTT	CTGTGCCTTT	TGCGATTCTG
51	CTTTAGTGCC	ACCAGAAAGAT	ACTACCTGGG	TGCAGTGGAA	CTGTCATGGG
101	ACTATATGCA	AAGTGATCTC	GGTGAGCTGC	CTGTGGACGC	AAGATTTTCCT
151	CCTAGAGTGC	CAAAATCTTT	TCCATTCAAC	ACCTCAGTCG	TGTACAAAAA
201	GACTCTGTTT	GTAGAATTCA	CGGATCACCT	TTTCAACATC	GCTAAGCCAA
251	GGCCACCCTG	GATGGGTCTG	CTAGGTCCTA	CCATCCAGGC	TGAGGTTTAT
301	GATACAGTGG	TCATTACACT	TAAGAACATG	GCTTCCCATC	CTGTCAGTCT
351	TCATGCTGTT	GGTGTATCCT	ACTGGAAAGC	TTCTGAGGGA	GCTGAATATG
401	ATGATCAGAC	CAGTCAAAGG	GAGAAAGAA	ATGATAAAGT	CTTCCCTGGT
451	GGAAGCCATA	CATATGTCTG	GCAGGTCCTG	AAAGAGAATG	GTCCAATGGC
501	CTCTGACCCA	CTGTGCCTTA	CCTACTCATA	TCTTTCTCAT	GTGGACCTGG
551	TAAAAGACTT	GAATTCAGGC	CTCATTTGGAG	CCCTACTAGT	ATGTAGAGAA
601	GGGAGTCTGG	CCAAGGAAAA	GACACAGACC	TTGCACAAAT	TTATACTACT
651	TTTTGCTGTA	TTTGATGAAG	GGAAAAGTTG	GCACTCAGAA	ACAAAGA ACT
701	CCTTGATGCA	GGATAGGGAT	GCTGCATCTG	CTCGGGCCTG	GCCTAAAATG

751	CACACAGTCA	ATGGTTATGT	AAACAGGTCT	CTGCCAGGTC	TGATTGGATG
801	CCACAGGAAA	TCAGTCTATT	GGCATGTGAT	TGGAATGGGC	ACCACTCCTG
851	AAGTGCACCTC	AATATTCCTC	GAAGGTCACA	CATTTCTTGT	GAGGAACCAT
901	CGCCAGGCGT	CCTTGGAAAT	CTCGCCAATA	ACTTTCCTTA	CTGCTCAAAC
951	ACTCTTGATG	GACCTTGGAC	AGTTTCTACT	GTTTTGTCAT	ATCTCTTCCC
1001	ACCAACATGA	TGGCATGGAA	GCTTATGTCA	AAGTAGACAG	CTGTCCAGAG
1051	GAACCCCAAC	TACGAATGAA	AAATAATGAA	GAAGCGGAAG	ACTATGATGA
1101	TGATCTTACT	GATTCTGAAA	TGGATGTGGT	CAGGTTTGAT	GATGACAACT
1151	CTCCTTCCTT	TATCCAAAAT	CGCTCAGTTG	CCAAGAAGCA	TCCTAAAAC
1201	TGGGTACATT	ACATTGCTGC	TGAAGAGGAG	GACTGGGACT	ATGCTCCCTT
1251	AGTCTCGCC	CCCGATGACA	GAAGTTATAA	AAGTCAATAT	TTGAACAATG
1301	GCCCTCAGCG	GATTGGTAGG	AAGTACAAAA	AAGTCCGATT	TATGGCATA
1351	ACAGATGAAA	CCTTTAAGAC	TCGTGAAGCT	ATTCAGCATG	AATCAGGAAT
1401	CTTGGGACCT	TTACTTTATG	GGGAAGTTGG	AGACACACTG	TTGATTATAT
1451	TTAAGAATCA	AGCAAGCAGA	CCATATAACA	TCTACCCTCA	CGGAATCACT
1501	GATGTCCGTC	CTTTGTATTC	AAGGAGATTA	CCAAAAGGTG	TAAAACATTT
1551	GAAGGATTTT	CCAATTCTGC	CAGGAGAAAT	ATTCAAATAT	AAATGGACAG
1601	TGACTGTAGA	AGATGGGCCA	ACTAAATCAG	ATCCTCGGTG	CCTGACCCGC
1651	TATTACTCTA	GTTTCGTTAA	TATGGAGAGA	GATCTAGCTT	CAGGACTCAT
1701	TGGCCCTCTC	CTCATCTGCT	ACAAAAGAATC	TGTAGATCAA	AGAGGAAACC
1751	AGATAATGTC	AGACAAGAGG	AATGTCATCC	TGTTTTCTGT	ATTTGATGAG
1801	AACCGAAGCT	GGTACCTCAC	AGAGAATATA	CAACGCTTTC	TCCCCAATCC
1851	AGCTGGAGTG	CAGCTTGAGG	ATCCAGAGTT	CCAAGCCTCC	AACATCATGC
1901	ACAGCATCAA	TGGCTATGTT	TTTGATAGTT	TGCAGTTGTC	AGTTTGTTTG
1951	CATAGGTGG	CATACTGGTA	CATTCTAAGC	ATTGGAGCAC	AGACTGACTT
2001	CCTTTCTGTC	TTCTTCTCTG	GATATACCTT	CAAAACAAAA	ATGGTCTATG
2051	AAGACACACT	CACCCTATTC	CCATTCTCAG	GAGAAACTGT	CTTCATGTCG
2101	ATGGAAAACC	CAGGTCTATG	GATTCTGGGG	TGCCACAAC	CAGACTTTTCG
2151	GAACAGAGGC	ATGACCGCCT	TACTGAAGGT	TTCTAGTTGT	GACAAGAACA
2201	CTGGTGATTA	TTACGAGGAC	AGTTATGAAG	ATATTTTCAGC	ATACTTGCTG
2251	AGTAAAAACA	ATGCCATTGA	ACCAAGAAGC	TTCTCTCAA	ACGGTACCTC
2301	AGAGTCTGCT	ACCCCGAGT	CAGGGCCAGG	ATCAGAGCCA	GCCACCTCCG
2351	GGTCTGAGAC	ACCCGGGACT	TCCGAGAGTG	CCACCCCTGA	GTCCGGACCC
2401	GGGTCCGAGC	CCGCCACTTC	CGGCTCCGAA	ACTCCCGGCA	CAAGCGAGAG
2451	CGCTACCCCA	GAGTCAGGAC	CAGGAACATC	TACAGAGCCC	TCTGAAGGCT
2501	CCGCTCCAGG	GTCCCCAGCC	GGCAGTCCCA	CTAGCACC	GGAGGGAACC
2551	TCTGAAAGCG	CCACACCCGA	ATCAGGGCCA	GGGTCTGAGC	CTGCTACCAG
2601	CGGCAGCGAG	ACACCAGGCA	CCTCTGAGTC	CGCCACACCA	GAGTCCGGAC
2651	CCGGATCTCC	CGCTGGGAGC	CCCACCTCCA	CTGAGGAGGG	ATCTCCTGCT
2701	GGCTCTCCAA	CATCTACTGA	GGAAGGAACC	TCAACCGAGC	CATCCGAGGG
2751	ATCAGCTCCC	GGCACCTCAG	AGTCGGCAAC	CCCGGAGTCT	GGACCCGGAA
2801	CTTCCGAAAG	TGCCACACCA	GAGTCCGGTC	CCGGGACTTC	AGAATCAGCA
2851	ACACCCGAGT	CCGGCCCTGG	GTCTGAACCC	GCCACAAGTG	GATGTGAGAC
2901	ACCAGGATCA	GAACCTGCTA	CCTCAGGGTC	AGAGACACCC	GGATCTCCGG
2951	CAGGCTCACC	AACCTCCACT	GAGGAGGGCA	CCAGCACAGA	ACCAAGCGAG
3001	GGCTCCGCAC	CCGGAACAAG	CACTGAACCC	AGTGAGGGTT	CAGCACCCGG
3051	CTCTGAGCCG	GCCACAAGTG	GCAGTGAGAC	ACCCGGCACT	TCAGAGAGTG
3101	CCACCCCCGA	GAGTGGCCCA	GGCACTAGTA	CCGAGCCCTC	TGAAGGCAGT
3151	GCGCCAGCCT	CGAGCGAAAT	AACTCGTACT	ACTCTTCAGT	CAGATCAAGA
3201	GGAAATTGAC	TATGATGATA	CCATATCAGT	TGAAATGAAG	AAGGAAGATT
3251	TTGACATTTA	TGATGAGGAT	GAAAATCAGA	GCCCCGCAG	CTTTCAAAG
3301	AAAACACGAC	ACTATTTTAT	TGCTGCAGTG	GAGAGGCTCT	GGGATTATGG
3351	GATGAGTAGC	TCCCCACATG	TTCTAAGAAA	CAGGGCTCAG	AGTGGCAGTG
3401	TCCCTCAGTT	CAAGAAAAGTT	GTTTTCCAGG	AATTTACTGA	TGGCTCCTTT
3451	ACTCAGCCCT	TATACCGTGG	AGAACTAAAT	GAACATTTGG	GACTCCTGGG
3501	GCCATATATA	AGAGCAGAAG	TTGAAGATAA	TATCATGGTA	ACTTTCAGAA
3551	ATCAGGCCTC	TCGTCCCTAT	TCCTTCTATT	CTAGCCCTAT	TTCTTATGAG
3601	GAAGATCAGA	GGCAAGGAGC	AGAACCTAGA	AAAACTTTG	TCAAGCCTAA

3651	TGAAACCAAA	ACTTACTTTT	GGAAAGTGCA	ACATCATATG	GCACCCACTA
3701	AAGATGAGTT	TGACTGCAAA	GCCTGGGCTT	ATTTCTCTGA	TGTTGACCTG
3751	GAAAAAGATG	TGCACTCAGG	CCTGATTGGA	CCCCTTCTGG	TCTGCCACAC
3801	TAACACACTG	AACCCTGCTC	ATGGGAGACA	AGTGACAGTA	CAGGAATTTG
3851	CTCTGTTTTT	CACCATCTTT	GATGAGACCA	AAAGCTGGTA	CTTCACTGAA
3901	AATATGGAAA	GAAACTGCAG	GGCTCCCTGC	AATATCCAGA	TGGAAGATCC
3951	CACTTTTAAA	GAGAATTATC	GCTTCCATGC	AATCAATGGC	TACATAATGG
4001	ATACACTACC	TGGCTTAGTA	ATGGCTCAGG	ATCAAAGGAT	TCGATGGTAT
4051	CTGCTCAGCA	TGGGCAGCAA	TGAAAACATC	CATTCTATTC	ATTTCACTGG
4101	ACATGTGTTT	ACTGTACGAA	AAAAAGAGGA	GTATAAAATG	GCACTGTACA
4151	ATCTCTATCC	AGGTGTTTTT	GAGACAGTGG	AAATGTTACC	ATCCAAAGCT
4201	GGAATTTGGC	GGGTGGAATG	CCTTATTGGC	GAGCATCTAC	ATGCTGGGAT
4251	GAGCACACTT	TTTCTGGTGT	ACAGCAATAA	GTGTCAGACT	CCCCTGGGAA
4301	TGGCTTCTGG	ACACATTAGA	GATTTTCAGA	TTACAGCTTC	AGGACAATAT
4351	GGACAGTGGG	CCCCAAAGCT	GGCCAGACTT	CATTATTCCT	GATCAATCAA
4401	TGCCTGGAGC	ACCAAGGAGC	CCTTTTCTTG	GATCAAGGTG	GATCTGTTGG
4451	CACCAATGAT	TATTCACGGC	ATCAAGACCC	AGGGTGCCCG	TCAGAAGTTC
4501	TCCAGCCTCT	ACATCTCTCA	GTTTATCATC	ATGTATAGTC	TTGATGGGAA
4551	GAAGTGGCAG	ACTTATCGAG	GAAATTCCAC	TGGAACCTTA	ATGGTCTTCT
4601	TTGGCAATGT	GGATTTCATCT	GGGATAAAAC	ACAATATTTT	TAACCCCTCCA
4651	ATTATTGCTC	GATACATCCG	TTTGCACCCA	ACTCATTATA	GCATTGCGAG
4701	CACTCTTCGC	ATGGAGTTGA	TGGGCTGTGA	TTTAAATAGT	TGCAGCATGC
4751	CATTGGGAAT	GGAGAGTAAA	GCAATATCAG	ATGCACAGAT	TACTGCTTCA
4801	TCCTACTTTA	CCAATATGTT	TGCCACCTGG	TCTCCTTCAA	AAGCTCGACT
4851	TCACCTCCAA	GGGAGGAGTA	ATGCCTGGAG	ACCTCAGGTG	AATAATCCAA
4901	AAGAGTGGCT	GCAAGTGGAC	TTCCAGAAGA	CAATGAAAGT	CACAGGAGTA
4951	ACTACTCAGG	GAGTAAAAATC	TCTGCTTACC	AGCATGTATG	TGAAGGAGTT
5001	CCTCATCTCC	AGCAGTCAAG	ATGGCCATCA	GTGGACTCTC	TTTTTTTCAGA
5051	ATGGCAAAGT	AAAGGTTTTT	CAGGGAAATC	AAGACTCCTT	CACACCTGTG
5101	GTGAACTCTC	TAGACCCACC	GTTACTGACT	CGCTACCTTC	GAATTCACCC
5151	CCAGAGTTGG	GTGCACCAGA	TTGCCCTGAG	GATGGAGGTT	CTGGGCTGCG
5201	AGGCACAGGA	CCTCTACGAC	AAAACTCACA	CATGCCCACC	GTGCCCAGCT
5251	CCAGAACTCC	TGGGCGGACC	GTCAGTCTTC	CTCTTCCCCC	CAAAACCCAA
5301	GGACACCCTC	ATGATCTCCC	GGACCCCTGA	GGTCACATGC	GTGGTGGTGG
5351	ACGTGAGCCA	CGAAGACCCCT	GAGGTCAAGT	TCAACTGGTA	TGTGGACGGC
5401	GTGGAAGTGC	ATAATGCCAA	GACAAAGCCG	CGGGAGGAGC	AGTACAACAG
5451	CACGTACCGT	GTGGTCAGCG	TCCTCACCCT	CCTGCACCAA	GACTGGCTGA
5501	ATGGCAAGGA	GTACAAGTGC	AAGGTCTCCA	ACAAAGCCCT	CCCAGCCCCC
5551	ATCGAGAAAA	CCATCTCCAA	AGCCAAAGGG	CAGCCCCGAG	AACCACAGGT
5601	GTACACCCTG	CCCCCATCCC	GGGATGAGCT	GACCAAGAAC	CAAGTTAGCC
5651	TGACCTGCCT	GGTCAAAGGC	TTCTATCCCA	GCGACATCGC	CGTGGAGTGG
5701	GAGAGCAATG	GGCAGCCGGA	GAACAACTAC	AAGACCACGC	CTCCCGTGT
5751	GGACTCCGAC	GGCTCCTTCT	TCCTCTACTC	CAAGCTCACC	GTGGACAAGA
5801	GCAGGTGGCA	GCAGGGGAAC	GCTTTCTCAT	GCTCCGTGAT	GCATGAGGCT
5851	CTGCACAACC	ACTACACGCA	GAAGAGCCTC	TCCCTGTCTC	CGGGTTGA

**Amino acid sequence of VWF059A protein – includes signal peptide and D1D2 region:
SEQ ID NO: 5**

1	MIPARFAGVL	LALALILPGT	LCAEGTRGRS	STARCSLFGS	DFVNTFDGSM
51	YSFAGYCSYL	LAGGCQKRSF	SIIGDFQNGK	RVSLSVYLGE	FFDIHLFVNG
101	TVTQGDQRV	MPYASKGLYL	ETEAGYYKLS	GEAYGFVARI	DGSGNFQVLL
151	SDRYFNKTCG	LCGNFNIFAE	DDFMTQEGTL	TSDPYDFANS	WALSSGEQWC
201	ERASPPSSSC	NISSGEMQKG	LWEQCQLLKS	TSVFARCHPL	VDPEPFVALC
251	EKTLCECAGG	LECACPALLE	YARTCAQEGM	VLYGWDHSA	CSPVCPAGME
301	YRQCVSPCAR	TCQSLHINEM	CQERCVDGCS	CPEGQLLDEG	LCVESTCEPC

351	VHSGKRYPPG	TSLSRDCNTC	ICRNSQWICS	NEECPGECLV	TGQSHFKSFD
401	NRYFTFSGIC	QYLLARDCQD	HSFSIVIETV	QCADDRDAVC	TRSVTVRLPG
451	LHNSLVKLKH	GAGVAMDGQD	IQLPLLKGD	RIQHTVTASV	RLSYGEDLQM
501	DWDGRGRLLV	KLSPVYAGKT	CGLCGNYNGN	QGDDFLTPSG	LAEPRVEDFG
551	NAWKHLHGDCQ	DLQKQHSDFC	ALNPRMTRFS	EEACAVLTSP	TFEACHRAVS
601	PLPYLRNCRY	DVCSCSDGRE	CLCGALASYA	AACAGRGVRV	AWREPGRCEL
651	NCPKGQVYLQ	CGTPCNLTCT	SLSYPDEECN	EACLEGCFCP	PGLYMDERGD
701	CVPKAQCPCY	YDGEIFQPED	IFSDHHTMCY	CEDGFMHCTM	SGVPGSLLPD
751	AVLSSPLSHR	SKRSLSCRPP	MVKLVCPADN	LRAEGLECTK	TCQNYDLECM
801	SMGCVSGCLC	PPGMVRHENR	CVALERCPCF	HQKEYAPGE	TVKIGCNTCV
851	CRDRKWNCTD	HVCDATCSTI	GMAHYLTFDG	LKYLFPGECQ	YVLVQDYCGS
901	NPGTFRILVG	NKGC SHPSVK	CKKRVITLVE	GGEIELFDGE	VNVKRPMKDE
951	THFEVVESGR	YIILLGLKAL	SVVWDRHLSI	SVVLKQTYQE	KVCGLCGNFD
1001	GIQNNDLTSS	NLQVEEDPVD	FGNSWKVSSQ	CADTRKVPLD	SSPATCHNNI
1051	MKQTMVDSSC	RILTSDVFDQ	CNKLVDPPEY	LDVCIYDTCS	CESIGDCAAF
1101	CDTIAAYAHV	CAQHKGKVVW	RTATLCPQSC	EERNLRENGY	EAEWRYNSCA
1151	PACQVTCQHP	EPLACPVQCV	EGCHAHCPPG	KILDELLQTC	VPEDCPVCE
1201	VAGRRFASGK	KVTLNPSDPE	HCQICHCDVV	NLTCEACQEP	GTSESATPES
1251	GPSEPATSG	SETPGTSESA	TPESGPGSEP	ATSGSETPGT	SESATPESGP
1301	GTSTEPSEGS	APGSPAGSPT	STEEGTSESA	TPESGPGSEP	ATSGSETPGT
1351	SESATPESGP	GSPAGSPTST	EESGSPAGSPT	STEEGASSDK	NTGDYYEDSY
1401	EDISAYLLSK	NNAIEPRSF	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT
1451	LMISRTPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY
1501	RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT
1551	LPPSRDELTK	NQVSLTCLVK	GFYPSTIAVE	WESNGQPENN	YKTTTPPVLD
1601	DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPG*

Nucleotide sequence encoding VWF059A protein: SEQ ID NO: 6

1	ATGATTCTCTG	CCAGATTTGTC	CGGGGTGCTG	CTTGCTCTGG	CCCTCATTTT
51	GCCAGGGACC	CTTTGTGCAG	AAGGAACTCG	CGGCAGGTCA	TCCACGGCCC
101	GATGCAGCCT	TTTCGGAAGT	GACTTCGTCA	ACACCTTTGA	TGGGAGCATG
151	TACAGCTTTG	CGGGATACTG	CAGTTACCTC	CTGGCAGGGG	GCTGCCAGAA
201	ACGCTCCTTC	TCGATTATTG	GGGACTTCCA	GAATGGCAAG	AGAGTGAGCC
251	TCTCCGTGTA	TCTTGGGGAA	TTTTTTGACA	TCCATTTGTT	TGTCAATGGT
301	ACCGTGACAC	AGGGGGACCA	AAGAGTCTCC	ATGCCCTATG	CCTCCAAAGG
351	GCTGTATCTA	GAAACTGAGG	CTGGGTACTA	CAAGCTGTCC	GGTGAGGCCT
401	ATGGCTTTGT	GGCCAGGATC	GATGGCAGCG	GCAACTTTCA	AGTCTGCTG
451	TCAGACAGAT	ACTTCAACAA	GACCTGCGGG	CTGTGTGGCA	ACTTTAACAT
501	CTTTGCTGAA	GATGACTTTA	TGACCCAAGA	AGGGACCTTG	ACCTCGGACC
551	CTTATGACTT	TGCCAACTCA	TGGGCTCTGA	GCAGTGGAGA	ACAGTGGTGT
601	GAACGGGCAT	CTCCTCCCAG	CAGCTCATGC	AACATCTCCT	CTGGGGAAAT
651	GCAGAAGGGC	CTGTGGGAGC	AGTGCCAGCT	TCTGAAGAGC	ACCTCGGTGT
701	TGCCCCGCTG	CCACCCTCTG	GTGGACCCCG	AGCCTTTTGT	GGCCCTGTGT
751	GAGAAGACTT	TGTGTGAGTG	TGCTGGGGGG	CTGGAGTGCG	CCTGCCCTGC
801	CCTCCTGGAG	TACGCCCCGA	CCTGTGCCCA	GGAGGGAAATG	GTGCTGTACG
851	GCTGGACCGA	CCACAGCGCG	TGCAGCCCAG	TGTGCCCTGC	TGGTATGGAG
901	TATAGGCAGT	GTGTGTCCCC	TTGCGCCAGG	ACCTGCCAGA	GCCTGCACAT
951	CAATGAAATG	TGTCAGGAGC	GATGCGTGGA	TGGCTGCAGC	TGCCCTGAGG
1001	GACAGCTCCT	GGATGAAGGC	CTCTGCGTGG	AGAGCACCGA	GTGTCCCTGC
1051	GTGCATTCCG	GAAAGCGCTA	CCCTCCCGGC	ACCTCCCTCT	CTCGAGACTG
1101	CAACACCTGC	ATTTGCCGAA	ACAGCCAGTG	GATCTGCAGC	AATGAAGAAT
1151	GTCCAGGGGA	GTGCCTTGTC	ACTGGTCAAT	CCCACTTCAA	GAGCTTTGAC
1201	AACAGATACT	TCACCTTCAG	TGGGATCTGC	CAGTACCTGC	TGGCCCGGGA
1251	TTGCCAGGAC	CACTCCTTCT	CCATTGTCAT	TGAGACTGTC	CAGTGTGCTG
1301	ATGACCGCGA	CGCTGTGTGC	ACCCGCTCCG	TCACCGTCCG	GCTGCCCTGGC
1351	CTGCACAACA	GCCTTGTGAA	ACTGAAGCAT	GGGGCAGGAG	TTGCCATGGA

1401	TGGCCAGGAC	ATCCAGCTCC	CCCTCCTGAA	AGGTGACCTC	CGCATCCAGC
1451	ATACAGTGAC	GGCCTCCGTG	CGCCTCAGCT	ACGGGGAGGA	CCTGCAGATG
1501	GACTGGGATG	GCCGCGGGAG	GCTGCTGGTG	AAGCTGTCCC	CCGTCTATGC
1551	CGGGAAGACC	TGCGGCCTGT	GTGGGAATTA	CAATGGCAAC	CAGGGCGACG
1601	ACTTCCTTAC	CCCCCTCTGGG	CTGGCGGAGC	CCCGGGTGGA	GGACTTCGGG
1651	AACGCCTGGA	AGCTGCACGG	GGACTGCCAG	GACCTGCAGA	AGCAGCACAG
1701	CGATCCCTGC	GCCCTCAACC	CGCGCATGAC	CAGGTTCTCC	GAGGAGGCGT
1751	GCGCGGTCTT	GACGTCCCCC	ACATTCGAGG	CCTGCCATCG	TGCCGTCAGC
1801	CCGCTGCCCT	ACCTGCGGAA	CTGCCGCTAC	GACGTGTGCT	CCTGCTCGGA
1851	CGGCCGCGAG	TGCCTGTGCG	GCGCCCTGGC	CAGCTATGCC	GCGGCCTGCG
1901	CGGGGAGAGG	CGTGCGCGTC	GCGTGGCGCG	AGCCAGGCCG	CTGTGAGCTG
1951	AACTGCCCCA	AAGGCCAGGT	GTACCTGCAG	TGCGGGACCC	CCTGCAACCT
2001	GACCTGCCGC	TCTCTCTCTT	ACCCGGATGA	GGAATGCAAT	GAGGCCTGCC
2051	TGGAGGGCTG	CTTCTGCCCC	CCAGGGCTCT	ACATGGATGA	GAGGGGGGAC
2101	TGCGTGCCCA	AGGCCCAGTG	CCCCTGTTAC	TATGACGGTG	AGATCTTCCA
2151	GCCAGAAGAC	ATCTTCTCAG	ACCATCACAC	CATGTGCTAC	TGTGAGGATG
2201	GCTTCATGCA	CTGTACCATG	AGTGGAGTCC	CCGGAAGCTT	GCTGCCCTGAC
2251	GCTGTCTCTA	GCAGTCCCCC	GTCTCATCGC	AGCAAAAGGA	GCCTATCCTG
2301	TCGGCCCCCC	ATGGTCAAGC	TGGTGTGTCC	CGCTGACAAC	CTGCGGGCTG
2351	AAGGGCTCGA	GTGTACCAAA	ACGTGCCAGA	ACTATGACCT	GGAGTGCATG
2401	AGCATGGGCT	GTGTCTCTGG	CTGCCTCTGC	CCCCCGGGCA	TGGTCCGGCA
2451	TGAGAACAGA	TGTGTGGCCC	TGGAAAGGTG	TCCCTGCTTC	CATCAGGGCA
2501	AGGAGTATGC	CCCTGGAGAA	ACAGTGAAGA	TTGGCTGCAA	CACTTGTGTC
2551	TGTCGGGACC	GGAAGTGGAA	CTGCACAGAC	CATGTGTGTG	ATGCCACGTG
2601	CTCCACGATC	GGCATGGCCC	ACTACCTCAC	CTTCGACGGG	CTCAAATACC
2651	TGTTCCCCGG	GGAGTGCCAG	TACGTTCTGG	TGCAGGATTA	CTGCGGCAGT
2701	AACCCTGGGA	CCTTTCGGAT	CCTAGTGGGG	AATAAGGGAT	GCAGCCACCC
2751	CTCAGTGAAA	TGCAAGAAAC	GGGTACCAT	CCTGGTGGAG	GGAGGAGAGA
2801	TTGAGCTGTT	TGACGGGGAG	GTGAATGTGA	AGAGGCCCAT	GAAGGATGAG
2851	ACTCACTTTG	AGGTGGTGGA	GTCTGGCCGG	TACATCATTC	TGCTGCTGGG
2901	CAAAGCCCTC	TCCGTGGTCT	GGGACCGCCA	CCTGAGCATC	TCCGTGGTCC
2951	TGAAGCAGAC	ATACCAGGAG	AAAGTGTGTG	GCCTGTGTGG	GAATTTTGAT
3001	GGCATCCAGA	ACAATGACCT	CACCAGCAGC	AACCTCCAAG	TGGAGGAAGA
3051	CCCTGTGGAC	TTTGGGAACT	CCTGGAAAGT	GAGCTCGCAG	TGTGCTGACA
3101	CCAGAAAAGT	GCCTCTGGAC	TCATCCCCTG	CCACCTGCCA	TAACAACATC
3151	ATGAAGCAGA	CGATGGTGGA	TTCTCTCTGT	AGAATCCTTA	CCAGTGACGT
3201	CTTCCAGGAC	TGCAACAAGC	TGGTGGACCC	CGAGCCATAT	CTGGATGTCT
3251	GCATTTACGA	CACCTGCTCC	TGTGAGTCCA	TTGGGGACTG	CGCCGCATTG
3301	TGCGACACCA	TTGCTGCCTA	TGCCCACGTG	TGTGCCCAGC	ATGGCAAGGT
3351	GGTGACCTGG	AGGACGGCCA	CATTGTGCCC	CCAGAGCTGC	GAGGAGAGGA
3401	ATCTCCGGGA	GAACGGGTAT	GAGGCTGAGT	GGCGCTATAA	CAGCTGTGCA
3451	CCTGCCTGTC	AAGTCACGTG	TCAGCACCCCT	GAGCCACTGG	CCTGCCCTGT
3501	GCAGTGTGTG	GAGGGCTGCC	ATGCCCACTG	CCCTCCAGGG	AAAATCCTGG
3551	ATGAGCTTTT	GCAGACCTGC	GTTGACCCTG	AAGACTGTCC	AGTGTGTGAG
3601	GTGGCTGGCC	GGCGTTTTGC	CTCAGGAAAG	AAAGTCACCT	TGAATCCCAG
3651	TGACCCTGAG	CACTGCCAGA	TTTGCCACTG	TGATGTTGTC	AACCTCACCT
3701	GTGAAGCCTG	CCAGGAGCCG	GGTACATCAG	AGAGCGCCAC	CCCTGAAAGT
3751	GGTCCCGGGA	GCGAGCCAGC	CACATCTGGG	TCGGAAACGC	CAGGCACATC
3801	CGAGTCTGCA	ACTCCCAGAT	CCGGACCTGG	CTCCGAGCCT	GCCACTAGCG
3851	GCTCCGAGAC	TCCGGGAACT	TCCGAGAGCG	CTACACCAGA	AAGCGGACCC
3901	GGAACCAGTA	CCGAACCTAG	CGAGGGCTCT	GCTCCGGGCA	GCCCAGCCGG
3951	CTCTCCTACA	TCCACGGAGG	AGGGCACTTC	CGAATCCGCC	ACCCCGGAGT
4001	CAGGGCCAGG	ATCTGAACCC	GCTACCTCAG	GCAGTGAGAC	GCCAGGAACG
4051	AGCAGTCCG	CTACACCGGA	GAGTGGGCCA	GGGAGCCCTG	CTGGATCTCC
4101	TACGTCCACT	GAGGAAGGGT	CACCAGCGGG	CTCGCCACC	AGCAGTGAAG
4151	AAGGTGCCTC	GTCTGACAAG	AACACTGGTG	ATTATTACGA	GGACAGTTAT
4201	GAAGATATTT	CAGCATACTT	GCTGAGTAAA	AACAATGCCA	TTGAACCAAG
4251	AAGCTTCTCT	GACAAAATC	ACACATGCCC	ACCGTGCCCA	GCTCCAGAAC
4301	TCCTGGGCGG	ACCGTCAGTC	TTCTCTTCC	CCCCAAAACC	CAAGGACACC

4351	CTCATGATCT	CCCGGACCCC	TGAGGTCACA	TGCGTGGTGG	TGGACGTGAG
4401	CCACGAAGAC	CCTGAGGTCA	AGTTCAACTG	GTATGTGGAC	GGCGTGGAAG
4451	TGCATAATGC	CAAGACAAAG	CCGCGGGAGG	AGCAGTACAA	CAGCACGTAC
4501	CGTGTGGTCA	GCGTCCTCAC	CGTCCTGCAC	CAAGACTGGC	TGAATGGCAA
4551	GGAGTACAAG	TGCAAGGTCT	CCAACAAAGC	CCTCCCAGCC	CCCATCGAGA
4601	AAACCATCTC	CAAAGCCAAA	GGGCAGCCCC	GAGAACCACA	GGTGTACACC
4651	CTGCCCCCAT	CCCGGGATGA	GCTGACCAAG	AACCAAGTTA	GCCTGACCTG
4701	CCTGGTCAAA	GGCTTCTATC	CCAGCGACAT	CGCCGTGGAG	TGGGAGAGCA
4751	ATGGGCAGCC	GGAGAACAAC	TACAAGACCA	CGCCTCCCGT	GTTGGACTCC
4801	GACGGCTCCT	TCTTCCTCTA	CTCCAAGCTC	ACCGTGGACA	AGAGCAGGTG
4851	GCAGCAGGGG	AACGTCTTCT	CATGCTCCGT	GATGCATGAG	GCTCTGCACA
4901	ACCACTACAC	GCAGAAGAGC	CTCTCCCTGT	CTCCGGGTTG	A

FVIII(ELNN)-Fc: SEQ ID NO: 7							
TRRYYLGA	VE	LSWDYMQSDL	GELPVDARFP	PRVPKSFFPN	TSVVYKKTLE	VEFTDHLFNI	60
AKPRPPWMGL	LGPTIQAEVY	DTVVITLKNM	ASHPVSLHAV	GVSYWKASEG	AEYDDQTSQR		120
EKEDDKVFP	GSHTYVWQVL	KENGPMASDP	LCLTYSYLSH	VDLVKDLNSG	LIGALLVCRE		180
GSLAKEKTQT	LHKFILLFAV	FDEGKSWHSE	TKNSLMQDRD	AASARAWPKM	HTVNGYVNR		240
LPGLIGCHRK	SVYWHVIGMG	TTEPVHSIFL	EGHTFLVRNH	RQASLEISPI	TFLTAQTLLM		300
DLGQFLLFCH	ISSHQHDGME	AYVKVDSCPE	EPQLRMKNNE	EAEDYDDDLT	DSEMDVVRFD		360
DDNSPSFIQI	RSVAKKHPT	WVHYIAAEEE	DWDYAPLVLA	PDDRSYKSQY	LNNGPQRIGR		420
KYKKVRFMAY	TDETFKTREA	IQHESGILGP	LLYGEVGDTL	LIIFKNQASR	PYNIYPHGIT		480
DVRPLYSRRL	PKGKVKHLKDF	PILPGEIFKY	KWTVTVEDGP	TKSDPRCLTR	YYSFVNMER		540
DLASGLIGPL	LICYKESVDQ	RGNQIMSDKR	NVILFSVFDE	NRSWYLTEI	QRFLPNPAGV		600
QLEDPEFQAS	NIMHSINGYV	FDSLQLSVCL	HEVAYWYILS	IGAQTDFLSV	FFSGYTFKHK		660
MVYEDTLTLF	PFSGETVFMS	MENPGLWILG	CHNSDFRNRG	MTALLKVSSC	DKNTGDYED		720
SYEDISAYLL	SKNNAIEPRS	FSQNGTSESA	TPESGPGSEP	ATSGSETPGT	SESATPESGP		780
GSEPATSGSE	TPGTSESATP	ESGPGTSTEP	SEGSAPGSPA	GSPTSTEEGT	SESATPESGP		840
GSEPATSGSE	TPGTSESATP	ESGPGSPAGS	PTSTEEGSPA	GSPTSTEEGT	STEPSEGSAP		900
GTSESATPES	PGTSESATP	ESGPGTSESA	TPESGPGSEP	ATSGSETPGS	EPATSGSETP		960
GSPAGSPTST	EEGTSTEPSE	GSAPGTSTEP	SEGSAPGSEP	ATSGSETPGT	SESATPESGP		1020
GTSTEPSEGS	APASSEITRT	TLQSDQEEID	YDDTISVEMK	KEDFDIYDED	ENQSPRSFQK		1080
KTRHYFIAAV	ERLWDYGMSS	SPHVLNRNAQ	SGSVPPQFKV	VFQEFDTGSE	TQPLYRGELN		1140
EHLGLLGPYI	RAEVEDNIMV	TFRNQASRPY	SFYSSLISYE	EDQRQGAEP	KNFVKPNETK		1200
TYFWKVQHMM	APTKDEFDCK	AWAYFSDVDL	EKDVHSGSLIG	PLLVCHTNL	NPAHGRQVTV		1260
QEFALFFTIW	DETKSWYTE	NMERNCRAPC	NIQMEDPTFK	ENYRFHAING	YIMDTLPGLV		1320
MAQDQIRIRWY	LLSMGSNENI	HSIHFSGHVF	TVRKKEEYKM	ALYNLYPGVF	ETVEMLPSKA		1380
GIWRVECLIG	EHLHAGMSTL	FLVYSNKCQT	PLGMASGHIR	DFQITASGQY	GQWAPKLARL		1440
HYSGSINAWS	TKEPFSWIKV	DLAPMIIHG	IKTQGARQKF	SSLYISQFII	MYSLDGKKWQ		1500
TYRGNSTGTL	MVFFGNVDSS	GIKHNI FNPP	IIARYIRLHP	THYSIRSTLR	MELMGCDLNS		1560
CSMPLGMESK	AISDAQITAS	SYFTNMFATW	SPSKARLHLQ	GRSNARWPQV	NNPKEWLQVD		1620
FQKTMKVTGV	TTQGVKSLLT	SMYVKEFLIS	SSQDGHQWTL	FFQNGKVKVF	QGNQDSFTPV		1680
VNSLDPELLT	RYLRIHPQSW	VHQIALRMEV	LGCEAQDLYD	KHTCTPPCPA	PELLGGPSVF		1740
LFPPKPKDTL	MISRTPEVTC	VVDVSHEDP	EVKFNWYVDG	VEVHNAKTKP	REEQYNSTYR		1800
VVSVLTVLHQ	DWLNGKEYKC	KVSNKALPAP	IEKTISKAKG	QPREPQVYTL	PPSRDELTKN		1860
QVSLTCLVKG	FYPSPDIAVEW	ESNGQPENNY	KTPPVLDSD	GSFFLYSKLT	VDKSRWQQGN		1920
VFSCSVMHEA	LHNHYTQKSL	SLSPG					1945

Table 4. Additional chimeric protein sequences

Description / SEQ ID NO.	Sequence
Full length FVIII	ATRRYYLGAV ELSWDYMQSD LGELPVDARF PPRVPKSFPF NTSVVYKKTLE FVEFTDHLFN 60
SEQ ID NO: 8	IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA VGSYWKASEG GAEDYDDQTSQ 120
	REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS HVDLVKDLNS GLIGALLVCR 180
	EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNLSMQDR DAASARAWPK MHTVNGYVNR 240
	SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300
	MDLGQFLLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKN EEAEDYDDDL TDSEMDVVRFD 360
	DDNSPSFIQ IRSVAKKHPT TWVHYIAAEE EDWDYAPLV APDDRSYKSQ YLNNGPQRIG 420
	RKYKKVRFMA YDETFKTRE AIQHESGILG PLYGEVGD LLIIFKNQAS RPYNIYPHGI 480
	TDVRPLYSRRL LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYYSFVNME 540

	RDLASGLIGP LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYL TEN IQRFLPNPAG 600 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS VFFSGYTFKH 660 KMYEDTTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720 DSYEDISAYL LSKNNAIEPR SFSQNSRHPS TRQKQFNATT IPENDIEKTD PWFARHTFMP 780 KIQNVSSSDL LMLLRQSPTP HGLSLSDLQE AKYETFSDDP SPGAIDSNN S LSEMTHFRPQ 840 LHHSGDMVFT PESGLQLRLN EKLGTAAATE LKKLDFKVSS TSNNLISTIP SDNLAAGTDN 900 TSSLGPPSMP VHYDSQLDIT LFGKSSPLT ESGGPLSLSE ENNDSKLLS GLMNSQESSW 960 GKNVSSSTESG RLFK GKRAHG PALLTKDNAL FKVSISLLKT NKTSNNSATN RKTHIDGPSL 1020 LIENSFSPVWQ NILESDFTEFK KVTPLIHDRM LMDKNATALR LNHMSNKTTS SKNMEMVQQK 1080 KEGPIPPDAQ NPDMSFFKML FLPE SARWIQ RTHGKNSLNS GQGSPKQLV SLGPEKSVEG 1140 QNFLSEKNKV VVGKGFEFTKD VGLKEMVFP S RNLF LTNL NLHENNTNQ EKKIQEEIEK 1200 KETLIQENVV LPQIHTVTGT KNFMKNLFL STRQNVESY DGAYAPVLQD FRS LNDSTNR 1260 TKKHTAHFSK KGEENLEGL GNQTKQIVEK YACTTRISP TSQQNFVTQR SKRALKQFRL 1320 PLEETELEKR IIVDDTSTQW SKNMKHLTPS TLTQIDYNEK EKGAITQSPL SDCLTRSHSI 1380 PQANRSPPLPI AKVSSFPSIR PIYLTRVLFQ DNSSHLPAAS YRKDSGVYR SSHFLQGA 1440 NNLSLAILTL EMTGDQREVG SLGTSATNSV TYKKVENTVL PKPDLPKTSG KVLLPKVHI 1500 YQKDLFPTET SNGSPGHLDL VEGSLQGT E GAIKWNEANR PGKVPFLRVA TESSAKTPSK 1560 LLDPLAWDNH YGTQIPKEEW KSQEKSP EKT AFKKKDTILS LNACESNHAI AAINEGQNK 1620 EIEVTWAKQG RTERLCSQNP PVLKRHQREI TRTTLQSDQE EIDYDDTISV EMKKEDFDIY 1680 DEDENQSPRS FQKKTRHYFI AAVERLWDY G MSSSPHVL RN RAQSGSVQF KKVVFQEF TD 1740 GSFTQPLYRG ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSLI SYEEDQRQGA 1800 EPRKNFVKPN ETKTYFWKVQ HHMAPTKDEF DCKAWAYFSD VDLEKDVHSG LIGPLLCHT 1860 NTLNPAHGRQ VTVQEFALFF TIFDET KSWY FTE NMERNCR APCNIQMEDP TFKENYRFHA 1920 INGYIMDTLP GLVMAQDQRI RWYLLSMGSN ENIHSIHFSG HVFTVRKKEE YKMALYNLYP 1980 GVFFTEVEMLP SKAGIWRVEC LIG EHLHAGM STLFLVYSNK CQTPLGMASG HIRDFQITAS 2040 GOYGQWAPKL ARLHYSGSIN AWSTKEPFSW IKVDLLAPMI IHGIKTQGAR QKFSSLYISQ 2100 FIIMYSLDGK KWQTYRGNST GTLMVFFGNV DSSGIKHNI NPPIIARYR LHPHYSIRS 2160 TLRMELMGCD LNSCSMPLGM ESKAISDAQI TASSYFTNMF ATWSPSKARL HLQGRSNAWR 2220 PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS LLTSMYVKEF LISSSQDGHQ WTLFFQNGKV 2280 KVFQGNQDSF TPVVNSLDP LLLTRYLRIHP QSVWHQIALR MEVLGCEAQD LY 2332
AE288 SEQ ID NO: 9	GTSESATPES GPGSEPATSG SETPGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP 60 GTSTEPSEGS APGSPAGSPT STEEGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP 120 GSPAGSPTST EEGSPAGSPT STEEGTSTEP SEGSA PGTSE SATPESGPAT SESATPESGP 180 GTSESATPES GPGSEPATSG SETPGSEPAT SGSETPGSPA GSPTSTEEGT STEPSEGSAP 240 GTSTEPSEGS APGSEPATSG SETPGTSESA TPESGPGTST EPSEGSAP 288
pSYN VWF059 SEQ ID NO: 10	TSTEEGASIS DKNTGDYYED SYEDISAYLL SKNNAIEPRS FSDKTH
pSYN VWF059A SEQ ID NO: 11	TSTEEGASSD KNTGDYYEDS YEDISAYLLS KNNNAIEPRSF SDKTH
pSYN FVIII 312 SEQ ID NO: 12	ATRRYYLGA V ELSWDYMQSD LGELPVDARF PPRVPKSF PF NTSVVYKKT L FVEFTDHLFN 60 IAKPRPPW MG LLGPTIQAEV YDTVVITLKN MASHPVSLHA VGVSYWKASE GA EYDDQTSQ 120 REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS HVDLVKDLNS GLIGALLVCR 180 EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNLSLMQDR DAASARAWPK MHTVNGYVNR 240 SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLL 300 MDLGQFLLFC HISSHQHDGM EAYVKVDS CP EEPQLRMKN EEAEDYDDDL TDSEMDVVRF 360 DDDNPSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLV APDDRYSKSQ YLNNGPQRIG 420 RKYKKVRFMA YTDETFKTRE AIQHESGILG PLYGEVGD T LLIIFKNQAS RPYNIYPHGI 480 TDVRPLYRR LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVNME 540 RDLASGLIGP LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYL TEN IQRFLPNPAG 600 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS VFFSGYTFKH 660 KMYEDTTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720 DSYEDISAYL LSKNNAIEPR SFSQNGTSES ATPESGPGSE PATSGSETPG TSESATPESG 780 PGSEPATSGS ETPGTSESAT PESGPGTSTE PSEGSAPGSP AGSPTSTEEG TSESATPESG 840 PGSEPATSGS ETPGTSESAT PESGPGSPAG SPTSTEEGSP AGSPTSTEEG TSTEPSEGA 900 PGTSESATPE SGPGTSESAT PESGPGTSES ATPESGPGSE PATSGSETPG SEPATSGSET 960 PGSPAGSPTS TEEGTSTEPS EGSAPGTSTE PSEGSAPGSE PATSGSETPG TSESATPESG 1020 PGTSTEPSEG SAPASSEITR TTLQSDQEEI DYDDTISVEM KKEDFDIYDE DENQSPRSFQ 1080 KKRTHYFIAA VERLWDYGMS SSPHVLNRRA QSGSVQPKK VVFQEF TDGS FTQPLYRGEL 1140 NEHLGLLGPY IRAEVEDNIM VTFRNQASRP YSFYSSLSY EEDQRQGAEP RKNFVKNET 1200 KTYFWKVQHH MAPTKDEFDC KAWAYFSDVD LEKDVHSGLI GPLLVCHTNT LNPAGHRQVT 1260 VQEFALFFTI FDETKSWYFT ENMERNCRAP CNIQMEDPTF KENYRFHAIN GYIMDTLPGL 1320 VMAQDQRIRW YLLSMGSNEN IHSIHFSGHV FTVRKKEEYK MALYNLYPGV FETVEMLP SK 1380

	AGIWRVECLI GEHLHAGMST LFLVYSNKCQ TPLGMASGHI RDFQITASGQ YGQWAPKLAR 1440 LHYSGSINAW STKEPFSWIK VDLLAPMIIH GIKTQGARQK FSSLYISQFI IMYSLDGKKW 1500 QTYRGNSTGT LMVFFGNVDS SGIKHNIFNP PIIARYIRLH PTHYSIRSTL RMELMGCDLN 1560 SCSMPLGMES KAISDAQITA SSYFTNMFAT WSPSKARLHL QGRSNAWRPQ VNNPKEWLQV 1620 DFQKTMKVVG VTTQGVKSLL TSMYVKEFLI SSSQDGHQWT LFFQNGKVKV FQGNQDSFTP 1680 VVNSLDPPLL TRYLRHPQS WVHQIALRME VLGCQAQDLY DKTHTCPCP APPELLGGPSV 1740 FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 1800 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK GQPREPQVYT LPPSRDELTK 1860 NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPPVLDS DGSFFLYSKL TVDKSRWQQG 1920 NVFSCSVME ALHNHYTQKS LSLSPGK
ELNN_AE288_2 SEQ ID NO: 13	GSPAGSPTST EEGTSESATP ESGPGSEPAT SGSETPGTSE SATPESGPGT STEPSEGSAP 60 GTSTEPSEGS APGTSTEPSE GSAPGTSTEP SEGSAAGTST EPSEGSAPGT STEPSEGSAP 120 GSPAGSPTST EEGTSTEPSE GSAPGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP 180 GSEPATSGSE TPGTSESATP ESGPGTSTEP SEGSAAGTSE SATPESGPGS PAGSPTSTEE 240 GSPAGSPTST EEGSPAGSPT STEEGTSESA TPESGPGTST EPSEGSAP 288
ELNN AE144_5A SEQ ID NO: 14	TSESATPESG PGSEPATSGS ETPGTSESAT PESGPGSEPA TSGSETPGTS ESATPESGPG 60 TSTEPSEGS PGSPAGSPTS TEEGTSESAT PESGPGSEPA TSGSETPGTS ESATPESGPG 120 SPAGSPTSTE EGSPAGSPTS TEEG
a2 Linker of chimeric protein SEQ ID NO: 15	DKNTGDYYED SYEDISAYLL SKNNAIEPRS FS 32
Signal Peptide of FVIII SEQ ID NO: 16	MQIELSTCFFLCLLRFCFS
FVIII fragment 1 of chimeric protein SEQ ID NO: 17	ATRRYYLGA V ELSWDYMQSD LGELPVDARF PPRVPKSPFP NTSVVYKKTLL FVEFTDHLFN 60 IAKPRPPWVG LLGPTIQAEV YDTVVITLKN MASHPVSLHA VGVSYWKASE GAEYDDQTSQ 120 REKEDDKVFP GGSHTYVWQV LKENGPMASD PLCLTYSYLS HVDLVKDLNS GLIGALLVCR 180 EGSLAKEKTQ TLHKFILLFA VFDEGKSWHS ETKNLSLMQDR DAASARAWPK MHTVNGYVNR 240 SLPGLIGCHR KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTL 300 MDLGQFLFC HISSHQHDGM EAYVKVDSCP EEPQLRMKNN EEAEDYDDDL TDSEMDVVR 360 DDDNSPSFIQ IRSVAKKHPK TWVHYIAAEE EDWDYAPLVL APDDRSYKSQ YLNNGPQRIG 420 RYKVKVRFMA YDTEFTKTR AIQHESGILG PLYGEVGD LLIIFKNQAS RPYNIYPHGI 480 TDVRPLYSRP LPKGVKHLKD FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVNME 540 RDLASGLIGP LLICYKESVD QRGNQIMSDK RNVILFSVFD ENRSWYL TEN IQRFLPNPAG 600 VQLEDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SIGAQTDFLS VFFSGYTFKH 660 KMVYEDTLTL FPFSGETVFM SMENPGLWIL GCHNSDFRNR GMTALLKVSS CDKNTGDYYE 720 DSYEDISAYL LSKNNAIEPR SFSQN
FVIII fragment 2 of chimeric protein SEQ ID NO: 18	EITRTTLQSD QEEIDYDDTI SVMKKEDFD IYDEDENQSP RSFQKKTRHY FIAAVERLWD 60 YGMSSSPHVL RNRAQSGSVP QFKKVVVFQEF TDGSFTQPLY RGELNEHLGL LGPYIRAEVE 120 DNIMVTFRNQ ASRPYSFYSS LISYEEDQRQ GAEPKRNFKV PNETKTYFWK VQHHMAPTKD 180 EFDCKAWAYF SDVDLEKDVH SGLIGPLLVC HTNTLNPAHG RQVTVQEFAL FFTIFDET 240 WYFTENMERN CRAPCNIQME DPTFKENYRF HAINGYIMDT LPGLVMAQDQ RIRWYLLSMG 300 SNENIHSIH F SGHVFTVRKK EYKMALYNL YPGVFETVEM LPSKAGIWRV ECLIGEHLHA 360 GMSTLFLVYS NKCQTPLGMA SGHIRDFQIT ASGQYQGWAP KLARLHYS GS INAWSTKEPF 420 SWIKVDLLAP MIIHGKIQG ARQKFSSLYI SQFIIMYSLD GKKWQTYRGN STGTLMVFFG 480 NVDSSGIKHN IFNPPIIARY IRLHPTHYSI RSTLRMELMG CDLNSCSMPL GMESKAISDA 540 QITASSYFTN MFATWSPSKA RLHLQGRSNA WRPQVNNPKE WLQVDFQKTM KVTGVTTQGV 600 KSLTSMYVK EFLISSSQDG HQWTLFFQNG KVKVFQGNQD SFTPVVNSLD PPLLTRYLRI 660 HPQSVWHQIA LRMEVLGCEA QDLY
VWF Signal Peptide SEQ ID NO: 19	MIPARFAGVL LALALILPGT LC

VWF D1D2 domain of chimeric protein	AEGTRGRSST ARCSLFGSDF VNTFDGSMYS FAGYCSYLLA GGCQKRFSI IGDFQNGKRV 60						
	SLSVYLGEFF DIHLFVNGTV TQGDQRVSM YASKGLYLET EAGYYKLSGE AYGFVARIDG 120						
SEQ ID NO: 20	SGNFQVLLSD RYFNKTCGLC GNFNIFAEDD FMTQEGTITS DPYDFANSWA LSSGEQWCER 180						
	ASPPSSSCNI SSGEMQKGLW EQCQLLKSTS VFARCHPLVD PEPFVALCEK TLCECAGGLE 240						
	CACPALLEYA RTCAQEGMVL YGWTDHSA SCS PVCAPAGMEYR QCVSPCARTC QSLHINEMCQ 300						
	ERCVDGCSCP EGQLLDEGLC VESTECPCVH SGKRYPPGTS LSRDCNTCIC RNSQWICSNE 360						
	ECPGECCLVTG QSHFKSFDNR YFTFSGICQY LLARDCQDHS FSIVETVQC ADDRDAVCTR 420						
	SVTVRLPGLH NSLVKLKHA GVAMDGQDIQ LPLLKGDRLI QHTVTASVRL SYGEDLQMDW 480						
	DGRGRLLVKL SPVYAGKTCG LCGNYNGNQG DDFLTPSGLA EPRVEDFGNA WKLHGDCQDL 540						
	QKQHSDFCAL NPRMTRFSEE ACAVLTSPTE EACHRAVSPL PYLRNCRYDV CSCSDGRECL 600						
	CGALASYAAA CAGRGVRVAW REPGRCELNC PKGQVYLQCG TPCNLTCRSL SYPDEECNEA 660						
	CLEGCFPCPPG LYMDERGDCV PKAQCPCYD GEIFQPEDIF SDHHTMCYCE DGFMHCTMSG 720						
VWF D' domain of chimeric protein	VPGSLLPDAV LSSPLSHRSK R						
SEQ ID NO: 21	SLSCRPPMVK LVCADNLRA EGLECTKTCQ NYDLECMSMG CVSGCLCPPG MVRHENRCVA 60						
	LERPCFHHQ KEYAPGETVK IGCNTCVCRD RKWNCTDHVC DAT 103						
VWF D3 domain of chimeric protein							
SEQ ID NO: 22	CSTIGMAHYL TFDGLKYLFP GECQYVLVQD YCGSNPGTFR ILVGNKGCSH PSVKCKKRV 60						
	ILVEGGEIEL FDGEVNVKRP MKDETHFEVV ESGRYIILLL GKALSVVWDR HLSISVVLKQ 120						
	TYQEKVCGLC GNFDGIQND LTSSNLQVEE DPVDFGNSWK VSSQCADTRK VPLDSSPATC 180						
	HNNIMKQTMV DSSCRILTSD VFQDCNKLVD PEPYLDVCIY DTCSCESIGD CAAFCDTIAA 240						
	YAHVCAQHGK VVTWRTATLC PQSCEERNLR ENG YEA EWRY NSCAPACQVT CQHPEPLACP 300						
	VQCVEGCHAH CPPGKILDEL LQTCVDPEDC PVCEVAGRRF ASGKKVTLNP SDPEHCQICH 360						
Fc region	CDVVNLTCEA CQEP 374						
SEQ ID NO: 23	DKTHTCPPCP APELLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED PEVKFNWYVD 60						
	GVEVHNATK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTISKAK 120						
	GQPREPQVYT LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTPPVLD 180						
	DGSFFLYSKL TVDKSRWQQG NVFSCSVME ALHNHYTQKS LSLSPG						
ELNN AE288_3							
SEQ ID NO: 24	GTSESATPES GPGSEPATSG SETPGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP 60						
	GTSTEPSEGS APGSPAGSPT STEEGTSESA TPESGPGSEP ATSGSETPGT SESATPESGP 120						
	GSPAGSPTST EEGSPAGSPT STEEGTSTEP SEGSA PGTS SATPESGPGT SESATPESGP 180						
	GTSESATPES GPGSEPATSG SETPGSEPA SGSETPGSPA GSPTSTEEGT STEPSEGSAP 240						
	GTSTEPSEGS APGSEPATSG SETPGTSESA TPESGPGTST EPSEGSAPAS S 291						

CLAIMS

1. A pharmaceutical composition comprising:
 - (a) a chimeric protein comprising a first polypeptide chain which comprises a Factor VIII ("FVIII") protein and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof;
 - (b) sucrose;
 - (c) histidine;
 - (d) arginine;
 - (e) calcium chloride; and
 - (f) a poloxamer.
2. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises about 1% (w/v) to about 7.5% (w/v) sucrose.
3. The pharmaceutical composition of claim 1 or 2, wherein the pharmaceutical composition comprises about 1% (w/v) to about 5% (w/v) sucrose.
4. The pharmaceutical composition of any one of claims 1-3, wherein the poloxamer is poloxamer 188 (P188).
5. The pharmaceutical composition of any one of claims 1-4, wherein the pharmaceutical composition comprises about 5 mM to about 15 mM histidine.
6. The pharmaceutical composition of any one of claims 1-5, wherein the pharmaceutical composition comprises about 200 mM to about 300 mM arginine.
7. The pharmaceutical composition of any one of claims 1-6, wherein the pharmaceutical composition comprises about 2.5 mM to about 10 mM calcium chloride.
8. The pharmaceutical composition of any one of claims 1-7, wherein the pharmaceutical composition comprises about 0.01% (w/v) to about 1.0% (w/v) poloxamer 188 (P188).
9. The pharmaceutical composition of any one of claims 1-8, wherein the pharmaceutical composition comprises:
 - (a) about 1% (w/v) to about 5% (w/v) sucrose;

- (b) about 5 mM to about 15 mM histidine;
- (c) about 200 mM to about 300 mM arginine;
- (d) about 2.5 mM to about 10 mM calcium chloride; and
- (e) about 0.01% (w/v) to about 1.0% (w/v) poloxamer 188.

10. The pharmaceutical composition of any one of claims 1-9, wherein the pharmaceutical composition comprises:

- (a) about 5% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

11. The pharmaceutical composition of any one of claims 1-10, wherein the pharmaceutical composition comprises:

- (a) about 5% (w/v) sucrose;
- (b) about 10 mM L-histidine;
- (c) about 250 mM L-arginine-HCl;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

12. The pharmaceutical composition of any one of claims 1-11, wherein the pharmaceutical composition comprises:

- (a) about 1% (w/v) sucrose;
- (b) about 10 mM histidine;
- (c) about 250 mM arginine;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

13. The pharmaceutical composition of any one of claims 1-12, wherein the pharmaceutical composition comprises:

- (a) about 1% (w/v) sucrose;
- (b) about 10 mM L-histidine;
- (c) about 250 mM L-arginine-HCl;
- (d) about 5 mM calcium chloride; and
- (e) about 0.1% (w/v) poloxamer 188.

14. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition comprises:

- (a) 10 mg/mL to 60 mg/mL sucrose;
- (b) 1.5 mg/mL to 2.0 mg/mL L-histidine;
- (c) 40 mg/mL to 70 mg/mL L-arginine-HCl;
- (d) 0.4 mg/mL to 0.9 mg/mL calcium chloride; and
- (e) 0.6 mg/mL to 1.6 mg/mL poloxamer 188.

15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

16. The pharmaceutical composition of any one of claims 14-15, wherein the pharmaceutical composition comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

17. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

18. The pharmaceutical composition of any one of claims 17-18, wherein the pharmaceutical composition comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;

- (d) 0.62 mg/ml calcium chloride; and
 - (e) 1.12 mg/ml poloxamer 188.
19. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:
- (a) about 50 mg/mL sucrose;
 - (b) about 1.6 mg/mL L-histidine;
 - (c) about 52.7 mg/mL L-arginine-HCl;
 - (d) about 0.7 mg/mL calcium chloride dihydrate; and
 - (e) about 1 mg/mL poloxamer 188.
20. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:
- (a) about 50 mg/mL sucrose;
 - (b) about 1.6 mg/mL L-histidine;
 - (c) about 43.6 mg/mL L-arginine;
 - (d) about 0.7 mg/mL calcium chloride dihydrate; and
 - (e) about 1 mg/mL poloxamer 188.
21. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:
- (a) about 50 mg/mL sucrose;
 - (b) about 1.6 mg/mL L-histidine;
 - (c) about 52.7 mg/mL L-arginine-HCl;
 - (d) about 0.6 mg/mL calcium chloride; and
 - (e) about 1 mg/mL poloxamer 188.
22. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:
- (a) about 10 mg/mL sucrose;
 - (b) about 1.6 mg/mL L-histidine;
 - (c) about 52.7 mg/mL L-arginine-HCl;
 - (d) about 0.7 mg/mL calcium chloride dihydrate; and
 - (e) about 1 mg/mL poloxamer 188.
23. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.7 mg/mL calcium chloride dihydrate; and
- (e) about 1 mg/mL poloxamer 188.

24. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 52.7 mg/mL L-arginine-HCl;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

25. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) about 10 mg/mL sucrose;
- (b) about 1.6 mg/mL L-histidine;
- (c) about 43.6 mg/mL L-arginine;
- (d) about 0.6 mg/mL calcium chloride; and
- (e) about 1 mg/mL poloxamer 188.

26. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

27. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

28. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 56.12 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

29. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.82 mg/ml calcium chloride dihydrate; and
- (e) 1.12 mg/ml poloxamer 188.

30. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 59.11 mg/ml L-arginine-HCl;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

31. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises:

- (a) 11.23 mg/ml sucrose;
- (b) 1.74 mg/ml L-histidine;
- (c) 48.88 mg/ml L-arginine;
- (d) 0.62 mg/ml calcium chloride; and
- (e) 1.12 mg/ml poloxamer 188.

32. The pharmaceutical composition of any one of claims 1 to 31, wherein the pharmaceutical composition has a pH of about 6.5 to about 7.5.

33. The pharmaceutical composition of any one of claims 1 to 32, wherein the pharmaceutical composition has a pH of about 7.0.

34. The pharmaceutical composition of any one of claims 1 to 32, wherein the pharmaceutical composition has a pH of about 6.8.
35. The pharmaceutical composition of any one of claims 1 to 34, wherein the pharmaceutical composition comprises less than 8.8 mg/mL sodium chloride (NaCl).
36. The pharmaceutical composition of any one of claims 1 to 35, wherein the pharmaceutical composition does not comprise NaCl.
37. The pharmaceutical composition of any one of claims 1 to 10, wherein the histidine is L-histidine.
38. The pharmaceutical composition of any one of claims 1 to 10, wherein the arginine is L-arginine.
39. The pharmaceutical composition of any one of claims 1 to 10, which comprises arginine-HCl.
40. The pharmaceutical composition of any one of claims 1 to 10, which comprises L-arginine-HCl.
41. The pharmaceutical composition of any one of claims 1 to 10, which comprises calcium chloride dihydrate.
42. The pharmaceutical composition of any one of claims 1 to 41, wherein the pharmaceutical composition has an osmolality about 525 to about 725 mOsm/kg.
43. The pharmaceutical composition of any one of claims 1 to 41, wherein the pharmaceutical composition comprises has an osmolality about 500 to about 650 mOsm/kg.
44. The pharmaceutical composition of any one of claims 1 to 43, wherein the pharmaceutical composition comprises has a turbidity of less than about 7 Nephelometric Turbidity Units (NTU).
45. The pharmaceutical composition of any one of claims 1 to 44, wherein the first polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 1 and the second polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between Fc domains in the first and second polypeptide chains.

46. The pharmaceutical composition of any one of claims 1 to 45, wherein the chimeric protein is efanesoctocog alfa.
47. The pharmaceutical composition of any one of claims 1 to 46, wherein the pharmaceutical composition has a chimeric protein concentration of about 0.8 to about 1.2 mg/mL.
48. The pharmaceutical composition of any one of claims 1 to 47, wherein the pharmaceutical composition comprises 75 IU/mL to 2,000 IU/mL of the chimeric protein.
49. The pharmaceutical composition of claim 48, wherein the pharmaceutical composition comprises about 250 IU, 500 IU, 1000 IU, 2000 IU, 3000 IU, or 4,000 IU of the chimeric protein.
50. The pharmaceutical composition of any one of claims 1 to 48, wherein the pharmaceutical composition comprises at least about 500 IU of the chimeric protein or from about 0.5 mg/ml to about 5 mg/ml of the chimeric protein.
51. The pharmaceutical composition of any one of claims 1-50, which (i) has been stored at a temperature of about -20°C to about -40°C for at least about 1 to about 36 months; and/or (ii) is a liquid formulation that has been frozen and then thawed 2-5 times.
52. A method of treating hemophilia A in a subject in need thereof, comprising administering to the subject an effective amount of the pharmaceutical composition of any one of claims 1 to 51.
53. The method of claim 52, wherein the pharmaceutical composition is self-administered.
54. The method of claim 52 or 53, wherein the pharmaceutical composition is administered intravenously.
55. The method of any one of claims 52 to 54, wherein the pharmaceutical composition is administered intravenously at a dose of 20 IU/kg to 70 IU/kg.
56. The method of any one of claims 52 to 55, wherein the pharmaceutical composition is administered intravenously at a dose of 50 IU/kg.
57. The method any one of claims 52 to 56, wherein the pharmaceutical composition is administered intravenously once every 7-10 days.

58. The method of claim any one of claims 52 to 57, wherein the pharmaceutical composition is administered intravenously once weekly.
59. A pharmaceutical kit comprising:
- (i) a first container comprising a lyophilized pharmaceutical composition comprising
 - (a) a chimeric protein comprising a first polypeptide chain which comprises a Factor VIII ("FVIII") protein or a portion thereof and a first immunoglobulin ("Ig") constant region or a portion thereof, and a second polypeptide chain which comprises a von Willebrand Factor ("VWF") protein and a second Ig constant region or a portion thereof;
 - (b) sucrose;
 - (c) histidine;
 - (d) arginine;
 - (e) calcium chloride; and
 - (f) poloxamer 188, and
 - (ii) a second container comprising sterile water.
60. The pharmaceutical kit of claim 59, wherein the lyophilized pharmaceutical composition comprises:
- (a) about 10 mg to about 200 mg sucrose;
 - (b) about 2.5 mg to about 7.5 mg histidine;
 - (c) about 140 mg to about 200 mg arginine;
 - (d) about 1.5 mg to about 5 mg calcium chloride; and
 - (e) about 1 mg to about 10 mg poloxamer 188.
61. The pharmaceutical kit of any one of claims 59-60, which does not comprise NaCl.
62. The pharmaceutical kit of any one of claims 59-61, wherein the histidine is L-histidine.
63. The pharmaceutical kit of any one of claims 59-62, wherein the arginine is L-arginine.
64. The pharmaceutical kit of any one of claims 59-63, which comprises arginine-HCl.
65. The pharmaceutical kit of any one of claims 59-64, which comprises L-arginine-HCl.
66. The pharmaceutical kit of any one of claims 59-65, which comprises calcium chloride dihydrate.

67. The pharmaceutical kit of any one of claims 59-66, wherein the lyophilized pharmaceutical composition comprises:
- (a) about 168.3 mg sucrose;
 - (b) about 5.2 mg L-histidine;
 - (c) about 177.3 mg L-arginine-HCl;
 - (d) about 2.5 mg calcium chloride; and
 - (e) about 3.3 mg poloxamer 188.
68. The pharmaceutical kit of any one of claims 59-66, wherein the lyophilized pharmaceutical composition comprises:
- (a) about 33.7 mg sucrose;
 - (b) about 5.2 mg L-histidine;
 - (c) about 146.6 mg L-arginine-HCl;
 - (d) about 2.5 mg calcium chloride; and
 - (e) about 3.3 mg poloxamer 188.
69. The pharmaceutical kit of any one of claims 59-68, wherein the second container comprises about 2 mL to about 5 mL of the sterile water.
70. The pharmaceutical kit of any one of claims 59-68, wherein the second container comprises about 3 mL of the sterile water.
71. The pharmaceutical kit of any one of claims 59-68, wherein the second container comprises about 3.3 mL of the sterile water.
72. The pharmaceutical kit of any one of claims 59-71, wherein the first container is a glass vial comprising a rubber stopper.
73. The pharmaceutical kit of any one of claims 59-72, wherein the second container is a syringe body.
74. The pharmaceutical kit of claim 73, wherein the sterile water is in the syringe body.
75. The pharmaceutical kit of claim 73 or 74, wherein the syringe body is associated with a plunger.
76. The pharmaceutical kit of any one of claims 73-75, further comprising an adaptor to connect the glass vial to the syringe body.

77. The pharmaceutical kit of any one of claims 73-76, further comprising infusion tubing associated with a needle to be connected to the syringe body, suitable for intravenous infusion.
78. The pharmaceutical kit of any one of claims 59-77, wherein the first polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 1 and the second polypeptide chain comprises the amino acid sequence set forth as SEQ ID NO: 2, wherein the first polypeptide chain and the second polypeptide chain are covalently linked by two disulfide bonds between Fc domains in the first and second polypeptide chains.
79. The pharmaceutical kit of any one of claims 59-78, which has been stored at a temperature of about -20°C, about -25°C, about -30°C, about -35°C, or about -40°C for at least about 1 to about 36 months.
80. A method of treating hemophilia A in a subject in need thereof, comprising combining the lyophilized pharmaceutical composition and the sterile water of the kit of any one of claims 59-79, and administering to the subject an effective amount of the resulting combination.
81. The method of claim 80, wherein the subject combines the lyophilized pharmaceutical composition and the sterile water of the kit.
82. The method of claim 80 or 81, wherein the combination is self-administered by the subject.
83. A method of storing a pharmaceutical composition or kit, comprising maintaining the pharmaceutical composition of any one of claims 1-50 or the kit of any one of claims 59-78 at a temperature of from about -20°C to about -40°C for at least about 1 to about 36 months.




FIG. 1




FIG. 2




FIG. 3






FIG. 4




Sucrose Concentration in the DS

FIG. 5



Sucrose Concentration in the DS

FIG. 6



25um Particles P188 -80C





FIG. 7B



10um Particles P188 -80C




FIG. 7A




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 9A




FIG. 9B





FIG. 9C



Sucrose Concentration in the DS

FIG. 10




FIG. 11




FIG. 12A




FIG. 12B




FIG. 13




FIG. 14




FIG. 15




FIG. 16A




FIG. 16B




FIG. 16C




FIG. 17

24 / 29




FIG. 18A




FIG. 18B




FIG. 18C




FIG. 19




FIG. 20




FIG. 21

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2022/078097

A. CLASSIFICATION OF SUBJECT MATTER INV. A61K9/19 A61K47/02 A61K47/18 A61K47/26 A61P7/04 A61K47/10 ADD. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) A61K A61P Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) EPO-Internal, EMBASE, BIOSIS		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 2019/222682 A1 (BIOVERATIV THERAPEUTICS INC [US]) 21 November 2019 (2019-11-21) paragraph [0222] paragraph [0304] - paragraph [0317] claims -----	1-83
Y	US 5 733 873 A (OESTERBERG THOMAS [SE] ET AL) 31 March 1998 (1998-03-31) column 3, line 29 - column 4, line 41 claims -----	1-83
☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.		
* Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance;; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance;; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 31 January 2023		Date of mailing of the international search report 08/02/2023
Name and mailing address of the ISA/ European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016		Authorized officer Muller, Sophie

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2022/078097

Box No. I Nucleotide and/or amino acid sequence(s) (Continuation of item 1.c of the first sheet)

1. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
 - a. ☒ forming part of the international application as filed.
 - b. ☐ furnished subsequent to the international filing date for the purposes of international search (Rule 13*ter*.1(a)).

☐ accompanied by a statement to the effect that the sequence listing does not go beyond the disclosure in the international application as filed.
2. ☐ With regard to any nucleotide and/or amino acid sequence disclosed in the international application, this report has been established to the extent that a meaningful search could be carried out without a WIPO Standard ST.26 compliant sequence listing.
3. Additional comments:

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2022/078097

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2019222682 A1	21-11-2019	AU 2019270184 A1	26-11-2020
		BR 112020022164 A2	02-02-2021
		CA 3099049 A1	21-11-2019
		CN 112512555 A	16-03-2021
		CO 2020014566 A2	10-12-2020
		EP 3793588 A1	24-03-2021
		JP 2021523878 A	09-09-2021
		KR 20210020030 A	23-02-2021
		MA 52630 A	26-05-2021
		SG 11202010767S A	27-11-2020
		TW 202015723 A	01-05-2020
		US 2019375822 A1	12-12-2019
		WO 2019222682 A1	21-11-2019
US 5733873 A	31-03-1998	AT 198277 T	15-01-2001
		AT 316981 T	15-02-2006
		AU 677797 B2	08-05-1997
		CA 2124690 A1	14-04-1994
		CZ 290342 B6	17-07-2002
		DE 69329795 T2	05-07-2001
		DE 69333974 T2	03-08-2006
		DK 0627924 T3	30-04-2001
		EP 0627924 A1	14-12-1994
		EP 1016673 A1	05-07-2000
		EP 1652534 A2	03-05-2006
		ES 2154650 T3	16-04-2001
		FI 942573 A	01-06-1994
		GR 3035472 T3	31-05-2001
		HU 211670 A9	28-12-1995
		HU 220194 B	28-11-2001
		JP 3905921 B2	18-04-2007
		JP H07501560 A	16-02-1995
		KR 100303872 B1	22-11-2001
		NZ 256921 A	28-05-1996
		PT 627924 E	31-05-2001
		SK 65994 A3	08-03-1995
		US 5733873 A	31-03-1998
		US 5919766 A	06-07-1999
		WO 9407510 A1	14-04-1994